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Abstract
Administration of erucin (3 and 15 m g/kg) and sulforaphane (15  m g/kg) to rats for 10 
days enhanced hepatic and pulmonary quinone reductase activity; sullforaphane also 
stimulated hepatic glutathione S-transferase, when monitored using 4-chloro-7- 
nitrobenzofurazan. Immunologically, both compounds increased the expression of 
hepatic and pulmonary glutathione 5-transferases class a and but not n, proteins. 
Neither compound influenced activity of selected cytochromes P450, although CYPIA and 
C YPIB I protein levels rose markedly in both tissues. The lack of concordance between 
activity and protein expression is due to the fact that isothiocyanates are mechanism- 
based inhibitors. A similar pattern of cytochrome P450 and Phase I I  enzyme modulation 
was observed when precision-cut rat liver and lung slices were incubated with either 
isothiocyanate. Both compounds elevated total glutathione, quinone reductase and 
glutathione S-transferase in rat liver and lung slices. In limited studies conducted with 
human slices, erucin and sulforaphane, in contrast to rat, were at best weak inducers of 
quinone reductase raising the possibility of species differences in the inducibility of this 
enzyme by isothiocyanates.
Both isothiocyanates antagonised the benzo(a)pyrene-mediated induction of CYPIA in 
rat liver slices, and this may contribute to their chemopreventive activity.
Urinary excretion of indirect-acting mutagens (unchanged 2-am ino-3-m ethylim idazo- 
[4,5-f]quinoline) was significantly suppressed in rats pre-treated with isothiocyanates for 
11 days prior to exposure to a single dose of 2-am ino-3-m ethylim idazo-[4,5-f]quinoline, 
but hepatic CYPIA and glutathione S-transferase activities were unaffected, indicating 
that they are not responsible for the increase in the metabolism of this carcinogen.
HPLC-MS methods were developed and validated for determining low sulforaphane levels 
in rat and human plasma. In rats, sulforaphane was rapidly absorbed, achieved high 
bioavailability but its pharmacokinetic behaviour was dose-dependent. Sulforaphane was 
also rapidly absorbed following intake of broccoli by human volunteers, achieving peak 
plasma levels within 1.5 hours. Repeated intake of broccoli did not alter its 
pharmacokinetic behaviour.
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Chapter 1: introduction
Chapter 1
Introduction
Chapter 1: introduction
1.1 Role o f D iet in Carcinogenesis
The appearance of a mutated cell, a process called initiation, is directly or indirectly 
linked to multiple factors implicated in carcinogenesis such as DNA damage following 
exposure to ionising or UV radiation or chemical carcinogens, insertion of a gene 
sequence capable of causing transformations following infection with certain types of 
DNA or RNA viruses (H IV , HPV etc.) and hereditary predisposition (e.g. familial 
retinoblastoma, lack of expression of certain classes of detoxifying enzymes and DNA 
repair enzymes). However, the above factors are only responsible for the minority of 
human cancers. Chemical agents present in tobacco smoke, occurring naturally as food 
contaminants or formed during cooking or food processing are implicated in DNA 
damage and the appearance of aberrant cells (Farber et al., 1982 and Wogan et al., 
2004). The majority of cancers, in theory, can be prevented by appropriate control of 
pollution, working conditions and especially changes in life style (e.g. cessation of 
smoking and reduced alcohol consumption) and change of diet (Doll and Peto, 1981).
The importance of diet in the incidence and prevalence of cancer has been widely 
recognised. Epidemiological evidence supports the relationship of excessive fat and red 
meat consumption, overeating and high alcohol intake with increased risk of colon, 
breast, ovary and prostate cancer. Even the method of cooking has been shown to be an 
important factor in carcinogenesis associated with diet as, for example, in the case of 
humans exposed to heterocyclic amines (HA) and polycyclic aromatic hydrocarbons 
(PAH) through smoking and/or consumption of well cooked, fried or barbecued meat and 
fish, who exhibit an increased risk of lung, colon, breast and prostate cancers (Ikeda et 
al., 1983).
In contrast, high consumption of fresh fruit, vegetables and whole grains has been 
strongly associated with a decreased risk of certain cancers (Steinm etz and Potter,
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1991,1996; Rogers et al., 1993) indicating that, as well as being a source of certain 
toxins and carcinogens, human diet contains substances that can effectively prevent 
chemical-initiated carcinogenesis. The chemopreventive effect of fruit and vegetables is 
attributed either to individual or combined action of fibre, phytochemicals and 
micronutrients.
Chemoprevention is the ability of a substance to prevent, delay or reverse cancer 
development at non-toxic doses (Sporn and Suh, 2000). As the western population is 
ageing and life expectancy increases, the high incidence of cancer is becoming a major 
problem. Ongoing efforts to identify therapeutically useful chemopreventative agents 
have led to the assessment of various plant-derived compounds that could be 
responsible for low incidence of cancer in individuals consuming large quantities of fruit 
and vegetables. A number of naturally occurring non-toxic substances present in the diet 
have some degree of anticarcinogenic activity, some of which are very potent and could 
be developed for use as human chemopreventive agents.
Many naturally occurring compounds are direct antioxidants that act as free radical 
scavengers, for example, vitamin C, (3-carotene and plant-derived polyphenols such as 
ellagic acid and o-tocopherol. Amongst other potential chemopreventive agents are 
plant-derived compounds such as coumarin (Maucher and von Angerer, 1994), diallyl 
disulphide (Dwivedi et al., 1992), flavonoids (Guthrie et al, 1998; Miyagi et al., 2000) 
and chlorphyllin (Smith et al., 2001).
1.2 Iso th iocyanates and Cancer Prevention.
Consumption of a single group of vegetables, cruciferous vegetables, especially 
belonging to the genus Brassica (broccoli, Brussels sprouts, green cabbage) has been 
linked to reduced cancer incidence in many tissues in humans (Block et al., 1992;
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Greenwald et al., 2001; Seow et al., 2002; Steinmetz and Potter, 1991 and Steinmetz 
and Potter, 1996). These plants contain a variety of substances including, carotenoids, 
vitamins, folic acid, selenium, dietary fibre, coumarins, flavonoids, fibre, chlorphyllin and 
glucosinolates that may contribute to the anticarcinogenic activity; amongst these, the 
glucosinolates are the most abundant class of phytochemicals.
The aglycone moiety of the glucosinolates is a precursor of a respective isothiocyanate 
(ITC). The ITCs are a class of compounds with diverse structures (Fig. 1 .1 ), which are 
thought to be almost solely responsible for the chemopreventive activity associated with 
high intake of these vegetables (Verhoeven et al., 1996). Much attention has been 
devoted to the potential chemopreventive activity of several ITCs including allyl 
isothiocyanate (A ITC), benzyl isothiocyanate (B ITC), phenethyl isothiocyanate (PEITC), 
erucin and sulforaphane (SFN), which are believed to boost the cell's capacity to detoxify 
reactive electrophiles by induction of phase I I  enzyme activity and increased cellular 
GSH levels (Fahey and Talalay, 1999) as well as reduced bioactivation of carcinogens 
associated with inhibition of a number of P450 enzymes.
=  C = S
c = s
N =  C
AITC
BITC
PEITC
SFN
ERUCIN
Figure 1.1: Structures of the major ITCs. Abbreviations: AITC -  allyl isothiocyanate; BITC -  
benzyl isothiocyanate; PEITC -  phenethyl isothiocyanate; SFN - sulforaphane
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Purified and chemically synthesised ITCs such as AITC, BITC, PEITC and SFN effectively 
inhibited bioactivation and DNA damage inflicted by experimental carcinogens (lARC, 
2004). This activity was consistent with the cancer chemopreventive activity in various 
organs in animal models (Hecht, 1996a, 1999b; Hetch et al., 1996b, 1999a; Conaway et 
al., 2000; Talalay and Fahey, 2001).
1.2 .1  Form ation o f ITC s
Isothiocyanates (Fig. 1.2) occur naturally in Brassica and cruciferous vegetables as 
glucosinolate precursors. More than 100 naturally occurring glucosinolates have been 
identified so far. Glucosinolates are polar, non-volatile and heat-stable compounds that 
have no or little biological activity in the absence of exogenous myrosinase. In intact 
plants, the glucosinolates are physically segregated from the plant enzyme myrosinase, 
but are brought into contact on disruption of plant tissue during harvesting, chewing or 
food processing. Following cleavage of the glucose and sulphate, the unstable aglycone 
intermediates undergo spontaneous intramolecular rearrangements to form, depending 
on reaction conditions and type of myrosinase, a variety of degradation products 
including lipophilic, volatile and biologically active ITCs (Hecht, 2000 and Fahey et ai.,
2001).
HO
^OH
OH
oso;
H2O glucose
MYROSINASE oso;
HSO;
R-N=G=S
Figure 1.2: Formation of ITCs from their glucosinolate precursors. Adapted from Hecht 
(2000)
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1 .2 .2  Chem opreventive a c tiv ity  o f  isothiocyanates
I t  is generally accepted that cancers induced by genotoxic chemicals begin with 
initiation, a process characterised by a DNA damage which remains unrepaired and/or 
misrepaired. Normally, most of such initiated cells are eliminated by apoptosis or by the 
cells of the immune system. Avoidance of apoptosis gives such initiated cells a growth 
advantage over the normal cells, which, as a resuit of cionai expansion, form foci of 
altered cells, a process called promotion. As the DNA of tum our cells is unstable and 
prone to further mutations, total loss of control over their survival, growth and 
proliferation will eventually result in malignancy.
The mechanism of anticarcinogenic activity of ITCs is multifactorial. I t  is believed that 
ITCs block emergence of carcinogen-induced aberrant cells as a result of their ability to 
modulate metabolism of carcinogenic compounds in favour of detoxification and 
excretion. Moreover, ITCs suppress tumour promotion and progression, operating mainly 
through a concerted modulation of multiple cellular signalling pathways involved in the 
regulation of apoptosis, cell growth, proliferation, differentiation and inflammation 
(Hecht et al., 2000; Myzak and Dashwood, 2006; Fimognari and Hrelia, 2007 and Juge 
et al., 2007).
1 .2 .3  ITC : In h ib itio n  o f  tum our in itia tion
It  is hypothesised that inhibition of cytochrome P450 and induction of phase I I  enzymes 
is one of the major mechanisms of tumour prevention by ITCs at the initiation stage 
(Thornalley, 2002; Hecht 1999). The notion that ITCs alter the balance between Phase 
I/Phase I I  metabolism to favour carcinogen deactivation has been strongly supported by 
experimental evidence. PEITC, consumed as a serving of watercress, enhanced urinary 
excretion of 4-m ethyln itrosam ino-l-(3-pyridyl)-l-bu tanone (NNK) in smokers (Hecht et 
ai., 1999a). Cruciferous vegetables administered simultaneously with 2-am ino-3-
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methyiimidazol [4 ,5 -f] quinoline (IQ ) inhibited formation of colonic and hepatic 
preneopiastic lesions in the F344 rats (Knasmuller, 2003). ITCs such as BITC and PEITC 
administered to rodents prior to, or around the tim e of, treatm ent with high doses of 
carcinogens, such as azoxymethane, NNK, dibenz[a,h]anthracene (DBA), 
benzo(a)pyrene (B (a)P ), 5-methylchrysene (5-M eC) and N-nitrosomethylbenzylamine 
(NMBA), have been shown to effectively inhibit tumorigenesis at different organ sites 
(Morse et al., 1991; Jiao et al., 1994; Chung et al., 1996; Hecht, 1999a and Hecht et 
al., 2002).
The chemopreventive activity of ITC appears to be tissue-specific, possibly reflecting the 
tissue-specific distribution and relative abundance of metabolizing enzymes. BITC 
administered to A/J mice concurrently with 5-MeC, DBA and B(a)P, potent animal lung 
carcinogens present in tobacco smoke, significantly reduced the incidence and 
multiplicity of the lung neoplastic lesions, while exerting no effect on stomach tumours in 
all PAH-treated groups (W attenberg, 1987).
1 .2 .3 .1  M odulation of Phase I  enzym e activ ities bv ITC
The majority of dietary, environmental and occupational carcinogens such as PAH, 
polycyclic aromatic amines (PAA), heterocyclic amines (HA) and nitrosamines are 
indirect acting carcinogens that require metabolic transformation by phase I  enzymes to 
ultimate carcinogens, a process referred to as bioactivation. Such reactive intermediates
are electrophilic in nature and covaiently bind to critical cellular macromolecules such as 
DNA and proteins. Although the majority of DNA adducts are effectively removed by the 
cell defence systems, some can be misrepaired and, if this occurs at critical sites of 
critical genes such as pro-oncogenes and/or tumour-suppressing genes, can give rise to 
initiated cells.
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Inhibition of Phase I  enzymes and consequent interruption of bioactivation pathway(s) of 
parent carcinogens by phytochemicais such as ITCs is associated with decreased DNA 
adduct formation, mutation frequency, and, ultimately, inhibition or retardation of 
tumorigenesis. I t  is feasible to assess the effects of ITC on the extent of DNA/protein 
adduct formation both in vitro and in vivo and this can be used as a biomarker of the 
carcinogen bioactivation/deactivation and, ultimately, of ITC effects on carcinogen 
metabolism. Pre-treatm ent with PEITC decreased the unscheduled DNA synthesis in 
mucosal fragments of hamsters following exposure to NMBA (Soit et al., 2003) and 
formation of B(a)P-induced DNA and protein adducts in A/J mice (Sticha et al., 2002). 
Similarly, PEITC reduced the levels of PhlP-DNA and PhlP-protein adducts (Dingley et 
al., 2003). Exposure to high levels of carcinogen(s) may overwhelm the cellular defence 
systems (Knasmuller et al., 1996). A study utilising dietary relevant doses of SFN and 
PhIP provided strong evidence that both ITC concentrations and levels of carcinogen 
affect the chemopreventive efficacy of ITCs. The highest degree of protection against 
PhlP-mediated DNA damage afforded by SFN was observed at the lowest concentrations 
of carcinogen (Bacon et al., 2003), highlighting the importance of assessment of the 
chemopreventive potential of ITC at dietary relevant levels of carcinogens and ITC.
Alternatively, a direct assessment of enzyme level/activity can be used as an indicator of 
chemopreventive potential of ITC. Individual ITCs vary considerably in their potency and 
selectivity as CYP inhibitors (Jiao et al., 1996; Smith et al., 1993; Smith et al., 1996). It  
was suggested that the length of aliphatic carbon chain might influence the potency of 
cytochrome P450 inhibition (Hamilton et al., 1994). The data supporting this theory 
indicated that the potency of arylalkyl isothiocyanates to inhibit rat C Y P lA l/2  and 
CYP2B1 increases if the length of the aliphatic carbon chain was Increased up to C6 
(Conaway et ai., 1996). In contrast, BITC, which has a very short a iky I chain, showed a 
potent mechanism-based inhibition of rodent C Y P lA l/2 , CYP2B1, CYP2E1 and CYP3A2 as
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weli as human CYP2B6 and CYP2D6 (Goosen et ai., 2001; Canistro et ai., 2004) and 
rabbit CYP2E1 (Moreno et al., 1999). While many ITCs were effective inhibitors of most 
cytochrome P450 enzymes in vitro (Conaway et al., 1996; Goosen et al., 2001; Moreno 
et al., 1999 and Canistro et al., 2004), the in vivo effects are inconsistent. ITCs have 
been shown to either induce or inhibit P450 content and activity, depending on the 
specific ITC studied, experimental conditions, treatm ent protocol and tissue examined. 
For example, a short-term  administration of PEITC to rodents resulted in inhibition of 
CYP2E1 and marked induction of CYP2B1 (Ishizaki et al., 1990). In contrast, hepatic and 
pulmonary CYP2E1 activity was elevated after chronic dietary administration of PEITC to 
mice (Smith et al., 1993). Dietary Brussels sprouts reduced IQ-initiated coion and iiver 
aberrant foci in rats despite elevated hepatic CYP1A2 activity (Kassie et al., 2003a). 
CYP1A2 activity was also elevated in humans after consumption of Brassica vegetables 
(Lampe et al., 2000). Both P450 inhibition and induction were observed in rats fed 
broccoli samples from different cultivars and growth conditions indicating complex 
interactions of the individual ITC (Vang et al., 2001b).
The cytochrome P450 enzymes have remarkable substrate specificity. Suppression of 
bioactivation can be highly specific and depends on the structures of both the ITC and 
the carcinogen, reflecting ITC-induced disruption of the bioactivation pathway specific to 
the carcinogen in question. For example, BITC was shown to be a highly effective 
inhibitor of B(a)P-initiated lung tumorigenesis, while PEITC effectively suppressed 
formation of NNK-induced neoplasm lesions (Conaway et al., 2000; Hecht, 2000; Hecht 
et al., 2002) and inhibited human CYPlA2-mediated oxidative metabolism of NNK 
(Smith et al., 1996). Although intake of a mixture of ITCs theoretically may have a 
synergistic effect or/and protect against a wider range of carcinogens, a mixture of 
dietary BITC and PEITC (1 and 3 pmol/g diet), failed to reduce the level of B(a)P-
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induced DNA and protein adducts, although It Inhibited the formation of NNK-lnduced 
adducts (Boysen et al., 2003).
1 .2 .3 .1 .1  M olecu lar m echanism s o f  cytochrom e P 450  inh ib ition  bv  IT C
Both mechanism-based and competitive Inhibition have been described as mechanisms 
of Cytochrome P450 enzymes Inactivation. PEITC competitively Inhibited NNK 
bloactlvatlon by mouse liver microsomes, but in vivo PEITC seems to act as a 
mechanism-based Inhibitor of NNK metabolism (Smith et al., 1993). Mechanism-based 
Inactivation Is defined as loss of catalytic activity of the P450 enzyme as a result of 
Irreversible adducts formation following bloactlvatlon of the enzyme's substrate to a 
reactive Intermediate. The mechanism-based Inhibitors are selective for specific P450 
enzymes and, unlike competitive Inhibitors, do not readily dissociate. Benzyl 
Isothlocyanate (B ITC), for example, was a mechanism-based Inactivator of rabbit 
CYP2E1 (Moreno et al., 1999), rat C Y P lA l, CYP1A2 and CYP2B1 as well as human 
CYP2B6 and CYP2D6 (Goosen et al., 2001). BITC Is metabolised to a reactive benzyl 
cyanate and benzylamlne that covalently bind to and Inactivate the enzyme. The 
covalent binding prevents further substrate binding and Is thought to occur at the active 
site of the apoprotein (Goosen et al., 2001; Moreno et al., 1999). The Inactivation of 
microsomal P450s caused by covalent modification or destruction of the haem moiety 
has not been observed experimentally (Goosen et al., 2001). Other enzymes, such as 
human CYP1A2 and CYP2C9, appear to be Inhibited by PEITC competitively, whereas
human CYP3A4 was Inhibited both competitively and non-competetlvely (Nakajima et 
a!., 2001).
1 .2 .3 .1 .2  E ffect o f  th io l conjugates o f IT C  on cytochrom e P 450
Thiol conjugates of ITCs have also been shown to Inhibit CYP enzymes, although they 
are less potent Inhibitors than their parent compounds. Thiol conjugates of ITCs Inhibited
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CYP2E1, C Y P lA l/2  and CYP2B1 (Jiao et a!., 1996; Conaway et a!., 1996). The Inhibitory 
potency of Individual thiol conjugates In aqueous solutions Is determined by the rate of 
their deconjugation to release the parent ITC. Inhibition of CYPIA and CYP2B by 
aqueous dithlocarbamates (DTC) was greater with Increased pre-lncubatlon time and 
positively correlated with the extent of decomposition of the ITC conjugates, Indicating 
that both the structure of parent ITC and the rate of the conjugate dissociation Influence 
enzyme Inhibition. However, In the presence of physiological concentrations of GSH, 
deconjugation of DTC Is expected only to be marginal. I f  the rates of dissociation of 
thIol-ITCs in plasma and tissues are slow, as anticipated, then this would suggest that 
ITC-lnduced Inhibition of P450 enzymes Is unlikely to be a principal mechanism of their 
chemopreventlve activity (Conaway, 2001).
1 .2 .3 .2  ITC; e ffec t o f phase I I  m etabolism
Reactive metabolites and ultimate carcinogens, generated as a result of bloactlvatlon by 
P450s, may be detoxified by conjugation with glucuronic acid, GSH and sulphate, 
catalysed by phase I I  enzymes. The biological purpose of conjugation Is to Increase 
polarity and excretion of highly lipophilic compounds such as most carcinogens. The 
relative abundance of Phase I  and I I  enzymes Is critical and carefully regulated. ITCs 
such as PEITC have been shown to shift this balance in favour of conjugating enzymes.
1 .2 .3 .2 .1  M odulation o f  phase I I  enzym es in an im als  b v  ITC s
Feeding Brussels sprouts to rodents resulted In upregulatlon of hepatic UGT and 
decreased IQ-Induced damage to hepatocytes (Humblot et al., 2004 ). PEITC Induced 
activity/levels of GST, QR and UGT In the rodent liver, lung and gastric mucosa (Van 
Lleshout et al., 1998a, 1998b; Guo et al., 1992 and Kassle et al., 2003a). AITC  
significantly Induced QR and GST In rat urinary bladder (Munday and Munday, 2002). 
The cysteine conjugates of BITC and PPITC similarly Induced GST In many tissues of
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female A/J mice (Zheng et a!., 1992), Indicating that certain ITC metabolites retain their 
bloactlvlty.
The Induction of phase I I  enzymes by ITC appears to be tissue-specific. For example, 
AITC significantly Induced QR and GST In rat urinary bladder. Moreover, while Induction 
of QR reached a plateau after 2 weeks of treatm ent with AITC, the activity of bladder 
GST continued rising even after 21 days, suggesting that duration of treatm ent also 
Influences the extent of Phase I I  enzyme Induction (Munday and Munday, 2002). A 
single oral administration of PEITC to rats (1 mmol/kg bw) resulted In significant 
elevation of the liver QR (5-fold) and GST activities (1 .5-fo ld ) whereas activities of these 
enzymes were not significantly affected In the lung (Guo et al., 1992). GSTTl was 
significantly elevated In gastric mucosa but not In the esophagus, colon, or liver of male 
W/A rats after dietary administration of PEITC (van Lleshout et al., 1998a; van Lleshout 
et al., 1998b).
1 .2 .3 .2 .2  Phase I I  enzym e m odulation in hum ans bv IT C
Dietary consumption of vegetables rich In glucoslnolates by humans has also been 
associated with phase I I  enzyme Induction, modulation of metabolism and, ultimately, 
excretion of carcinogens and hence decreased risk of cancer. Consumption of two ounces 
of watercress, which contains gluconasturtlln, the glucoslnolate precursor of PEITC, 
Increased the urinary excretion of NNAL and Its glucuronlde, the metabolites of the 
tobacco-specific nitrosamlne NNK In smokers (Hecht et al., 1995). A recent 
epidemiological study In Chinese men has found a link between concentration of ITC 
metabolites In urine, G S T M l/T l polymorphism and Incidence of lung cancer. The 
G S T M l/T l-nu ll smokers that had detectable levels of ITC metabolites In their urine were 
at the lowest risk of lung cancer, while G S T M l/T l-n u ll smokers who had no detectable 
urinary ITC metabolites were at the greatest risk. This Is the first epidemiological study
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that established a direct link between ITCs and reduced risk of lung and colon cancer. 
Interestingly, individuals with the wild type of G S T M l/T l genes had no appreciable 
protection from the consumption of Brassica vegetables. I t  has been hypothesised that 
the potent chemopreventlve activity of ITCs observed In G S TM l/T l-deflc len t Individuals 
was due to decreased excretion of ITCs so that their tissue concentrations would be 
considerably Increased, and/or elevated global GST activity that might be sufficient to 
compensate for the function of missing enzymes encoded by silenced genes (Seow et al,
2002). Moreover, ITC-lnduced Increase In plasma GSTA and peripheral lymphocyte 
GSTM was more pronounced In female than In male subjects (Thornalley, 2002). The 
major limitation of the above studies Is lack of differentiation between Individual 
glucoslnolates and ITCs, because the cyclocondensation method often used to estimate 
ITC content does not allow differentiating between Individual ITCs. The biochemical 
effects observed In human volunteers after consumption of Brassica vegetables are most 
likely to be a net result of bloactlvlty of the complex mixture of all plant glucoslnolates. 
In other words, no individual glucoslnolate can account for the cancer chemopreventlve 
activity observed after consumption of Brassica vegetables (Vang et al., 2001a). For 
example, watercress contains at least three phase I I  enzyme Inducers, two of which, 7- 
methylsulflnylheptyl and 8-methylsulflnyloctyl Isothlocyanates, are 10-25 times more 
potent than PEITC (Rose et al., 2000).
1 .2 .3 .2 .3  M echanism  o f  phase I I  induction b v  IT C
In  vitro studies have shown significant differences In the phase I I  enzyme Inducing 
potential of Individual ITCs which appears to correlate strongly with the Intracellular 
accumulation of the ITCs. In turn, the extent of the Intracellular accumulation of the ITC  
appears to be dependant on the ITC structure. The length of the side chain Is of little 
Importance while the oxidation state has a pronounced effect on the Inducer activity as 
can be Illustrated by comparing the Inducing potency of erucin and SFN, the latter being
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more than twice as potent as erucin at Inducing OR and GST activities In the Murine 
Hepatoma Cells (Zhang et al., 1992).
ITCs are highly reactive towards GSH. Among ITCs, erucin and SFN have the highest 
rate of spontaneous, non-enzymatic reaction with GSH (Kolm et al., 1995). The 
Intracellular accumulation of ITCs is accompanied by a rapid decline In the GSH levels 
and brings about oxidative stress. Experimentally Induced depletion of GST In Hepa cells 
prior to treatm ent with ITCs enhanced their QR and GST Inducing potency (Zhang and 
Talalay, 1998). Moreover, low llpophlllclty and high reactivity towards GSH have been 
shown to Increase Inhibitory activity of ITC toward NNK-lnltlated lung tumorlgenesis 
(Jiao et al., 1994), supporting the central role of GSH depletion and oxidative stress In 
Induction of phase I I  enzymes by ITCs. Being highly reactive towards cellular GSH, the 
ITCs rapidly accumulate mostly as GSH conjugates, also known as dithlocarbamates 
(DTCs), and Induce depletion of cellular GSH following transporter-mediated expulsion of 
DTCs out of the cell (Zhang, 2000). ITCs were characterised as monofunctional Inducers 
that selectively upregulate Phase I I  enzymes without concurrent Induction of Phase I 
enzymes (Mlao et al., 2004). The 5'-flanklng regulatory region of genes encoding phase 
I I  enzymes such as OR and GST contain Antloxldant Response Element (ARE), a binding 
site for the nuclear transcriptional factor Nrf2 (erythrold p45-related factor-2) activated 
by ITCs (Thornalley, 2002).
ITC
Keapl
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Figure 1.3: Activation by isothiocyanates of Nrf2 pathway regulating expression genes 
encoding phase I I  enzymes
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The Nrf2 normally resides In the cytosol bound to Kelch-llke ECH-assoclated protein 1 
(K eap l). In response to oxidative stress, Nrf2 dissociates from K eapl and translocates 
to the nucleus where It binds to ARE sequence In the upstream promoter of phase I I  
genes (Fig. 1 .3). The molecular mechanism of N rf2-K eapl complex dissociation In 
response to ITC-lnduced oxidative stress Is not fully understood (Thornalley, 2002).
1 .2 .4  ITC -associated  inh ib ition  o f  tum our progression
In addition to the altered ratio of phase I/phase I I  enzymes that suppresses 
carcinogenesis at the Initiation phase, ITCs inhibit experimentally induced tumorlgenesis 
at the post-lnltlatlon and promotion phases. Dietary BITC and PEITC Induced apoptosis 
In the lungs of rats following exposure to cigarette smoke for 28 consecutive days 
(D'Agostlnl et al., 2001). Furthermore, orally administered NAC conjugates of BITC and 
PEITC also decreased a multiplicity of (B(a)P)-lnltlated lung adenomas In A/J mice when 
administered using a post-lnltlatlon protocol. The Inhibition of tumorlgenesis was 
attributed to the Induction of apoptosis (Yang et al., 2002). ITC-lnduced apoptosis and 
Inhibition of cell proliferation have been reported In a number of studies (Huang et al., 
1998; Chen et al., 1998; Yu et al., 1998; Gamet-Payrastre et al., 2000).
1 .2 .4 .1  P ro-apoptotic  activ ity  o f ITCs
Pro-apoptotic activity of ITC Is another Important aspect of the chemopreventlve 
potential of ITCs as the majority of human cancers are resistant to apoptosis. There Is 
some evidence that ITCs preferentially Induce apoptosis In cells with malignant 
genotypes. For example, PEITC and AITC-lnduced apoptosis and growth Inhibition was 
> 10-fold greater In human leukaemia (HL60) cells compared with normal cells (Xu and 
Thornalley, 2000; Xu and Thornalley, 2001a).
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Commitment of cells to apoptosis and Inhibition of progression through the cell cycle 
appear to Involve ITC-lnduced protein modification as a result of GSH depletion and 
oxidative stress (Xu and Thornalley, 2000; Pa yen et al., 2001). It  has been suggested 
that ITC-assoclated activation of caspases and mitogen activated protein kinase (MAPK) 
family members occurs as a result of thiol modification and subsequent activation of 
protein tyrosine kinase and/or Inhibition of protein tyrosine phosphatase activity and, 
ultimately. Increased overall protein tyrosine phosphorylation (Xu and Thornalley, 
2001b). Additionally, ITCs may alter expression of genes associated with apoptosis and 
regulation of cell progression through the cell cycle through change In the activity of 
stress-response transcription factors such as (activator protein) AP-1 and NF-kB, the 
downstream targets of MAPK, as well as transcription and/or activity of p53 protein 
(Yang et al., 2002 and Juge et al., 2007).
ITC-medIated apoptosis and Inhibition of cell cycle progression associated with ITCs 
appears to Involve Induction of oxidative stress caused by GSH depletion following 
expulsion of the ITC-GS conjugates through the MRP protein channel (Xu and 
Thornalley, 2000; Payen et al., 2001). PEITC-lnduced apoptosis correlated with initial 
depletion of Intracellular GSH and accumulation of the GSSG and GSH conjugates of 
PEITC, and was prevented by high concentrations of GSH (Xu and Thornalley, 2000; Xu 
and Thornalley, 2001a). The data on Inhibitory activity of thiol-contalning antloxldant N- 
acetyl cysteine on pro-apoptotic effects of ITCs are discordant: some studies reported 
Inhibition (Chen et al., 1998), whereas others found that exposure to high 
concentrations of N-acetyl cysteine had no effect on the activation of MAPK pathway(s) 
(Xu and Thornalley, 2001b).
The mechanism of apoptosis Induced by ITCs Is not fully elucidated. ITCs have been 
shown to Induce apoptosis by several distinct pathways, possibly activating more than
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one pathway simultaneously. The MAPK pathway was one of the first pathways found to 
be activated by ITCs. Alternatively, ITC can Induce apoptosis by activating the extrinsic 
or "death receptor" (DR) pathway or through activation of the mitochondrial pathway. 
Involving release of the mitochondrial cytochrome C Into the cytosol, and P53 pathway 
(Juge et al., 2006 and FImognary and Hrella, 2007).
1 .2 .4 .2  Cell cycle arres t
Inhibition of progression through the cell cycle Is associated with reduction In DNA 
synthesis and apoptosis. Progression through the cell cycle requires the presence of 
specific complexes of cyclln-dependent kinases (CDK) and their cycllns formed at specific 
stages of the cell cycle. The Inhibition and activation of cycllns and CDK and, ultimately, 
the formation of the complexes are controlled by phosphorylation. ITCs Induce cell cycle 
arrest that Is characterised by the accumulation of cells at different stages of the cell 
cycle and sensitisation of cells to apoptosis, possibly as a result of ITC-lnduced 
suppression of transcription and /o r  function of cyclln-dependent kinases and up- 
regulated transcription of cycllns. The effects of ITCs on cell growth and cell cycle 
progression were Initially studied In HeLa cells. The accumulation of cells In the G2 /M
phase Interface and Inhibition of cell growth was observed after treatm ent with AITC, 
BITC, or PEITC. These results suggest that ITC Inhibit progression of cells through the 
cell cycle. Inhibiting cell growth and predisposing cells to apoptosis (Hasegawa et al., 
1993; Tang and Zhang, 2004).
1 .2 .5  ITC -induced  ox idative  stress
Oxidative stress Is a condition arising In a cell from an Imbalance between generation of 
free radicals and reactive oxygen species (ROS) and the ability of the cell antloxldant 
system to render them harmless. Free radicals and ROS are continuously produced as 
unavoidable by-products of cellular life processes such as substrate oxidation by P450
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enzymes, mitochondria and peroxisomes. Mild and transient oxidative stress Induced by 
low, dietary relevant doses of ITCs has been shown to alter cellular signalling pathways 
and transcription of genes encoding Phase I I  response proteins (conjugating, antloxldant 
and cellular thiol-syntheslsing enzymes). Such transient alterations In cellular 
homeostasis Induced by ITCs at non-toxic levels boost cell antloxldant capacity and, 
consequently, diminish damage of tissues by chemical carcinogens and ROS (Fahey and 
Talalay, 1999 and Mu rata et al., 2000).
In contrast to the beneficial effects of mild changes In the cellular redox status In 
response to non-toxic concentrations of ITCs (In the lower pM range), toxic levels of 
ITCs are likely to result In excessive depletion of cellular GSH leading to extensive 
oxidative stress that exceeds cell antloxldant defences and leads to mutagenicity. 
Induction of apoptosis and frank necrosis (Musk and Johnson, 1993). Treatm ent of cells 
with low, dietary achievable concentrations of ITCs Induces only transient depletion of 
GSH levels followed by rebound elevation after 24h of exposure. While this Is true for 
low concentrations of ITCs, exposure to high concentrations (5 0 -5 0 0  pM) resulted In 
profound depletion of GSH levels and cytotoxicity (Zhang, 2000).
1.3 SFN as a Potential Chem opreventlve Agent
SFN (Fig. 1.5) was first Isolated from broccoli and Identified as a potential 
chemopreventlve agent In 1992 (Zhang et al., 1992). Glucoraphanin, the glucoslnolate 
precursor of SFN, Is the most abundant phytochemical found In cruciferous vegetables 
such as broccoli, Brussels sprouts, cabbage, and other cruciferous vegetables (Carlson et 
al., 1981; Zhang et al. 1992). A combination of factors such as prevalence of SFN In the 
Western diet, low toxicity and potent chemopreventlve activity render SFN the most 
Important ITC In relation to the human diet. Epidemiological data reveal an Inverse 
relationship between high Intake of cruciferous vegetables and risk of lung (Spitz et al.,
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2000 and Zhao et al., 2001 ), colorectal, breast (Ambrosone et al., 2004 ), bladder (Zhao 
et al., 2007) and prostate cancer (Joseph et al., 2004). The experimental evidence 
supports a direct causal relationship between administration of SFN and suppression of 
chemically Induced tum our development In animal models. SFN Inhibited Incidence and 
growth of m am m ary and colon tumours In rodents (Zhang et al., 1994; Chung et al, 
2000, Shen et al., 2007). Treatm ent of rodents with SFN resulted In suppression of 
development of B(a)P-lnltlated forestomach (Fahey et al., 2002) and lung tumours 
(Hecht et al., 2002). SFN also suppressed formation of Intestinal polyps In ApcMln/+ 
mice (Hu et al., 2006) and azoxymethane-lnduced ACF In mouse colon (Chung et al., 
2000). Similarly, SFN protected against development of DMBA-lnduced mammary 
tumours (Zhang et al., 1994). Even topical application of SFN antagonised MBA-Induced 
(Xu et al., 2006) and UV-llght Induced (DInkova-Costova, 2006) skin tumourlgenesis In 
rats.
Similarly to the other ITCs with chemopreventlve activity, SFN evokes plelotropic 
biological responses that reflect the chemopreventlve activity of this phytochemical at 
different stages of carcinogenesis (Fig. 1 .4). The mechanism responsible for the 
chemopreventlve effects of SFN at the Initiation stage appear to Involve suppression of 
the bloactlvatlon of carcinogens coupled with enhanced detoxification and elimination. At 
the promotion stage, SFN exerts chemoprotectlve activity through Induction of 
apoptosis, cell cycle arrest (Juge et al., 2006 and FImoganarl and Hrella, 2006) and 
permanent differentiation of tumour cells (Lee et al., 1999). Additional mechanisms 
Include Inhibition of histone deacetylase (HDAC) (Myzak et al., 2004, Myzak et al., 
2006a, 2006b), antl-lnflam m atory activity (Wu et al., 2004, RItz et al., 2006 and Talalay 
et al., 2007), antibacterial activity (Fahey et al., 2002) and upregulatlon of multldrug 
resistance-associated proteins (Payen et al., 2001). Finally, recent studies suggest that 
SFN also retards tumour progression as a result of Inhibition of anglogenesis (BertI et
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al., 2006 and Jackson et al., 2007) and suppression of activation of matrix 
metailoproteinases (Thejass and Kuttan, 2006).
Increased
apoptosis
Inhibition of ^  Induction of
HDAC ^  : .▼ differentiation
Induction of   SFN  ^  Supresslon of
detoxification and anglogenesis and
antloxldant . anti-inflammatory
enzymes #  \  activity
Suppressed Cell cycle arrest and 
metabolic Inhibition of cell
activation growth
Figure 1.4: SFN: multiple targets for cancer chemoprevention
1.3 .1  M odulation o f  cytochrom e P 450  expression by  SFN
Selective Inhibition of specific P450s coupled with concomitant Induction of Phase I I  
enzymes Is thought to be one of the most Important mechanisms of the 
chemopreventlve activity of SFN during the Initiation stage of tumourlgenesis. Several in 
vitro studies have shown selective Inhibition of specific cytochrome P450 enzymes. SFN 
Inhibited activities of C Y P lA l/2  and CYP2B1/2 enzymes In rat hepatocytes and CYP3A4 
In human hepatocytes (Maheo et al., 1997, Zhou et al., 2007). The activity of CYP1A2 
and CYP3A4 enzymes was also Inhibited by SFN In parenchymal liver cells (Jiao et al.,
1996). Unlike BITC, which Is a potent mechanism-based Inactivator of CYP2E1, SFN was 
a weak competitive Inhibitor of this enzyme (Barcelo et al., 1996). In human liver cells, 
SFN at low concentrations reflecting human Intake Inhibited CYP1A2 and CYP2E1, the 
major catalysts of bloactlvatlon of IQ and NDMA respectively, as exemplified by 
Inhibition of DNA damage (Barcelo et al., 1998). In a different study, however, even 
relatively high concentrations of SFN (40 pM) failed to alter the activity of human 
cytochrome P450s (Langouet et al., 2000).
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SFN appears to be a rather weak inhibitor of cytochrome P450 enzymes. A 50%  
reduction in activity of rat CYP2E1 was observed at SFN concentration of 68 pM (Barcelo 
et al., 1996). At lower concentrations, (up to 40 pM), SFN had no effect on activity of 
either of the five m ajor human cytochrome P450 studied, including C Y P lA l, CYP1A2, 
C YPIB I, CYP2E1 and CYP3A4 (Langouet et al., 2000). At plasma levels achieved by 
dietary Intake (2 -7  pM), SFN failed to modulate expression of genes encoding for Phase I 
enzymes In human gastric mucosa (Gasper et al., 2007).
Contrary to the notion that SFN Is a monofunctional Inducer that selectively Induces 
expression of Phase I I  enzymes without concurrent Induction of Phase I  enzymes (Zhang 
et al., 1992 and Mlao et al., 2004), several cytochrome P450 enzymes were shown to be 
Induced by SFN and Its glucoslnolate precursor glucoraphanin, suggesting the possibility 
of a cross-talk between the antloxldant response element (ARE) and xenoblotic response 
element (XRE) pathways. SFN Induced CYP1A2 apoprotein levels (Yoxali et al., 2005) 
and up-regulated expression of genes encoding CYPIA, CYP2B and CYP3A In rat livers 
(Hu et al., 2004). Both, single and repeated oral administration of glucoraphanin to rats 
also resulted In upregulatlon of activity and apoprotein levels of hepatic C Y P lA l/2 , 
CYP3A2 and CYP2E1 (Perocco et al., 2006) and pulmonary C Y P lA l/2 , CYP2B1/2, 
CYP3A1/2 and CYP2C11 (Paollnl et al., 2004). Collectively, these data suggest that 
Inhibition of cytochrome P450 enzymes by dietary SFN plays, at best, a minor role In the 
chemoprevention afforded by this phytochemical.
1 .3 .2  E ffect o f  SFN on Phase I I  enzym es
Phase I I  enzyme Inducer activity appears to correlate well with the antlcarclnogenic 
potential of ITCs (Talalay and Fahey, 2001) of which sulforaphane [(-)-l-lso th locyanate - 
4-(m ethylsulflnyl)butane] Is the most potent Inducer Identified so far (Zhang et al., 
1992; Zhang and Talalay 1998; Brooks et al., 2001 and Zhang and Callaway, 2002).
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SFN suppressed development of B(a)P-lnduced forestomach tumours In ICR mice with 
functional nrf2 gene, the product of which regulates transcription of phase I I  enzymes. 
Antlcarclnogenic activity correlated with Phase I I  enzyme Induction and was abrogated In 
mice lacking the Nrf2 gene (Fahey et al, 2002). Another study showed that Nrf2-null 
mice had a higher burden of B(a)P-lnduced tumours and lower basal GST activity, 
underscoring the role of Inducible phase I I  enzymes In ITC-m edlated chemopreventlve 
effects (Ramos-Gomez et al., 2001).
QR protects the cell from quinone-semlqulnone redox cycling and generation of ROS 
through obligatory two-electron reduction of exo- and endogenous quinones. QR Is 
Induced coordlnately with other ARE-regulated phase I I  and antl-oxldant enzymes and 
may be used as a blomarker for global phase I I  enzyme Induction (Jeong et al., 2006).
SFN Is a potent Inducer of phase I I  enzymes, such as QR, UGT and GSTs In primary rat 
and human liver hepatocytes, various cell lines and In a number of organs Including skin, 
liver, lung, duodenum, forestomach, stomach, small Intestine and urinary bladder 
following administration to animal models (Zhang et al., 1992; Zhang et al., 1994; 
Gerhauser et al., 1997; Fahey et al., 1997; Gao and Talalay, 2004; Maheo et al., 1997; 
Rose et al., 2000; Brooks et al., 2001; MIslewIcz et al., 2004; Munday and Munday, 
2004; RItz et al., 2006 and DInkova-Kostova et al., 2007) as well as In the skin of 
human volunteers (Xu et al., 2006 and DInkova-Kostova et al., 2007).
Although after a single administration ITCs are rapidly conjugated and excreted almost 
completely during the Initial 24h, their biological effects are prolonged because Induced 
enzymes have a half-life of several days and can cope with a wide range of toxins. 
Significant elevation of QR activities In human adult retinal pigment epithelial cells, 
ARPE-19 cells, human HaCaT keratlnocytes and L1210 mouse leukemia cells treated for
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24 h with SFN was associated with markedly reduced cytotoxicity of the oxidative 
stressors (menadione, ferf-butyl hydroperoxide, 4-hydroxynonenal, and peroxynltrlte). 
The protection lasted several days after SFN removal until GSH levels and QR activity 
returned to control levels (Gao et al., 2001).
The induction of specific classes of GST appears to be tissue-specific. The SFN analogue 
compound-30 potently elevated levels of rodent GST0 In the stomach and GSTA In the 
small Intestine and liver while GSTM and GSTP were Induced In the stomach and small 
Intestine (van Lleshout et al., 1998a; van Lleshout et al., 1998b). The potency of SFN to 
upregulate the GST mRNAs also varied depending on the specific class of the enzyme. 
For example, SFN upregulated G S TA l/2  and GSTPl mRNA levels, while transcription of 
GSTMl remained unaltered (Maheo et al., 1997). The Increased total expression/activity 
of GSTs may compensate for the lack of activity of a missing class of GST. GSTMl and 
GSTTl null polymorphism are present In at least 20%  of Individuals In most populations. 
Regular consumption of cruciferous vegetables by smokers, who are exposed to tobacco 
carcinogens such as PAHs, with one or both non-functloning genes encoding GSTM l and 
GSTTl, Is associated with a decreased risk of lung cancer (Sapone et al., 2007).
1 .3 .3  M odulation o f  ce iiu iar redox s tatus by  SFN
Mammalian cells generate ROS during normal aerobic metabolism such as cellular 
respiration and biotransformation of endogenous and exogenous chemicals. However, 
cells are equipped with complex mechanisms for neutralising ROS and free radicals 
Including recycled ROS scavengers (cytoplasmic GSH and nuclear thioredoxin), 
antloxldant enzymes (superoxide dismutases, catalase, glutathione reductase, 
thioredoxin reductase and various types of peroxidases) and phase I I  enzymes (UGT, 
GSTs and QR). Plant-derived phytochemicals can enhance cell antloxldant capacity 
directly by scavenging ROS, or Indirectly by modulating expression of genes coding for
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antloxldant and conjugating enzymes and cellular thiols. ITCs, Including SFN, are Indirect 
antloxldants that are not consumed themselves In redox reactions and exert their 
protective long-lasting effects even at low, physiologically achievable levels.
1 .3 .4  A ntim utagen ic  effects  o f  SFN
The level of formation of DNA adducts following exposure to genotoxic carcinogens Is 
one of the blomarkers of their bloactlvatlon. Although most DNA adducts are removed by 
the cell DNA repair systems, the level of the DNA adduct formation can be used to 
assess the overall bloactlvatlon of carcinogens and their detoxication by 
chemopreventlve agents. Even at low concentrations (up to 2 pM), SFN substantially 
suppressed formation of BaP- and 1,6-dlnltropyrene-lnduced DNA adducts In the human 
mammary epithelial cell line MCF-lOF and In cultured human epithelial cells BEAS-2B 
(Lee at al., 1999). The observed reduction In genotoxiclty positively correlated with a 
potent Induction of QR and GST expression (Singletary and MacDonald, 2000). SFN also 
afforded effective protection against formation of PhlP-lnduced DNA adducts In human 
hepatocytes. The decreased level of NDA adducts was accompanied by Induction of 
G S T IA I. Inhibition of genotoxiclty of PhIP was ascribed to the Increased detoxication of 
the carcinogen by Induced conjugating enzymes, as SFN had no effect on CYP1A2 
activity, an enzyme catalysing the first step In the bloactlvatlon of the parent PhIP, and 
failed to reduce levels of PhlP-DNA adducts after binding had occurred (Bacon et al., 
2003).
Inhibition of selective rat and human CYPs Including CYP1A2 and CYP2E1 by SFN has 
also been associated with the antimutagenic effect of SFN. At low concentrations, 
reflecting human Intake (0 .1 -1 0  pM), SFN Inhibited IQ - and NDMA-lnduced DNA damage 
In human liver cells expressing human CYP1A2 and CYP2E1 respectively (Barcelo et al., 
1998). Sulphoraphene, a structural analogue of SFN, at concentrations ranging from 100
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to 500 nmol/plate Inhibited the mutagenicity of a wide range of food-derived 
heterocyclic amines Including IQ and PhIP In the Ames test In the presence of Aroclor 
1254-lnduced rat liver 59 , Indicating Inhibition of CYPlA2-m edlated bloactlvatlon of the 
heterocyclic amines (Shlshu et al., 2002).
1 .3 .5  SFN -induced apoptosis and  ceii cycie a rres t
SFN Induced cell cycle arrest and/or apoptosis In mouse embryonic fibroblasts, non­
transformed human T-lymphocytes, human medulloblastoma cells, human glioblastoma 
cells and In many cell lines (Gamet-Payrastre et al., 2000; Bonnesen et al., 2001; Chlao 
et al., 2002; Jackson and Singletary, 2004; GIngras et al., 2004; FImognarl et al., 2002; 
MIslewIcz et al., 2004; Singh et al., 2004; Tang and Zhang, 2004; Choi and Singh, 
2005; Karmakar et al., 2006).
1 .3 .5 .1  SFN-induced ox idative  stress and qenotoxicitv
Very high concentrations of SFN (> 1 0  mmol) Induced excessive oxidative stress and 
ROS-medlated mutagenicity In cultured yeast cells (Paollnl et al., 2004). However, SFN 
failed to Induce a mutagenic response when tested In the Salmonella assay (Moreno et 
al., 1999). At doses ranging from 0.1 to 10 pM, SFN was neither cytotoxic nor mutagenic 
to human liver cells (Barcelo et al., 1998).
1 .3 .6  In h ib itio n  o f  tu m o u r prom otion and  progression
Other putative mechanisms that might contribute to the chemopreventlve activity of SFN 
Include modulation of signalling pathways Involved In cell differentiation and 
maintenance, antibacterial activity and suppression of anglogenesis.
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1.3 .6 .1  Induction  o f d iffe ren tia tion
SFN has been shown to Induce terminal differentiation of HL-60 cells possibly as a result 
of Inhibition of ornithine decarboxylase (ODC) activity In cultured mouse epidermal cells 
ME 308. ODC Is a rate-llm lting enzyme In the synthesis of polyamines that are Involved 
In cell proliferation, differentiation and neoplastic transformation (Lee et al., 1999).
1 .3 .6 .2  A ntibacteria l activ ity
SFN was bactericidal to Intracellular H. pylori of human epithelial cell line HEp-2 and was 
a potent bacteriostatic agent against 3 reference strains and 45 clinical Isolates of H. 
pylori, Irrespective of their resistance to conventional antibiotics. The antibacterial 
activity of this phytochemical might contribute to protection against gastric cancer In 
humans (Fahey et al, 2002).
1 .3 .6 .3  Induction  o f Phase I I I  transporters
In addition to the modulation of Phasel/Phase I I  enzyme levels/activity, treatm ent with 
SFN upregulated expression of the multldrug resistance-associated protein (MRP2) In 
primary rat and human hepatocytes. MRP2 Is an 190 kDa export pump Integrated 
predominantly Into the bllllary domain of the plasma membrane of hepatocytes and Is 
responsible for the efflux of reactive electrophlllc carcinogens out of the cell before they 
attack cellular DNA. Increased levels of export pump protein MRP2 may contribute to the 
chemopreventlve activity of SFN by facilitating bllllary excretion of carcinogens. 
Additionally, Induced expression of MRP may facilitate rapid expulsion of GS-SFN adducts 
and trigger apoptosis (Payen et al., 2001).
1 .3 .6 .4  M odulation o f transcriptional activ ity
In the nucleus, DNA Is associated with histones. Acetylatlon/deacetylatlon of nuclear 
histones Is an Important mechanism of regulation of gene transcription and often
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malfunctions In cancerous cells. Histone deacetylases (HDAC) catalyse acétylation of 
histones, a reaction that confers a negative charge on positively charged histones, 
breaking electrostatic Interaction between histones and DNA, causing local relaxation of 
the chromatin and allowing the transcriptional factors and transcriptional machinery to 
access the DNA. Recently, SFN has been shown to Inhibit HDAC activity both in vitro and 
in vivo (Myzak et al., 2004, 2006a and 2006b). HDAC Inhibitors are thought to act 
through enhanced transcription of Important tumour suppressing genes that might be
silenced In cancer cells such as the cyclln-dependent kinase Inhibitor p 2 i^ 'P l /^ 3 f l^  and 
genes promoting apoptosis, cell cycle arrest and terminal differentiation (Higdon et al., 
2007).
1 .3 .6 .5  A n ti-in flam m ato rv  activ ity
Excessive generation of pro-inflammatory cytokines such as TNF-c and enzymes such as 
nitric oxide synthase, cyclooxygenase and prostaglandins Is associated with suppressed 
Immune response. Inhibition of apoptosis, enhanced cell proliferation and Increased 
Invasiveness of cancer cells (Nuge et al., 2007). Pre-treatm ent with SFN suppressed pro- 
inflammatory effects of diesel extract In BEAS-2 cells (RItz et al., 2006), protected 
human retina cells RPE against photooxldatlve damage (Gao and Talalay, 2004) and 
decreased oxidative stress and Infiltration with macrophages In cardiovascular and 
kidney tissues of rats prone to hypertension and stroke (Wu et al., 2004). Topical 
application of a broccoli sprouts extract protected mouse and human skin from UV 
radiation damage (Talalay et al., 2007).
1 .3 .6 .6  Suppression o f anqioqenesis
Growth of tumours requires development of a new Internal capillary network to supply 
oxygen and nutrients. Inhibition of anglogenesis by SFN has been recently reported In 
Immortalized human microvascular endothelial cells HMECC-1 (BertI et al., 2006),
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human umbilical vein endothelial cells and mice bearing plugs Impregnated with vascular 
endothelial growth factor (Jackson et al., 2007)
1.4 D ietary In ta k e  o f ITCs
Total human Intake of glucoslnolates from raw cruciferous vegetables varies between 8 
and 300 mg per day per person In the UK, the Netherlands, Canada, the United States, 
and In Japan (Sones et al., 1984; Krul et al., 2002) and can be as high as 350 mg In 
Singapore (Zhao et al., 2001).
In Western countries, Brassica vegetables are consumed mostly cooked. Method of 
cooking can significantly Influence glucoslnolate Intake. Almost 90%  of all glucoslnolates 
are lost due to leaching Into boiling water. Other cooking methods such as microwaving, 
stIr-fryIng or steaming, retain glucoslnolates (Song and Thornalley, 2005). Excessive 
microwaving, however, can significantly diminish glucoslnolate content. The estimated 
Intake of SFN was 3-fold greater when the duration of broccoli microwaving was reduced 
from 5.5 to 2 mln (Rungapamestry et al., 2007). Substantial quantities of glucoslnolates 
are also lost during storage of cruciferous vegetables. For example, up to 26%  of 
broccoli glucoslnolate were lost after just 7 days of storage (Song and Thornalley, 2007). 
Moreover, since cooking deactivates plant myroslnase, only 10 -20%  of glucoslnolates 
are expected to be converted to ITCs almost exclusively by gut bacteria (Conaway et al., 
2000 and Shapiro et al., 2001).
Dietary Intake of SFN can result In plasma concentrations of SFN In the lower pM range 
(Ye et al., 2002 and Song at al, 2005 and Gasper et al., 2005 ), although the Intake of 
specific glucoslnolates and of their corresponding ITC Is difficult to calculate because of 
wide variations In the dietary habits among Individuals In different geographical areas 
and vast variations In glucoslnolate and ITC content. Different species and even different
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cultivars of the vegetable vastly differ in the type, proportion and level of glucoslnolates. 
These are further Influenced by the environmental and agricultural conditions during 
cultivation, duration and conditions of storage, age and part of the plant used. About the 
same amount of glucoraphanin can be provided by a lOg portion of young plants (young 
broccoli sprouts) containing 10-100 times higher levels of glucoraphanin than mature 
plants (Fahey et al., 1997; Howard et al., 1997).
1.5 Pharm acokinetics o f SFN
1.5 .1  Absorption
Little Is known about the pharmacokinetics of SFN In humans. Previous studies have 
shown that SFN Is relatively well absorbed from the GIT after hydrolysis by plant or 
bacterial myroslnase (Shapiro et al., 1998, Rouzaund et al., 2004 and Vermeulen et al., 
2006). Intact glucoslnolates are also absorbed from the gut. Following oral 
administration of glucoraphanin to F344 rats, a small fraction was detected In urine as 
Intact glucoraphanin and In Its reduced form glucoerucin, while 20%  of the oral dose was 
hydrolysed by the gut microflora and recovered In urine as N-acetyl cysteine conjugates 
of SFN (SFN-NAC), free SFN and erucin (Bheemreddy and Jeffery, 2007). Since cooking 
deactivates plant myroslnase, degradation of glucoslnolates to ITC In humans depends 
on activity of mammalian gut microflora with myroslnase activity. Rats and humans 
treated with broad-spectrum antibiotics had no urinary metabolites of ITC detected after 
consumption of cooked broccoli (Shapiro et al., 2001). I t  appears that the amount of ITC  
metabolites recovered In the urine over a 24 h period correlates with the estimated 
Intake of ITC. This relationship can be used to Indirectly assess the bloavallablllty of ITC  
from the plant matrix.
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The activity of plant myroslnase and, consequently, the bloavallablllty of ITCs from raw 
vegetables are considerably higher than the myroslnase activity of gut microflora and 
the bloavallablllty of cooked vegetable-derived ITCs. Consequently, the absorption 
profile would be very different between orally administered glucoslnolates and ITC. Pre­
formed ITC, being small llpophyllc molecules, are expected to be rapidly absorbed 
throughout the gastro-lntestlnal tract (G IT) but mostly from the stomach and upper GIT, 
giving a steep rise In plasma concentration soon after their administration (Conaway et 
al., 1999). In contrast, absorption of ITCs following Ingestion of plant glucoslnolates Is 
limited by their hydrolysis to ITC by gut microflora and takes place mainly In the lower 
Intestines. Moreover, glucoslnolates may be absorbed Intact and undergo enterohepatic 
circulation (Bheemreddy and Jeffery, 2007). Therefore absorption of ITCs generated 
from their corresponding glucoslnolate precursor Is likely to be gradual and prolonged. It  
Is unknown whether and to what extent such differences In absorption profile and site of 
absorption might Influence biological effects of ITC (Johnson, 2002).
1 .5 .2  M etabolism
I t  Is unknown whether administered and/or newly formed ITCs are subject to further 
metabolism by the gut microflora. ITCs are formed during hydrolysis at neutral pH. 
NItrlles, epithlonltrlles, thiocyanates or oxazolldlne-2-thlones may also be produced at
low pH and In the presence of metals such as Fe"^*  ^ Ions and chemicals that might alter 
myroslnase activity (Bones and Rosslter, 1996; Fenwick et al., 1983). Only marginal 
Induction of phase I I  conjugating enzymes has been observed after feeding broccoli 
subjected to autolysis Intended to facilitate generation of free ITCs (Keck et al., 2003), 
because autolysis favours formation of SFN-nltrlles (Howard et al., 1997), which are 
weak Inducers of conjugating enzymes (MatusheskI and Jeffery, 2001).
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The major elimination pathway of SFN and of its phase I I  metabolites is the mercapturic 
acid pathway (F ig .1 .6) (Kassahun et al., 1997; Rungapamestry et al., 2007; Janobi et 
al., 2006). Following absorption, SFN and other ITCs are metabolised to the 
corresponding mercapturic acids (N-acetyl-L-cysteine S-conjugates). All four 
mercapturates (glutathione, cysteineglyclne, cysteine and N-acetyl cysteine conjugates 
of SFN) were detected in plasma of human volunteers after consumption of broccoli 
(Janobi et al., 2006). The m ajor plasma metabolite was the cysteine conjugate of SFN, 
followed by the cysteineglyclne conjugate. The GSH and N-acetyl cysteine conjugates of 
SFN were the least abundant plasma metabolites of SFN (Janobi et al., 2006). Following 
Intraperltoneal administration of SFN In corn oil (50  m g/kg) to male Sprague-Dawley 
rats, GSH conjugate of a desaturated derivative of SFN, as well as GSH and NAC 
conjugates of SFN and erucin, the sulfide analogue of SFN, were detected In the bile.
(Glutathione)
Glu-Cys-Gly
H - i
+
GST G'“-cy=-<3iy QTP T - ' " ' '
R-N=c=s R-NH-è=S R -NH -èrS
(Isothlocyanate)
CGase
S-Cys-WAc s-Cys
f "-----  4
R-NH-C=S R-NH-è=S
(Mercapturic Acid)
Figure 1.5: The m ajor pathway of ITC metabolism: mercapturic pathway. Abbreviation: 
GST- Glutathlone-S-Transferase; GTP -  y-Glutamyltranspeptldase; CGase -  cysteinylglycinase; 
AT -  Acetyltransferase (Shapiro et al., 1998)
Urinary metabolites were Identified as the NAC conjugates of SFN and ERN, and 
respectively amounted to ~ 6 0 %  and ~12%  of the SFN dose. Indicating that oxidative
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metabolism of ERN Is favoured over reductive metabolism of SFN (Kassahun et al.,
1997). The m ajor plasma metabolite In the urine of human volunteers following 
Ingestion of broccoli was also the N-acetyl cysteine conjugate of SFN. In contrast to rat, 
SFN-Cys was also present In human urine (Janobi et al., 2006). ITCs have also been 
shown to undergo oxidative metabolism by microsomal Cytochromes P450. In  vivo, SFN 
appears to be metabolized by the phase I  enzyme-mediated S-oxlde reduction and 
dehydrogenation generating a desaturated derivative of SFN (Kassahun et al., 1997). 
BITC Is metabolized by rat C Y P lA l/2  and CYP2E1 to reactive Intermediates such as 
benzyl cyanate and benzylamlne that covalently bind to and Inactivate the apoprotein 
(Goosen et al., 2000). No such Intermediates were Identified in vivo. In aqueous 
solutions. Isocyanates are converted to corresponding amines, for example, PEITC Is 
rapidly converted to phenethylamlne In rats (Thorlalley, 2002).
1 .5 .3  D istribution
ITCs Interact with sulfhydryl groups of cellular proteins to form reversible complexes, 
while Interactions with amino groups are typically Irreversible and give rise to thiourea 
derivatives (Thorlalley, 2002). Free ITCs diffuse freely through the cell plasma 
membrane Into the cell where they become trapped after enzymatic and/or spontaneous 
conjugation with cellular thiols such as GSH. This conjugation Is thought to be the major 
driving force responsible for the Intracellular accumulation of SFN where It can reach 
concentrations a few orders of magnitude higher than extracellular levels. Almost 98%  
of SFN In Hepa lc lc 7  cells was In the form of GSH conjugates that were not metabolised 
further (Zhang, 2000). Exposure of Hepa lc lc 7  cells to SFN (5 pM) resulted In a very 
rapid cellular uptake and accumulation to 600 pM after 30 mln of exposure (Zhang and 
Talalay, 1998). Rapid cellular accumulation Is followed by a significant transport- 
mediated expulsion of DTCs (Zhang and Callaway, 2002 and Callaway et al., 2004).
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In plasma SFN exists predominantly as DTCs, which appear to dissociate, releasing 
parent SFN that diffuses through the plasma membrane Into the cells (Ye et al., 2002). 
None or very little ITCs can enter the cell In conjugated form, rather 'free' ITC fractions 
appear to diffuse through the plasma membrane following reductive cleavage of GSH 
and other thiol conjugates. Free ITCs either re-enter the cells or are hydrolysed (under 
physiological conditions) to their Inactive corresponding amines (Thornalley, 2002).
1 .5 .4  Excretion
Studies In animals and humans have shown that, similarly to other ITCs, the majority of 
the vegetable-derived, as well as synthesised SFN Is rapidly excreted In the urine within 
24 h mainly as mercapturates. About 60%  of a single portion of broccoli sprouts 
containing 200 pmol of a mixture of SFN, erucin and Iberin were recovered In urine as 
DTCs during the Initial 8 h after consumption. Indicating very short half-life of ITCs. The 
rate of urinary excretion of DTC following consumption of broccoli followed first-order 
kinetics (Shapiro et al., 1998) and was more than double that of the passive glomerular 
filtration rate. Indicating net tubular secretion of DTC (Ye et al., 2002; Keck et al.,
2003). Since the conjugation Is reversible, accumulation of conjugates In the urinary 
bladder after administration of excessively high doses of ITC can result In toxicity and 
enhancement of tumourlgenesis. For example, BITC orally administered at 50 mg/kg  
BW/day for 36 weeks to rats produced hyperplasia, dysplasia and carcinomas of the 
urinary bladder, while no other organs of the urinary system were affected. Such 
selective toxicity Indicates non-genotoxic mechanisms of the cancer promoting activity of 
ITCs, Involving chronic damage to the urinary bladder epithelium following spontaneous 
dissociation of the ITC conjugates (Okazaki et al., 2003). Metabolites of SFN emanating 
from the mercapturic add pathway are excreted In the bile (Kassahun et al., 1997) and 
urine (Shapiro et al., 1998; Ye et al., 2002; Keck et al., 2003 and Janobi et al., 2006).
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1.6 C hem opreventative A ctiv ity  o f Erucin
Erucin [l-isothlocyanato-4-(m ethylth io)butane], Is another naturally occurring ITC, 
which differs from SFN only by the oxidation state of Its sulphur atom (Fig. 1.1) and, 
which Is consequently relatively less polar. It  occurs as the glucoslnalate glucoerucin In 
rocket salad {Eruca sativa), where It Is a major glucoslnolate, and broccoli (Bennett et 
al., 2002 and Vaughn and Berhow, 2004). There Is experimental evidence to suggest 
that glucoraphanin can be reduced to glucoerucin by mammalian enzymes (Bheemreddy 
and Jeffery, 2007). Glucoerucin Is normally hydrolysed by plant myroslnase or gut 
bacteria to produce erucin. In broccoli, erucin comprises almost a quarter of all ITCs 
(Shapiro et al., 1998). I t  Is also formed in vivo as a result of the oxidative metabolism of 
SFN (Kasssahun et al., 1997).
In the Western diet, most cruciferous vegetables are usually cooked by boiling. During 
cooking, almost a third of all glucoslnolates leach Into the cooking water, although other 
cooking processes such as steaming and microwaving have minimal effects on 
glucoslnolate loss (de Vos et al., 1988). More Importantly, cooking of vegetables 
Inactivates myroslnase, the enzyme that converts the glucoslnolates to the active ITCs 
and, consequently, the bloavallablllty of ITC Is very significantly reduced, with only 10- 
20%  of all glucoslnolates being converted to ITCs by mammalian gut bacteria (Conaway 
et al., 2000 and Shapiro et al., 2001). An advantage of rocket salad, the m ajor source of 
the erucin glucoslnolate. Is that It Is largely consumed raw and, consequently, neither 
glucoslnolate levels nor myroslnase activity are adversely affected.
While SFN Is arguably the most Investigated ITC, the chemopreventlve activity of erucin 
has been little studied. The experimental data suggest that erucin appears to share 
many of the biological activities of sulforaphane related to Its chemopreventlve activity. 
In some cases being far more potent.
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Erucin has been shown to modulate expression of Phase I I  enzymes both in vitro and in 
vivo. Mechanistic data show that the rate of spontaneous, non-enzymatic reaction of 
erucin with GSH is as high as that of SEN. Moreover, in contrast to SEN, which is a poor 
substrate for human GSTs, erucin is weii metabolized by ail m ajor human GSTs, 
including G S T lA l G S T IM I GST1M4 andGSTPl (Koim et ai., 1995). Since the inducing 
potential of individual ITCs appears to correlate well with the extent of their intracellular 
accumulation (Zhang and Talalay, 1998), the level of erucin accumulation within the  
cells is likely to mach, or even surpass, that of SEN's, suggesting that the Phase I I  
enzyme inducer potency of erucin is likely to be high. Both ITCs were equipotent 
inducers of GST and OR activities in the lung, liver, forestomach, glandular stomach and 
mucosa of proximal small intestine of mice as well as in the forestomach, duodenum and 
urinary bladder of female Spraque-Dawley rats following repeated oral administration 
(Zhang at al., 1992 and Munday and Munday, 2004). Erucin was also an effective 
inducer of QR and GST activity in murine hepatoma cells (Zhang at al., 1992), mRNA 
levels coding for QR and U G T lA l in Caco-2 cells (Jacubikova et al., 2005) and mRNA 
levels of thioredoxin reductase (Wang et al., 2005).
Erucin profoundly decreased mitochondrial membrane potential, an early biomarker of 
apoptosis, disrupted progression of cells through the cycle, leading to accumulation of 
Caco-2 cells at the Gz/M stage, a point where arrest of the cells cycle leads to loss of 
viability and commitment to apoptosis and enhanced expression of MRP2 in Caco-2 cells 
(Jacubikova et al., 2005). Upregulation of MRP2 transporter-related protein may 
facilitate efflux of carcinogens out of the cell, while rapid expulsion of GS-erucin adducts 
can trigger apoptosis.
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1.7 Project O bjectives
1. To develop and validate an LC/MS method for detection of SFN in rat and human 
plasma following dietary levels of exposure.
2. To determine bioavailability and pharmacokinetic characteristics of SFN in rats.
3. To determine the pharmacokinetic parameters of SFN after single and repeated 
ingestion of broccoli by human volunteers.
4. To establish whether the major cytochromes P450 and Phase I I  conjugating enzymes 
are modulated by SFN and erucin in the rat liver and lung following exposure to low 
doses.
5. To evaluate ability of SFN and erucin to modulate cytochromes P450 and Phase I I  
conjugation system in human and rat liver in comparative studies using precision-cut 
slices.
6. To investigate whether erucin, like SFN, can function as mechanism-based inhibitor of 
Cytochromes.
7. To determine whether exposure to erucin influences metabolism of the heterocyclic 
amine IQ.
8. To establish whether erucin, in comparison to SFN, modulates the B(c)P-induced 
upregulation of CYPl as a possible mechanism of its anticarcinogenic activity.
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2.1. Chemicals and Apparatus  
Abeam, UK
Human recombinant QR polyclonal antiserum raised in rabbit
Alabam a Research and Developm ent Corporation, M unsford, A labam a, U.S.A
Krumdieck Tissue Slicer
Am ersham  Life Sciences
ECL advance detection kit, blocking reagent, Hybond P PVDF membrane and mini 
camera
BD Biosciences, O xford, UK
7-Benzyloxyquinoline (7-B Q ), 7-hydroxyquinoline (7 -H Q ), rat C YP lA l goat polyclonal 
antiserum, rat C Y P IB I rabbit polyclonal antiserum, rat CYP2B1 goat polyclonal 
antiserum and rat CYP3A2 rabbit polyclonal antiserum
BDH Chemicals Ltd, Poole, UK
Ethylenediaminetetra-acetic acid disodium salt
BIO-RAD Laboratories CA, U.S.A
Bio-rad protein assay dye reagent, acrylamide (4 0 % ), b/s-acrylamide (2 % )
Cam brex Bio Science Rockland, Rockland, US
Low melting point agarose
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Difco
Bacto agar
Direct Medical Supplies Ltd, UK
IV  Venflon cannulae (20G )
Fisher Scientific  UK Ltd, Loughborough, UK
Acetonitrile, Tris base, dimethyl sulphoxide, potassium chloride and sodium chloride 
Fluka Buchs SG, S w itzerland
2, 5, 10 and 20 ml plastic syringes, formic acid, 4-chloro-7-nitrobenzofurazan (NBF-CI) 
and needle microlance 8G
Gibco Life Sciences ( In v itro g e n ), Paisley, UK
Earle's balanced salt solution (EBSS), foetal bovine serum, gentamycin and RPMI 1640
Helena Biosciences, Sunderland, UK
12-Well Plates and 96-well plates
Hawksley, Sussex, UK
Cristaseal and heparinised capillary tubes (75m m  in diam eter)
LKT Laboratories, In c . M innesota, US.
Sulforaphane and erucin (99%  pure)
London Analytical bioscience Lab M
Agar N o .l
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Melford Laboratories Ltd., Ip sw ich , UK
(3-nicotinamide adenine dinucleotidePhoshate (NADP) and (3-nicotinamide adenine 
dinucleotide phoshate reduced (NADPH)
Sigma -  Aldrich, Dorset, UK
Ammonium persulphate, secondary anti-rabbit monoclonal antibody, secondary anti­
goat monoclonal antibody, bovine serum albumin, l-chloro-2,4-din itro-benzene (CDNB), 
3, 4-dichloronitro-benzene (DCNB), 5, 5' - dithio-bis(2-nitro)- benzoic acid (DTNB), 7- 
ethoxycoumarin, ethoxyresorufin, D-glucose, glucose-6-phosphate, glucose-6-phosphate 
dehydrogenase, glutathione reductase, glutathione, 7-hydroxycoumarin, glycerol, (3- 
glucuronidase, hydrocortisone-21-hemisuccinate, HRP-conjugated anti-rabbit and anti­
goat secondary antibodies, insulin, p-mercaptoethanol, 7-methoxyresorufin, 2-m ethyl-
1,4-naphthoquinone (m enadione), 3-(N-morpholino)propanesulforic acid (MOPS), tween 
20, thiazoyl blue tétrazolium bromide (MTT), 7-pentoxyresorufin, polaroid film, pyronin 
Y, resorufin, D-saccharic acid, sodium dodecyl sulphate (SDS), sulphatase and 
N,N,N ' ,N ' -tetramethylethylenediamine (TEMED)
Oxoid Ltd, Basingstoke, UK
Oxoid nutrient broth No. 2
Roche Diagnostics, M annheim , Germ any
Cytotoxicity detection kit (LDH)
RSCH Pharm acy, G uildford, UK
Sterile IV  sodium chloride 0 .9%  (500m l)
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2.2 Methods
2.2 .1  Anim als
Male Wistar albino rats (200 -250g) were purchased from Bantin and Kingman (B&K) 
Universal Ltd (Hull, UK). The animals were housed on sterilised sawdust in solid 
bottomed polypropylene cages, with 2 -4  rats per cage except experiments involving 
urine collection where animals were housed singly in metabolic cages for no longer than 
4 days. The ambient tem perature was maintained at 22°C  ±  3°C and humidity 
controlled in the range of 30 -70% . Lighting was artificial, with a 12h light/12h dark 
cycle. W ater and standard dry rodent food in the form of pellets was freely available at 
all times. The animals were allowed to acclimatise to the above conditions for at least 
24h before sacrificing.
2 .2 .2  P reparation  and  m aintenance o f  p recis ion-cut tissue slices
Precision-cut tissue slices, of uniform thickness and diameter, were cut from human liver 
and rat liver and lung tissues and incubated under controlled conditions as described by 
Hashemi et al. (1999a).
2 .2 .2 .1  P reparation of liver slices
Immediately after sacrifice of rats by cervical dislocation, livers were excised and placed 
in ice-cold EBSS enriched with D-glucose (25m M ) and gassed with 95%  oxygen/ 5%  
CO2  for Ih . The liver lobes were cut free. With respect to the human liver, the tissue,
delivered as 170-200g single piece, was cut into 1 cm thick sections using a scalpel. 
Tissue cylinders were cut with a hand-held coring tool (Vitron, Tuscan, US) to a diam eter 
of 8 mm from the sections of human liver or whole lobes of rat livers. The tissue was 
kept submerged in ice-cold EBSS throughout the procedure. Liver slices (8m m  in
diameter) were cut to a thickness of 200-300pm  from the tissue cylinder using a
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Krumdieck tissue slicer (Alabama Research and Development corporation, Alabama, US) 
filled with chilled (4°C ) oxygenated EBSS. The parts of the slicer that came into contact 
with the buffer and the tissue were wiped with 70%  ethanol prior to use. The slicer was 
set to operate in the interm ittent mode with a cycle speed of 40 cycles/min in order to 
minimise mechanical trauma to the tissue.
2 .2 .2 .2  P reparation of lung slices
The process of preparation of lung slices is similar to that of the liver, but with a few 
differences. The first difference was that the lungs had to be stabilised with agarose. For 
this purpose, lungs were slowly infused with 0 .75%  solution of warm (37 ° C) low- 
melting point agarose (48m l/kg body weight) through a cannulated trachea (IV  cannulae 
Venflon 20G). The trachea was clamped and the lungs were kept submerged in ice-cold 
(4°C) EBSS until the agarose solidified. At this point, the lobes of the lung were cut free 
and tissue cylinders were prepared in the same way as discribed for the liver. The 
second difference was that the thickness of the lung slices, set at 400 -600  pm, was 
double that of the liver. The thickness of the lung slices, optimal for their viability during 
the maintenance in the culture medium, was determined experimentally (Umachandran 
and loannides, 2006).
2 .2 .2 .3  Preparation of culture m edium
Tissue slices were pre-incubated in the culture medium prepared as described by Lake 
et al. (1993 ), and consisted of RPMI 1640 supplemented with insulin ( Ip M ), L- 
methionine (0 .5m M ), hydrocortisone-21-Hemisuccinate (O .lm M ), foetal bovine serum  
(5%  v /v ) and gentamycin (50pg/m L). The incubation media contained, in addition, a 
series of concentrations of the test compound(s) prepared in DMSO. The final 
concentration of DMSO was equal in all treatm ent groups and did not exceed 0 .5%  
(v /v ).
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2 .2 .2 .4  Incubation  o f tissue slices
The tissue slices were transferred into 12-well culture plates (Dogterom, 1993), with 
each slice occupying a separate well containing the described above culture medium (1 .5  
ml), and were maintained at 37°C  in an incubator equipped with an orbital shaker 
(Stuart orbital shaker, Barloword Scientific Ltd, Staffordshire, UK), in a humidified 
atmosphere containing 5%  CO2 (Galaxy B CO2 incubator. Scientific Laboratory supplies 
Ltd, Nottingham, UK).
Tissue slices were initially pre-incubated under these conditions in order to allow the the 
damaged cells to slough from the viable tissue. The pre-incubation period for liver slices 
was 0.5 h while the pre-incubation of the lung slices lasted 1 h in order to allow the 
agarose to melt. Tissue slices were then transferred to a fresh culture medium  
containing either test compound(s) or relevant solvent and were incubated further for up 
to 24 h. At the end of the incubation period, the slices were removed from the culture 
medium, briefly rinsed in KCL (0 .154M ) containing Tris (50m M , pH 7 .4 ) and 
homogenised in the KCL-Tris buffer (12  slices in 1.2 ml).
2 .2 .3  LDH leakage
Lactate dehydrogenase (LDH) is an intracellular enzyme. LDH release from tissue slices 
into the incubation medium was used as an indicator of cytotoxicity. The LDH
concentration was measured using a cytotoxicity detection kit (Roche Diagnostics,
Mannheim, Germ any), according to the manufacturer's instructions. Three slices were
used per each concentration of the test compound(s). On completion of incubation (24
h), the culture medium was aspirated and the remaining tissue slices were each
homogenised in 1.5 ml of 0.01 M phosphate buffered saline (PBS), pH 7.4. The media
and homogenates were centrifuged at 2000 x g for 5 min at 4 °C  using a bench
centrifuge. Duplicate aliquots (0 .1 ml) of either the medium or homogenate
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supernatants were mixed with 0.1 ml of freshly prepared reaction mixture (11 .25  ml of 
dye were mixed with 0 .25  ml of catalyst) using a 96-well plate. The plate was incubated 
at room tem perature for 15 min. The reaction was terminated by addition of 0 .05 ml of 
stop solution and absorbance was read at 492 nm. Leaked LDH was expressed as 
percent of total slice LDH released into the culture media (LDH medium +  LDH slice 
homogenate = total LDH; LDH media/total LDH x 100 = %  of total LDH released).
2 .2 .4  M etabolism  o f  7 -ethoxycoum arin
The 7-hydroxylation of 7-ethoxycoumarin by tissue slices was determined using the 
method of van lersel et al. (1994 ) and Steensma et al., (1994 ). Liver or lung slices were 
incubated with 7-ethoxycoumarin (50  pM) for various time periods up to 6 hours. At the 
end of each time period, the incubation medium was aspirated and divided into three 
equal aliquots. The slices were removed, briefly rinsed in 0.01 M PBS buffer, pH 7.4  
collected into 1 ml of NaOH (0.5M ) and sonicated (3X10 seconds bursts), allowing at 
least 1 minute time intervals between the bursts in order to prevent overheating. The 
protein content of the sonicated slices was determined as described in section 2 .2 .6 .
Two of the aliquots of the aspirated incubation media, 100 pi in case of the liver and 400  
pi in case of the lung slices, were incubated with Vi volumes of sodium acetate buffer 
(0 .5M ), pH 5.0  containing either (3-glucuronidase (5000U /m l) or a combination of 
sulphatase (250U /m l) and D-saccharic acid 1,4-lactone (17m M ), for 16h at 37°C  in a 
shaking water-bath in a light-protected environment. The third aliquot was incubated 
under the same conditions but with Viz volume of the sodium acetate buffer (0 .5M ) only.
All three media aliquots and a series of known 7-hydroxycoumarin concentrations (0 -5  
pM) were diluted to 1 ml with KCL (0 .154  M) containing Tris (50  mM) buffer, pH 7.4,
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acidified with 250 pi of HCL (4M ), and extracted with 6 ml of chloroform for 30 minutes. 
At the end of the extraction process, an aliquot (5  ml) of the chloroform layer was 
transferred into clean test tubes and extracted with 3 ml of glycine-sodium hydroxide 
(0 .5M ), pH 10.5 for a further 30 minutes. The fluorescence of the aqueous layer was 
determined using an excitation wavelength of 380 nm and an emission wavelength of 
452 nm. All samples and standards were analysed in triplicate replicates.
2 .2 .5  P reparation  o f  subceiiu iar fractions
Hepatic and pulmonary subceiiuiar fractions were prepared as described by loannides 
and Parke (1975 ). The tissue was kept at 4°C  throughout the procedure. On completion 
of the incubation, the slices were removed from the incubator, briefly rinsed in Tris 
(50m M) buffer containing KCI (0 .154M ), pH 7.4 and homogenised (12  slices per replicate 
in 1.2 ml of buffer) in Tris (50  mM) buffer containing KCI (0 .154  M), pH 7.4. The 
homogenates prepared from the tissue slices were centrifuged at 9000 x g for 
20 minutes at 4°C  in eppendorf tubes using a bench micro-centrifuge (Eppendorf, model 
5404). The whole livers, scissor-minced in three volumes of potassium chloride (1 .15  %  
w /v) and lungs, scissor-minced in one volume of potassium chloride (1 .15  % w /v ), were 
homogenised in the same way as the tissue slices and homogenates were centrifuged at 
9000 X g for 20 minutes at 4°C  using a Beckman J2-21 floor centrifuge fitted with a JA- 
17 fixed angle rotor (Beckman Coulter Ltd, Bedfordshire, UK). The resulting supernatant 
(post-mitochondrial S9 fraction) was decanted, divided into aliquots and stored at - 
80°C  prior to analysis.
The S9 aliquots were thawed at 4°C , and microsomal and cytosolic fractions were 
prepared by centrifugation at 105,000 x g for 45 min at 4°C  using a Beckman L8-70M  
floor ultracentrifuge and a fixed angle 70 IT I type rotor (Beckman Coulter Ltd, 
Bedfordshire, UK). The supernatant (cytosolic fraction) was transferred to storage at -
45
Chapter 2: Materials and nnethods
80°C for subsequent analysis, whilst the microsomal pellet was immediately re­
suspended in a volume of Tris (50  mM) buffer containing KCI (0 .154  M), pH 7.4, equal to 
the volume of decanted cytosol.
2 .2 .6  D eterm in ation  o f  p ro te in  content
Protein concentration was determined by the method of Bradford (1976 ). Aliquots (0 .02  
ml) of tissue sample were diluted with aqueous sodium hydroxide solution (0.5M ) such 
that the protein concentration in the sample did not exceed 0.5m g/m l. The serial dilution 
of bovine serum albumin (0 -0 .5  m g/m l), prepared in sodium hydroxide solution (0 .5M ), 
was used to construct a calibration curve. Triplicate aliquots (10  pi) of either sample or 
standard were mixed with 0.2 ml of BioRad protein dye (diluted 5-fold with distilled 
water) using a 96-well plate. The samples were incubated at room tem perature for 5 
minutes and the absorbance was measured at 595 nm using an iEMS spectrometer plate 
reader. Results are expressed as milligrams of protein per millilitre of subceiiuiar fraction 
preparation.
2 .2 .7  D eterm in ation  o f  m icrosom al CYPIA  and  CYP2B a c tiv ity
Microsomal CYPIA subfamily predominantly 0-deethylates ethoxyresorufin (EROD) and 
0-dem ethylates methoxyresorufin (MROD), while the CYP2B subfamily predominantly O- 
depentylates pentoxyresorufin (PROD) to a fluorescent product resorufin. 
Ethoxyresorufin, methoxyresorufin and pentoxyresorufin were used as model substrates 
in simple, direct fluorimetric assay (Burke and Mayer, 1974, 1983; Lubet et al., 1985). 
The microsomes derived from the tissue slices had a low enzymatic activity and were 
pre-warm ed to 37°C for 5min in water bath prior to adding to a cuvette. The following 
reagents were added in a fiuorimetric cuvette:
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Microsomes W hole liv e r/lu n g
from  tissue slices microsom es
Tris - HCL buffer (O .IM , pH 7 .8 ) 1.80 2 .00
Microsomal suspension* 0 .25 0 .05
EROD/MROD/PROD (0 .5  mM) 0.01 0.01
*2 5 %  (w /v ) for whole liver, 50%  (w /v ) for whole lung or 12 slices/ml
The reaction was initiated by addition of 0.01 ml of NADPH (50m M ) and the rate of 
resorufin formation was monitored for up to 10 min at + 37°C  using a Varian fluorimeter 
controlled by Carry Eclipse software, at excitation and emission wavelengths set at 571 
and 586 nm respectively; the slit widths were set at 5 mm. Enzyme activities were 
calculated using a standard curve constructed by plotting fluorescence against known 
concentrations of resorufin (0 -250  pmole) and are expressed in units of pmol per minute 
per mg of microsomal protein.
2 .2 .7 .1  M odulation of EROD activ ity  bv erucin or SFN in hepatic m icrosom es
These studies were carried out to determine whether erucin and SFN can function as 
competitive inhibitors of rat C YP IA I. The rate of the 0-dealkylation of ethoxyresorufin 
was monitored by adapting the method described in section 2 .2 .7 . EROD activity was 
measured in the presence of either erucin or SFN (10 and 25 pM) using microsomes 
prepared from the livers of rats induced with Aroclor 1254 as described in section 
2 .2 .16 .4 . An aliquot (0 .0 4  ml) of each of the stock solutions of the relevant test 
compound (0 .5  and 1.25 mM), prepared in 50%  ethanol, was added to the reaction 
mixture (2 ml) to achieve the required final concentration. Both test compounds at each 
concentration were tested against five concentrations of the substrate ethoxyresorufin.
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An aliquot of the relevant stock solution (10 pi) of the substrate (2 , 10, 20, 100 and 200  
pM) was added to the reaction mixture (2 ml) to achieve the required final substrate 
concentration (0 .01 , 0 .05 , 0 .1 , 0.5 and 1 pM respectively). Each activity was measured 
in triplicate. The following reagents were added in a fluorimetric cuvette:
Tris - HCL buffer (O .IM , pH 7 .8 ) 1.90 ml
Microsomal suspension (25%  w /v ) 0.05 ml
EROD (2 -  200 pM) 0.01 ml
Test compound (0 .5  or 1.25 mM) 0.04 ml
The reaction was initiated by addition of 0.01 ml of NADPH (50m M ) and the rate of 
resorufin formation was monitored for up to 1 min at 37°C as described above.
2 .2 .7 .2  In h ib itio n  o f EROD activ ity  bv erucin, SFN and th e ir  m etabolites
These studies were undertaken to determine whether erucin and SFN are mechanism- 
based inhibitors of rat C Y P IA I. EROD activity in presence of erucin or SFN (25 pM) was
determined by adapting the method described in section 2 .2 .7 . Each activity was
measured in triplicate. The following reagents were added in a fluorimetric cuvette:
Tris - HCL buffer (O .IM , pH 7 .8 ) 1.90 ml
Microsomal suspension (25%  w /v )*  0 .05 ml
NADPH (0 .5  mM) 0 .0 1 m l
Test compound (1 .25  mM) 0 .04  ml
*microsomes were prepared from the livers of rats induced with Aroclor 1254 as 
described in section 2 .2 .1 6 .4
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All components of the assay except the substrate were pre-incubated for periods of time 
up to 1 h in a shaking water bath at 37°C to facilitate the metabolism of ITCs. The 
reaction was initiated by addition of an aliquot (10 pi) of ethoxyresorufin (0 .5  mM) and 
the rate of resorufin formation was monitored for up to 1 min at 37°C  as described 
above.
2 .2 .7 .3  Effect o f g lu ta th ione on EROD activ ity  a fte r  pre-incubation  w ith  
erucin /SFN
These studies were undertaken to determine whether oxidized or reduced glutathione 
could reverse erucin/SFN-associated inhibition of rat C Y P IA I activity. EROD was 
assessed adapting the method described in section 2 .2 .7 , the only difference being that, 
once again, all components of the assay except 7-ethoxyresorufin were pre-incubated in 
the presence of erucin/SFN (25 pM) and reduced or oxidized glutathione (5 -200  pM). 
Each determination was carried out in triplicate. The following reagents were added in a 
fluorimetric cuvette:
Tris - HCL buffer (O .IM , pH 7 .8 ) 1.90 ml
Microsomal suspension (25%  w /v )*  0 .05 ml
NADPH (0 .5  mM) 0.01 ml
Test compound (1 .25  mM) 0 .04 ml
GSH or GS-SG (0 .2 -8  mM) 0 .05 ml
*microsomes were prepared from the livers of rats induced with Aroclor 1254 as 
described in section 2 .2 .1 6 .4
All components of the assay except the substrate were pre-incubated for 0.5  h in a 
shaking water bath at 37°C to facilitate the metabolism of ITCs. The reaction was
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initiated by addition of an aliquot (10  pi) of ethoxyresorufin (0 .5  mM) and the rate of 
resorufin formation was monitored for up to 1 min at 37°C  as described above.
2 .2 .8  D eterm in ation  o f  m icrosom al CYP3A activ ity
7-Benzyloxyquinoline (7-BQ ) is demethylated, predominantly by CYP3A, to the 
fluorescent product 7-hydroxyquinoline (7-HQ ). The assay was based on a method 
described by Stresser e t al. (2002 ), and utilises 7-BQ as a marker substrate for the 
CYP3A subfamily of the cytochrome P450 mixed-function enzyme system. The following 
reagents were added to a fluorimetric cuvette:
Microsomes W hole liv e r/lu n g
from  tissue slices m icrosom es
Tris buffer (O .IM , pH 7 .8 ) 1.75 ml 1.95 ml
Glucose-6-phosphate (G -6-P , 3.3 mM) 0 .02 ml 0.02m l
G-5-P dehydrogenase (0 .4  U /m l) 0 .04 ml 0 .04  ml
Microsomal suspension 0.25 ml 0 .05 ml
7-BQ (4 mM) 0.01 ml 0.01 ml
The reaction was initiated by addition of 0.01 ml of NADP (1 .3m M ) and the contents of 
the cuvette were mixed by inversion. The rate of 7-HQ formation was monitored for up 
to 10 min at excitation and emission wavelengths set at 410 and 538 nm respectively, 
the slit widths being set at 5 mm. The enzyme activities were calculated using a
standard curve constructed by plotting fluorescence against 7 - HQ (0 to 0.5 nm ole/m l).
2 .2 .9  D eterm in ation  o f  NADPH-Cytochrom e C reductase a c tiv ity
This enzyme is localised in the microsomes and functions as a component of the mixed- 
function oxidase system. The activity is measured essentially by the method described
by Williams and Kamin (1962 ). The activity of NADPH-cytochrome C reductase was
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measured in the presence of either erucin or SFN using microsomes prepared from the 
livers of control rats. An aliquot (0 .1  ml) of each of the stock solutions of the relevant 
test compound (0 .03 , 0 .075 , 0 .15 , 0 .3 , 0.75 and 1.5 mM), prepared in 50%  ethanol, 
was added to the reaction mixture (3 ml) to achieve the required final concentration (1, 
2.5, 5, 10, 25 and 50 pM respectively). The solvent vehicle (50%  ethanol) was used as a 
control. The following reagents were added to both cuvettes:
Test cuvette  Reference cuvette
Potassium phosphate buffer (50m M ),
pH 7.6 containing KCN (1 mM) 1.8 ml 1.9 ml
Cytochrome C (0 .1  mM) 1.0 ml 1.0 ml
Test compound (0 .03  -  1.5 mM) or solvent 0.1 ml 0.1 ml
Microsomal suspension 0.1 ml 0.1 ml
An aliquot (0 .1m l) of NADPH (30m M ) was added to the test cuvette to initiate the 
reaction. The contents of the cuvettes were mixed by inversion. The increase in 
absorbance over tim e was followed at 550 nm for up to 2 min using a Kontron 860  
spectrophotometer. Enzyme activities were calculated using a molar extinction 
coefficient of 18.5 mM cm and were expressed in units of nmol per minute per mg of 
microsomal protein.
2 .2 .1 0  D eterm in ation  o f  to ta l g lu ta th ione content
The total cytosolic glutathione content was measured essentially as described by 
Akerboom and Sies (1981 ). An aliquot (0 .2  ml) of the cytosolic fraction prepared from 
whole livers or lungs (diluted 8 fold with KCI, 1 .15% , w /v ) or tissue slices (undiluted) 
was mixed with perchloric acid (2 M; 0.2 ml) containing EDTA (4  mM) to precipitate the 
proteins. The mixture was neutralised with potassium hydroxide (2  M; 0 .2  ml)
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containing MOPS (0 .3  M). Standards of glutathione were taken through the same 
procedure. All standards and samples, analysed in duplicate, were centrifuged at 2 ,000 x 
g for 10 mins. The supernatant was decanted and used in the assay. The following 
reagents were added to a spectrophotometer cuvette:
Potassium phosphate buffer (0 .1  M, pH 7) containing EDTA (2 .5m M ) 1.00 ml
NADPH (1 .5  m g/m l) 0 .05 ml
Glutathione reductase (6U /m l) 0 .02 ml
Sample or standard 0 .10 ml
The reaction was initiated by addition of 0.10 ml of 5,5'-dithio-bis(2-nitro)-benzoic acid 
(DTNB, 3.8m M ). The contents of the cuvette were mixed by inversion and the reaction 
was followed at 412 nm for up to 2 min using a Kontron 932 spectrophotometer. Total 
glutathione concentration was calculated from a standard curve constructed by plotting 
glutathione reductase activity against glutathione concentrations.
2 .2 .11  D eterm in ation  o f  quinone reductase a c tiv ity
The assay was performed using the method described by Prohaska and Santamaria 
(1988), which is based on measuring an increase in absorbance due to reduction of a 
yellow dye 3-[4,5-dim ethylth iazolyl-2-yl]-2,5diphenyl tétrazolium bromide (MTT) to a 
blue-coloured product, formazan, in the presence of the electron acceptor menadione. 
The following reagents were added in both spectrophotometer cuvettes:
Tris buffer (25  mM, pH 7 .4 ) 
containing tween 20 (0 .0 8 3 % , w /v )
MTT (10 mM)
Test cuvette
1.00 ml 
0.10 ml
Reference cuvette
1.00 ml 
0.10 ml
52
Chapter 2: Materials and methods
NADPH (50 mM)
Cytosol (diluted 10 to 50-fold) 
Potassium chloride (1 .1 5 % , w /v )
0.01m l 
0.05 ml
0.01 ml
0 .05 ml
The reaction was initiated by addition of 0.1ml of menadione (lO m M ) to both cuvettes 
and followed at room tem perature at 610 nm for 1 min using a dual beam Contron 
Uvikon 860 spectrophotometer. Enzyme activities were calculated using a molar 
extinction coefficient of 11.3 mM cm and were expressed in units of nmol per minute 
per mg of total cytosolic protein.
2 .2 .1 2  D eterm in ation  o f  g iu ta th ione-S -transferase  activ ities
The glutathione-S-transferases (GSTs) are a family of cytosolic enzymes catalysing the 
conjugation of glutathione to electrophiles. The assay was carried out using 1-chloro-
2,4-dinitrobenzene (CDNB), 3,4-dichloronitrobenzene (DCNB) or 4-chloro-7- 
nitrobenzofurazan (NBD-CI) as accepting substrates using an adaptation of method 
described by Habig et al., (1974 ) for CDNB and DCNB and Ricci et al., (1994 ) for NBD- 
CI. The change in absorbance over time due to the conjugation of substrate with 
glutathione was monitored at room temperature for 1 min in a dual beam Contron 
Uvikon 860 spectrophotometer at 340 nm for CDNB, 345 nm for DCNB and 419 nm for 
NBF. All samples were analysed in duplicate.
For measurement of GST activity using CDNB and DCNB as m arker substrates, the 
following were added to both cuvettes:
Reference cuvette
Sodium phosphate buffer (0 .1  M, pH 7.4) 1.00 ml
CDNB/DCNB (25 mM) 0 .05 ml
Test cuvette
1.00 ml 
0.05 ml
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Reduced glutathione (25  mM) 
Cytosol (10  to 50 fold diluted) 
Potassium chloride (1 .1 5 % , w /v )
0 .30 ml
0 .05 ml
0 .30 ml 
0 .05 ml
For measurement of GST activity using NBD-CI as the accepting substrate the following 
were added to both cuvettes:
Sodium acetate buffer (0 .1  M, pH 5.0) 
containing reduced glutathione (0.5m M )
NBD-CI (4 mM)
Cytosol (10 to 50 fold diluted)
Potassium chloride (1 .1 5 % , w /v )
Reference cuvette
1.00 ml 
0.05 ml
0.05 ml
Test cuvette
1.00 ml 
0.05 ml 
0.05 ml
Enzyme activities were calculated using the molar extinction coefficients of 8 .5 , 9 .6  and 
14.5 mM cm for CDNB, DCNB and NBD-CI respectively, and were expressed in units 
of nmol per minute per mg of cytosolic protein.
2 .2 .1 3  Q uantification o f  p ro te in  levels b y  W estern b lo t analysis
Western blot is commonly used in the analysis of proteins in complex mixtures. Initially, 
proteins are separated by electrophoresis through a polyacrylamide gel using a Bio-Rad 
Mini Protean 3 kit (Bio-Rad, Hertfordshire, UK) acceding to the method devised by 
Laemmli (1970 ). The separated proteins are then transferred to a polyvinylidene fluoride 
(PVDF) membrane (pore size of 0.2 pm) as described by Towbin et al. (1979 ) where 
they are immobilised and the proteins of interest are visualised by a mean of antibody 
binding (Burnette, 1981). This technique is a useful tool in the qualitative and 
quantitative analysis of proteins of interest in complex mixtures.
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2 .2 .1 3 .1  Discontinous polvacrvlam ide aels
All Western blot equipment was cleaned with 70%  methanol prior to use. Gels were 
prepared in glass cassettes, each assembled from a spacer plate with permanently 
bonded spacers (0 .75m m ) and a short plate aligned together and secured in a casting 
frame. The casting fram e was then clamped upright onto the casting stand securing the 
gel cassette perpendicular to the bench surface and sealing it off by pushing down 
against the grey rubber gasket. The resolving gel monomer solution was prepared by 
combining 5 .43 ml of water, 4 .50  ml of resolving gel buffer (Tris-HCI (1 .5M ) containing
SDS (0 .4%  w /v ), pH 8 .8 ), 5 .62 ml of acrylamide (40%  w /v , 2 .95 ml of bis-acrylamide 
(2%  w /v ), 0 .18 ml of ammonium persulphate (10%  w /v, freshly prepared) amd 0.018  
ml of TEMED. The resoloving gel monomer solution was poured up to a marked level 
(1cm below the teeth of the completely inserted comb), immediately overlayed with 
water (1m l) to avoid gel dehydration and allowed to polymerise for 30 min. The excess 
water was drained.
The stacking gel monomer solution consisted of 7 .15 ml of water, 2 .5  ml of stacking gel 
buffer (0.5M Tris containing SDS (0 .4%  w /v , pH 6 .8 ), 0.7 ml of acrylamide (40%  w /v ), 
0.4 ml of bis-acrylamide (2%  w /v ), 0 .05 ml of freshly prepared ammonium persulphate 
(10%  w /v ,) and 0.01 ml of TEMED. The stacking gel monomer solution was poured 
between the glass plates above the resolving gel. The combs were inserted into the 
glass cassette and the gel was allowed to polymerise for 45 minutes to 1 hour, after 
which the combs were carefully removed. The gel cassette sandwiches, released from 
the casting frame, were mounted onto a clamping frame and inserted into the Electrode 
Assembly placed into the electrophoresis tank filled with running buffer diluted 5-fold. 
The 5x concentrated running buffer, pH 8 .3 , was prepared in advance by dissolving 
15.15g Tris base, 72g glycin and 5g SDS in IL  of water.
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2 .2 .1 3 .2  Sam ple preparation  and loading
The samples with equal total protein concentration (1 to 2 m g/m l) were diluted 1:1 with 
sample loading buffer consisting of 4 .80 ml of water, 1.20 ml of Tris buffer (0 .5M ), pH 
6.8, 0 .96 ml of glycerol, 0 .92  ml of SDS (10%  w /v ), 0 .48 ml of (3-mercaptoethanol and 
0.60 ml of pyronin Y (0 .0 5 %  w /v ). The samples in loading buffer were heated for 5min 
at 95°C  in a heating block, cooled and centrifuged at 3000g for 10 sec. Equal volumes of 
each sample (1 0 -6 0  pi) were loaded into the corresponding wells using gel loading tips,
reserving one well in each gel for a molecular marker (5 pi) to aid identification of 
sample and protein of interest. The molecular marker was also used as a quality control 
sample to ensure the quality of the running and transfer procedures. The gels were run 
for 75 to 90 min at a constant current of 40 mA until the band of pink dye reached the 
lower end of the gel. At this point the power pack was switched off and the electrode 
assembly was taken out of the buffer tank.
2 .2 .1 3 .3  Transfer o f polypeptides to PVDF m em brane
The gel cassette sandwiches were released from the electrode assembly and the glass 
plates were separated with a gel releaser. The gels were floated off the glass plate in a 
tray filled with transfer buffer (25 mM Tris, 192 mM glycine, 20%  v /v  methanol, pH 8 .3 ). 
The PVDF membrane (pre-wetted in 100%  m ethanol), blotting paper, scotch brite and 
the gels were equilibrated in transfer buffer for 15 min. A PVDF membrane and the gel 
were sandwiched between two single pieces of blotting paper, cut to the size of the gel, 
and secured between two pieces of scotch brite in the transfer cassette. The gel was 
facing the black side (electronegative) of transfer cassette. The cassettes were inserted 
into the transfer module placed in the electrophoresis tank filled with transfer buffer. 
The proteins from the gel were transferred onto the membrane at a constant current of 
100 mA for 15 h at room temperature.
56
Chapter 2: Materials and methods
2 .2 .1 3 .4  Detection and visualisation of proteins
The blotting sandwich was disassembled upon completion of the transfer procedure, and 
the membrane was placed into disposable 50 ml plastic containers. The detection of 
proteins bound to the membrane was a three step process, each of which lasted 1 h and 
was performed at room tem perature. Each membrane was first blocked to prevent non­
specific binding of primary and secondary antibodies with ECL Advance blocking reagent 
(20m l, 2%  w /v ) dissolved In a washing buffer (TBS, pH 7.6 , containing 0 .1%  tween 20),
then incubated with the primary antibody and, lastly, incubated with secondary 
antibody conjugated with horse radish peroxidase (HRP). The membrane was washed 
(3x l0m in ) in washing buffer at the end of each of these three procedures. The
apoprotein bands were visualised using an ECL Advance detection kit and an ECL mini­
camera. The development and exposure periods varied from 15 sec to 2min depending 
on the intensity and clarity of the image on the photograph. The optical density of the 
protein bands was quantified using the GeneTool software (Syngene corporation, 
Cambridge, UK). The band representing the control was assigned a value of 100% , while 
the bands representing treatm ent(s) were expressed as percentage of the control.
2 .2 .1 4  The Am es m u tag en ic ity  tes t
The assay (Maron and Ames, 1983) was performed in a class I I  microbiological safety 
cabinet swabbed with 70%  ethanol immediately prior to use. All solutions and equipment 
were autoclaved at 120°C for 15 minutes. Each assay incorporated positive and negative 
(spontaneous reversion rate) control and was performed in triplicate.
2 .2 .1 4 .1  M inim al aaa r plates
A molten solution of bactoagar (1 .5%  w /v) was supplemented with 25 ml of D-glucose 
(40%  w /v) and 10 ml of Vogel Bonner salts (1%  magnesium phosphate, 10%  citric acid.
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50%  di-potassium hydrogen orthophosphate and 17.5%  of sodium ammonium  
phosphate w /v ). A 30 ml aliquot of the bactoagar mix was then poured into a single petri 
dish and allowed to solidify. The minimal plates were prepared in advance and stored at 
4°C up to one month before use.
2 .2 .1 4 .2  P reparation o f bacterial culture
The YG1024 bacteria used in the current studies were freshly grown from permanent 
copies, stored at -80°C , by incubating the inoculated nutrient broth containing ampicilin
(0 .025m g/m l) at 37°C  for 12h in a shaking water bath. The fresh cultures were either 
used immediately or after storage at 4°C  for up to 72h. The permanent copies were 
prepared from fresh cultures, which were mixed with the cryopreservative dimethyl 
sulphoxide (DMSO, 9%  v /v ) and stored at -80°C .
2 .2 .1 4 .3  Testing th e  qua lity  o f bacteria
The following tests were carried out in duplicate on the tester strain used in a 
mutagenicity assays to confirm that bacteria were viable and retained the required, 
genetically-engineered mutations.
2 .2 .1 4 .3 .1  H istid ine auxotroohv
A fresh bacterial culture was streaked across the minimal agar plate supplemented with 
an aliquot (100 pi) of "high" histidine solution (0 .1  M) and biotin (0 .5  m M), smeared 
with a sterile plastic spreader. For comparison, a fresh bacterial culture was also 
streaked across the minimal agar plate without the "high" histidine solution. The plates 
were then left at + 3 7 °C  for 24h in an Astell Hearson incubator. Growth only in the 
histidine-streaked plates indicates histidine requirement.
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2 .2 .1 4 .3 .2  R -fac to r p lasm id
An aliquot of fresh culture (lOOpI) was plated with top agar (2  ml) supplemented (5%  
v /v ) with the "high" histidine solution containing histidine (0 .1  M) and biotin (0 .5  mM). 
The top agar was allowed to set and a sterile filter disk, with 25 pi ampicillin (8m g/m l), 
was placed in the center of the plate which was then incubated at + 37°C  for 24h. The 
presence of the plasmid is indicated by the absence of bacterial growth around the 
ampicillin-impregnated disk.
2 .2 .1 4 .3 .3  Presence o f  rfa  m utation
An aliquot of fresh culture (lOOpI) was plated with top agar (2 ml) supplemented (5%  
v /v ) with the "high" histidine solution containing histidine (0 .1  M) and biotin (0 .5  mM). 
The top agar was allowed to set and a sterile filter disk, impregnated with 25 pi crystal 
violet solution ( Im g /m l)  was placed in the center of the plate. The plate was then 
incubated at + 3 7 °C  for 24h. The presence of the rfa factor is indicated by the lack of 
bacterial growth around the crystal violet-impregnated disk.
2 .2 .1 4 .4  A ctivation system
The activation system consisted of potassium phosphate buffer (0 .2M , 70%  v /v , pH 7 .4 ) 
containing co-factors (NADP, 20 pmol/ml; glucose-6-phosphate, 25 pm ol/m l), potassium 
chloride (0 .33  M, 10%  v /v ), magnesium chloride (0 .08  M, 10%  v /v ) and liver S9 (10%  
v /v ). The S9 fraction was prepared from livers of W /A rats injected intraperitonealy with 
a single dose of Aroclor 1254 (0 .5  g/kg of body weight) dissolved in corn oil (0 .2  g /m l), 
and killed on the 5^  ^ day after dosing.
2 .2 .1 4 .5  P late incorporation test
Molten top agar (0 .6 %  w /v ) containing sodium chloride (0 .5 %  w /v ), histidine (0 .05  mM)
and biotin (0 .05  mM), was dispensed as aliquots (2 ml) into sterile plastic tubes and
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kept at 45°C  in a w ater bath. An aliquot (0 .1  ml) of filtered urine (Millipore filter, 0.2  
mp), a solution of 2-am ino-3-m ethylim idazo-[4,5-f]quinoline (IQ ) in DMSO (0 .5 -1 0  
pg/m l) or a relevant solvent (1 .15%  KCI and DMSO respectively), bacterial culture (0 .1  
ml) and activation system (0 .5  ml) were added to each plastic tube containing top agar 
in the order described. Im m ediately after addition of the activation system, the contents 
of the tube were mixed and plated on a minimal agar plate. Once the top agar solidified, 
the plates were inverted and incubated for 48h at 37°C for 24h in an Astell Hearson 
incubator. The colonies were counted using a Gallenkamp Colony counter. Each assay 
was carried out in triplicate.
2 .2 .1 5  S ta tis tica l evaiuation
Results are expressed as mean ±  standard deviation. The significance of the differences 
between the means was analyzed using the unpaired Student's t-test. The effects of a 
second compound were analysed using two-way analysis (ANOVA) of variance. The 
statistical significance is expressed as follows:
P>0.05 not significant
P<0.05 significant ( * )
P<0.01 very significant ( * * )
P<0.001 extremely significant ( * * * )
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3.1 In troduction
Reactive ITCs can spontaneously and non-specifically bind to thiol groups of 
macromolecules, forming reversible thiocarbomoyl complexes with thiol groups of 
proteins (Thornalley, 2002). Moreover, the principal metabolic pathway of ITC in 
mammals involves enzymatic conjugation with cellular glutathione, the first step in the 
mercapturic acid pathway, followed by further metabolic transformation to generate 
sequentially the cystelnylglycine-, cysteine- and, finally, /V-acetylcysteine conjugates 
(Kassahun et al., 1997; Conaway et al., 2002 and Bheemreddy and Jeffery, 2007). 
These reversible conjugates, knows as dithiocarbamates (DTCs), are the predominant 
form of ITCs in plasma (Mennicke et al., 1983). Total ITC/DTC concentrations in 
vegetable extracts and biological fluids can be quantified using the cyclocondensation 
assay (Zhang et al., 1996 and Ye et al., 2002). The m ajor limitation of this method is 
lack of differentiation between ITC and their DTC derivatives. Use of LC/MS 
instrumentation allows identifying and quantifying of individual ITCs in biological 
materials.
Many studies reporting the biological activity of SFN have been carried out In vitro 
(Conaway et al, 2002, Higdon et al., 2007), but in order to relate these data to the in 
vivo studies, it is essential that the pharmacokinetic behaviour of this phytochemical is 
established. In the present studies, an LC/MS method was developed, validated and 
employed for the specific, accurate and sensitive analysis of SFN in rat plasma following 
single oral administration of low doses. Moreover, intravenous administration of SFN was 
used to determine its absolute bloavailability at doses reflecting human intake.
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3 .2  M ethodology  
3 .2 .1  A nim als
The conditions at which the animals were maintained during acclimatisation and study 
periods are described in section 2 .2 .1 . Rats were allowed to acclimatise to the study 
conditions for 4 days.
3 .2 .1 .1  P relim inary  study
Three male Wistar albino rats (200g ±  10% ) were treated with a single dose of 1.0, 5.0  
mg/kg or 20 m g/kg, corresponding to 5.6 , 28 and 112 pm ol/kg, of SFN, dissolved In 1 
ml of water. Blood samples (100  pi) were withdrawn from the tipped rat tail at regular 
time intervals for up to 8 hours, and placed into lithium-heparinised centrifuge 
microtubes. A sample was also obtained 24 h prior from untreated rats.
3 .2 .1 .2  Main pharm acokinetic  study
Sixteen male Wistar albino rats (200g ±  10% ), randomly assigned to 4 groups of 4 
animals each, were treated with SFN either as a single intravenous dose (0 .5  m g/kg), In 
a volume of 100 pi, or single oral doses of 0 .5 , 1.0 and 5 .0  m g/kg, corresponding to 2.8,
5.6 and 28 pmol/kg, dissolved in 1 ml of water. Blood samples (100  pi) were withdrawn 
from the rat tail at regular time intervals for 8 hours, and placed into lithium-heparinised 
centrifuge microtubes. A sample was also obtained 24 hours after SFN administration as 
well as from untreated rats.
3 .2 .2  Sam ple p rep ara tio n
Aliquots of the plasma (40  pi) were made to 1 ml with 0 .01 M phosphate-buffered saline 
(pH 7 .3 ) and were subsequently extracted with chloroform (5  ml) twice for 30 minutes;
the layers were separated by centrifugation at 510g for 10 minutes. The combined
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chioroform extracts were evaporated under nitrogen using a N-EVAP modei 111 
(Organomation Assoc. Inc, USA) and reconstituted in 40 pi of the HPLC mobiie phase 
(10 %  acetonitriie in water containing 0 .1%  formic acid), and 20 pi was injected for 
analysis. Quality control and standard suiforaphane solutions of known concentrations 
(0 .05 , 0.5  and 1.8 pg/m l) were also carried through the same extraction procedure. 
Calibration curves were constructed by plotting a peak area of SFN standards versus 
their theoretical concentration (0 .0 1 - 2 pg/m l).
3 .2 .3  D eterm in ation  o f  su iforaphane in ra t  piasm a
Plasma levels of SFN in rat plasma were determined by LC-MS/MS. Separation of SFN 
from matrix constituents was achieved using an Ultimate 3000 (Dionex, Camberley, UK) 
HPLC employing a Synergi 4u Fusion-RP analytical column (80Â particle size, 150 x 1 
mm) fitted with a KrudKatcher in-line filter, both supplied by Phenomenex (Macclesfield, 
UK). Mobiie phase consisted of solvent A (10 % acetonitriie in water containing 0 .1%  
formic acid) and solvent B (90 % acetonitriie in water containing 0 .1%  formic acid). The 
analyte was eluted with a linear gradient (0  to 20% ) of organic solvent B over 22 min. 
The column was then washed with 80%  of solvent B over 3 min and re-equilibrated for a 
further 10 min; the eluent flow rate was 0 .05 m l/m in. Under these conditions, the 
retention time of SFN was about 18 minutes in a total run tim e 35 minutes.
1 7 8 ->  114
1 7 8 -> 7 2
: C = S
+
Figure 3.1; Structures of SFN transitions monitored in the MRM mode
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SFN was detected on-line using an API 2000 triple quadrupole mass spectrometer 
(Applied Biosystems, Warrington, UK) equipped with a turbo-ion electrospray probe, 
operating in the positive ionisation mode. The analyte was detected by monitoring the 
m /z 114 and 72 mass transitions (Fig. 3 .1) in the multiple reaction monitoring (MRM) 
scan mode, under the following conditions: turbo ion-spray interface tem perature, 
350°C; collision-activated dissociation gas pressure and curtain gas pressure, 3 and 40  
p.s.i. respectively; turbo ion-spray voltage, 5000 V; deciustering, entrance and focusing 
potential, 11, 10 and 300 V respectively; collision energy 18 and 41 V for m /z 114 and 
72 transitions respectively; collision cell exit potential, 15 V. Acquisition of data was 
achieved using the Analyst software (version 1.4; Applied Biosystems).
3 .2 .4  Pharm acokinetic  anaiysis
Pharmacokinetic analysis was carried out using PK solutions™ software package (version 
2.0, Summit Research Services, Ohio, USA). Because of the very long terminal phase 
( t i /2  = 65.6  hours after intravenous administration), pharmacokinetic parameters were 
calculated from the better defined AUCo-2 4 , rather than from AUCq-oc, to avoid introducing 
an inaccuracy in extrapolating the terminal phase to tim e infinity. AUCo-24 was calculated 
using the trapezoidal rule utilising the time data determined experimentally. Absolute 
bioavailability (F) was determined from the ratio of the oral to intravenous dose- 
normaiised AUCo-24 values. Apparent volume of distribution (Vd) was calculated from the 
equation Vd = FD/ AUCo-24 K\, where D is the dose and kei is the elimination rate 
constant. Piasma clearance (Ci) was determined using the equation Ci =  FD/ AUCo-24- 
Finally, Cmax and T^ax were determined graphically from the piasma concentration versus 
time plots.
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3 .2 .5  S ta tis tica l eva iuation
Animal data, analysed individuaiiy, are presented as mean ± standard deviation, where 
n=4. The significance of the differences between the means was analyzed using the 
unpaired Student's t-test. The statistical significance is expressed as follows:
P>0.05 not significant
P<0.05 significant ( * )
P<0.01 very significant ( * * )
P<0.001 extremely significant ( * * * )
3.3  Results
3 .3 .1  O ptim isation o f  chrom atographic separation  a n d  sam pie p repara tion  
procedure
The Ultimate 3000 HPLC system was connected to a API 3000 triple quadrupole mass 
spectrometer equipped with a TurboIonSpray source (TIS). The direct combination of LC with 
mass spectrometer reduces the stress on chromatographic separations because of the mass 
selectivity and distinctive fragmentation patterns, but a satisfactory chromatography is required to 
achieve good peak shapes. Sharp peak shape of SFN was achieved with a Synergi 4u Fusion-RP 
analytical column (80Â particle size, 150 x 1 m m ), selected based on manufacturer's 
recommendation as the most suitable for small and weakly hydrophobic molecules and 
fitted with a KrudKatcher in-line filter. The best peak shape of SFN was achieved with a 
linear gradient (0  to 20% ) of acetonitriie in water over 22 min, resulting in SFN elution 
time of about 18 minutes at flow rate of 0 .05 m i/m in.
Sampie ciean-up procedures, including protein precipitation with acids or methanol or 
acetonitriie, solid phase extraction (SPE) and liquid-liquid extraction with hexanoi or
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chloroform, were evaluated. Due to the small sample volume and low analyte 
concentrations, protein precipitation with acids resulted in an unacceptabiy high loss of 
sample (results not shown). Extraction of SFN using solid phase extraction (SPE) Oasis 
MCX (mixed ion exchange and hydrophobic interactions mode) cartridges resulted in 
highly inconsistent recoveries of SFN from plasma matrix, which varied up to 4-foid 
between replicates (results are not shown). Almost complete loss of SFN, which 
remained in aqueous phase, was observed when highly hydrophobic hexanoi was used 
for extraction. Finally, extraction of SFN with the more polar chioroform, as detailed in 
section 3 .3 .3 , resulted in high recoveries at low, medium and high concentrations.
3 .3 .2  O ptim isation o f  M S /M S  detection o f SFN
The optimal source-dependent parameters recommended by the manufacturer for the 
API 2000 triple quadrupole mass spectrometer, equipped with a turbo-ion electrospray 
(T IS ) probe, operating in the positive ionisation mode, at 50 pl/m in LC flow rate were: 
TIS interface tem perature, 350°C; collision-activated dissociation gas pressure and 
curtain gas pressure, 3 and 40 p.s.i. respectively; TIS  voltage, 5000 V; including TIS  
sprayer.
The compound-dependent parameters of the instrument for the MRM scan were 
optimised using a direct infusion of SFN (5 pg/m l) dissolved in solvent comprising 1:1 
water:acetonitriie and acidified with formic acid (0 .1  %  v /v ). SFN spectra were acquired 
over the mass range m /z  100-300 using fuil-scan (Q1 scan) operating in the positive 
mode (Fig. 3 .2 ). The protonated SFN ion [M + H]"^  of m /z  178 was selected for the product 
ion scan to establish the optimal pressure of the CAD gas (colision gas in the collision 
ceil) and collision energy (CE) necessary to yield the characteristic transitions (product 
ions) of SFN (precursor ion) that can be monitored in the multiple reaction
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monitoring (MRM) mode. The optimal CAD gas and CE for fragmentation of m /z  178 to 
m /z 114 and 72 transitions were 18 and 41 V respectively (Fig. 3 .3 ).
8.0.8 ■!
Figure 3.2: Mass spectrum of SFN acquired in the fuil-scan mode
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Figure 3.3: Collision-induced dissociation of SFN. Product ion spectra of the (M+H)+ ion of 
SFN (m /z 178) at CE set to 0 (A) and formation of m /z  178 114 and 178 —> 72
transitions (product ions) at CE set at 18 (B) and 41 V (C) respectively. CAD was set to 3
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3 .3 .3  Validation L C /M S /M S  m ethod  fo r determ in ing  SFN in ra t  p iasm a
At the retention time for SFN (18 min), there were no interfering peaks on the 
chromatograms obtained from blank plasma extracts (Fig. 3 .4 ). The calibration curve for 
SFN (Fig. 3 .5 ), constructed using the least square linear regression analysis of 14 data 
points, had excellent linearity over the tested range (0 .01 to 2 pg/m l).
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Figure 3.4: A representative chromatogram of extracted blank rat plasma. No significant 
matrix interferences were observed at the retention time for SFN (18 min).
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Figure 3.5: Calibration curve for determination of SFN in rat plasma.
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The limit of detection (LOD), defined as the lowest concentration of the analyte that 
generates signal to noise ratio of 3 was calculated to be 1 pmole/injection (5 ng/ml, 
following a 20 pi injection) (Fig. 3.6 A). The limit of quantification (LOQ), defined as the 
lowest concentration that produces an instrument response with a signal to noise ratio of 
5, was 3 pmole/injection (15  ng/m l, following a 20 pi injection) (Fig. 3 .6  B).
1 8  2 0  2 2  2 4
B
Figure 3.6: Representative LC/MS/MS chromatograms (MRM mode, 114 and 72 m/z transitions) of 
suiforaphane in spiked plasma extracts at the lim it of detection (A ) and quantification
(B). The outer peak is the more abundant 114 transition, whereas the inner peak represents the 
less abundant 72 m/z transition.
Recovery for SFN, determined by comparing the instrument response obtained from 
spiked plasma samples taken through the extraction procedure and the analyte added
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directly to the blank matrix extract and representing 100%  at three different 
concentrations (0 .05 , 0 .5  and 1.5 pg/m l, n = 6 ), was 91, 91 and 88%  respectively. At the 
same concentrations, inter-assay variation was 1.0, 2 .2  and 3.2 %  CV respectively, 
whereas intra-assay variation was for the same concentrations was 1.5, 6 .5  and 5 .0  %  
CV respectively (n = 4 ).
3 .3 .4  Pharm acokinetics o f  SFN in ra ts
A preliminary dose-ranging study showed that SFN was easily detectable in plasma of 
rats treated orally with either of the three dose levels (1 .0 , 5 .0  and 20 m g/kg) and that 
the lowest oral dose, compatible with the developed detection method, could be 
decreased to 0 .5  mg/kg (results not shown).
In the main pharmacokinetic study, four groups of male Wistar albino rats (n = 4 ), 
received either a single intravenous (0 .5  m g/kg) or oral (0 .5 , 1.0 and 5.0 m g/kg) dose 
of SFN. Analysis of the time-course changes in the plasma levels of SFN, plotted using a 
semi logarithmic plot, following intravenous administration to rats showed that the 
plasma profile was best described by a two-compartment pharmacokinetic model (Fig. 
3.7). Within two hours, plasma levels declined to about 10%  of the 0 .5  h level, they 
then remained fairly constant indicating a long terminal phase. Similarly, following oral 
administration of the same dose, a marked and rapid decline in plasma levels of SFN 
was evident between 1 hour after administration, when peak levels were achieved, and 
2 hours after administration, followed by a prolonged terminal phase (Fig. 3 .7 ). At the  
higher doses, however, the decline in plasma levels, after maxima have been attained, 
was more gradual. The pharmacokinetic parameters of SFN following oral and 
Intravenous administration are shown in table 1. The C^ax and AUCo-24 values in orally- 
treated rats increased with dose, but not proportionately; rise in AUCo-24 and Cmax values
was lower than would be anticipated. Comparison of AUTo-24 values between the
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intravenously- and oraliy-treated groups, at the 0 .5  m g/kg dose, indicate an absolute 
bioavailabllty of 82%  which, however, decreased at the higher doses. Finally, the rate of 
absorption constant kab, biological half-life tyz and apparent volume of distribution 
decreased at the highest dose used.
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Figure 3.7: Concentration of SFN in rat plasma versus tim e curves. Male Wistar albino rats 
were exposed to a single intravenous dose of 0.5 mg/kg (A) or single oral doses of 0.5, 1.0 and
5.0 mg/kg (B, C and D respectively) of SFN. Blood samples (100 pi) were withdrawn from the rat 
tail at time intervals for up to 24 hours after SFN administration. Values represent the mean ±  
SD, where n=4.
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Parameter Intravenous 
(0.5 m g/kg)
Oral 
(0.5 m g/kg)
Oral 
(1 .0  m g/kg)
Oral 
(5.0 m g/kg)
Cmax (ng/ml) - 46.4 ± 19.4 84.0 ± 19.6* 211.3 ±  24 .3 ***
Tmax (h) - 0.5 ± 0.0 0.8 ± 0.3 1.0 ± 0.7
kab (h'^) - 5.78 ± 1.70 3.74 ± 0.44 2.57 ± 1.36*
kei (h‘ )^ 0.011 ± 0.003 0.012 ± 0.002 0.015 ± 0.005 0.028 ± 0.009*
tl/2(h) 65.6 ± 16.3 62.2 ± 20.07 50.5 ± 16.0 27.3 ± 10.8**
CIp (ml/h) 265 ± 28 264 ± 18 260 ± 28 263 ± 10
Vd (1) 25.4 ± 8.3 23.8 ±  5.8 19.3 ± 7.7 10.4 ± 4.4*
AUCo-24 (ng ml'  ^ h) 476 ± 46 392 ± 26 493 ± 69* 1001 ± 3 7 ***
F% 100 82.4 ± 5.3 51.8 ±  7 .2 *** 21.0 ± 0 .8 ***
Table 3.1: Absolute bioavailability and pharmacokinetic parameters of suiforaphane 
following administration of low doses. Results are presented as mean ± SD for four animals. 
*P<0.05; **P<0.01; ***P<0.001, when compared to the 0.5 mg/kg oral dose.
3 .4  Discussion
An analytical method, utilising LC-MS/MS, that allows the determination of SFN in small 
volumes of rat plasma following exposure to low dietary doses was developed, validated 
and employed to determine its absolute bioavailability and pharmacokinetic 
characteristics in the rat following intravenous and oral administration. An 150g serving 
of fresh broccoli is expected to release 56-112 mg of SFN (Howard et al., 1997) so that 
the intake for a 70 kg individual would be 0 .8 -1 .6  m g/kg. The doses employed in this 
study of 0 .5 -5 .0  m g/kg were chosen to represent similar levels of intake.
In the current studies the animals were not deprived of food prior to administration of 
SFN, as it could have an impact on its metabolic clearance. The principal pathway of 
metabolism of this compound involves conjugation with glutathione, followed by further 
processing of the conjugate to the mercapturate (Kassahun at al., 1997). Withdrawal of
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food can result in a rapid decline in the cellular levels of glutathione (Pessayre et al., 
1979).
Following oral administration, SFN peak plasma concentrations were attained at about 
one hour, indicating rapid absorption, compatible with its lipophilicity and small 
molecular size. Similarly, in studies conducted in human volunteers, isothiocyanates, 
measured as total dithiocarbamates, were rapidly absorbed reaching peak plasma levels 
one hour after ingestion of broccoli sprout preparations (Ye et al., 2002). At the highest 
dose only, the absorption rate constant decreased, and this may explain in part the fact 
that Cmax vaiues did not rise proportionately to the dose. These observations raise the 
possibility that SFN may to some extent be absorbed by a carrier-mediated transport 
mechanism that is saturated at this dose level.
Oral absolute bioavailability of SFN in rats was over 80%  at the lowest oral dose studied. 
I t  is likely that SFN is subjected to modest first-pass metabolism as glutathione and 
mercapturate metabolites of this isothiocyanate can be generated by intestinal as well as 
hepatic enzymes, or even possibly in the blood as it contains low levels of glutathione 
that can interact chemicaliy with the isothiocyanate. Studies using human jejunum  in 
situ have established that SFN is weil absorbed by enterocytes where it is conjugated 
with glutathione during absorption and secreted back into the lumen (Petri et al., 2003).
In the present study, the oral bloavailability of SFN was dose-dependent, being only 
about 20%  at the highest dose studied of 28 pmol/kg, i.e. a quarter of that observed at 
a dose of 2.8 pmol/kg. These observations imply that intake of SFN supplements may 
not be as effective as envisaged in achieving high plasma levels of the compound. 
Isothiocyanates display high protein binding (Ji et al., 2005 and Kassie et al., 2000 ),
presumably because of their facile interaction with -S H  groups, and it is conceivable that
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at the higher doses protein-binding sites are saturated so that SFN remains free and 
available for metabolism and excretion. I t  is relevant to point out that albumin contains 
a single residue of cysteine (Cys34). The observed dose-dependent decrease in 
biological half-life values concord with such a mechanism of action. Non-linear 
pharmacokinetics in rats have also been reported for PEITC, having an aromatic 
substituent (Ji et ai., 2005 ), and collectively these observations indicate that the 
isothiocyanate group is more likely to be responsible for this effect rather than the 
substituent.
Following intravenous and oral dosing a rapid marked drop was observed in the plasma 
levels of SFN, and this most likely reflects cellular uptake. Isothiocyanates such as SFN, 
attain very high intracellular concentrations as a result of their interaction with 
glutathione (Zhang and Taialay, 1998, Ye and Zhang, 2001 and Zhang and Callaway, 
2002). As the absorbed SFN is readily conjugated with glutathione and possibly other 
thiols, the concentration gradient drives the further cellular uptake of the isothiocyanate, 
which can achieve mM concentrations, and is accompanied by a marked drop in 
glutathione levels (Conaway et al., 2005). The glutathione and cystelnylglycine 
conjugates are exported through membrane transporters such as P-glycoprotein (Zhang, 
2000 and Callaway et al., 2004). It  has been demonstrated in in vitro studies that peak 
intracellular levels of isothiocyanates are attained within 3 hours of exposure, and 
intracellular concentration may be as much as 100-foid higher than extracellular 
concentration (Zhang and Taialay, 1998). Such extensive intracellular localisation would 
explain the large apparent volume of distribution. Elimination of SFN was characterised 
by a long terminal phase; in fact, no major difference was evident in plasma levels 
between 6 and 24 h following intravenous administration or oral administration at the 
lower doses. Most likely this was a consequence of protein binding, rendering the 
isothiocyanate unavailable for elimination through metaboiism and excretion.
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In summary, the present study demonstrates that in the rat, following oral 
administration of dietary doses, SFN was rapidly absorbed, achieving high absolute 
bloavailability at low doses. However, dose-dependent pharmacokinetics was evident, 
with bloavailability decreasing with increasing dose levels.
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4.1  In troduction
The possibility of SFN accumulation foilowing repeated daily exposure was indicated by 
an observation that SFN plasma levels did not significantly differ between 6 and 24 h 
after a singie administration to rats by oral gavage (Chapter 3 ), and following ingestion 
of a single portion of broccoli preparations by humans (Gasper at ai., 2005 and Janobi et 
al., 2006). Moreover, in epidemiologicai studies the chemopreventive effect of Brassica 
vegetables was related to the level of consumption (reviewed by Conaway et al., 2002  
and Higdon et al., 2007). Additionally, suppression of the genotoxic effects of 
experimental carcinogens by ITCs in animals was noted after their addition to the diet 
continuously for extended periods of time (Staretz et al., 1997; Sticha et al., 2002 and 
Dingley et al., 2003). Thus knowledge of the pharmacokinetic behaviour of SFN following 
repeated intake will enhance our understanding of its mechanism of action. Currently, it 
is unknown whether SFN accumulates in humans regularly consuming Brassica 
vegetables, since the previous studies (Conaway et al., 2005; Gasper at al., 2005; Song 
et al., 2005 and Janobi et al., 2006) focused only on its fate following ingestion of a 
single serving of broccoli. The present study aimed to evaluate the pharmacokinetic 
behaviour of SFN in human volunteers following single and repeated intake of 
commercially available broccoli purchased locally.
A nano-flow LC-tandem mass spectrometry (LC-M S/M S) method was developed and 
successfully applied to determine SFN concentration in human plasma. Among various 
tandem mass analysers, triple quadrupole has very good quantitative capabilities in the 
multiple reactions monitoring (MRM) mode, ailowing monitoring of two or more 
characteristic transitions of each analyte, thus ensuring its unambiguous identification 
and accurate quantification at low levels in complex matrices (Willoughby et al., 2002).
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4 .2  M ethodology
4 .2 .1  Broccoli p rep ara tio n , storage and  adm in is tra tion
Raw broccoli florets, purchased locally, were washed, liquidised using a Russell Hobbs 
blender, strained, divided into portions (300m l) and frozen at -20°C. Each portion of 
liquidised broccoli was defrosted at room temperature (18  -  22°C) prior to consumption.
4 .2 .2  Hum an volunteers
The study was ethically approved by the University of Surrey Ethics Committee 
(reference EC /2007/41/SB M S) and conducted in the Clinical Investigation Unit (C IU) of 
the University. All participants gave a written informed consent and their good health 
was confirmed by their doctors (general practitioners). Six volunteers (Table 4 .1 ) were 
recruited according to the following criteria:
• Aged between 18-60 years old, male and female
• Non-smoker
• Healthy (no known medical complications)
• Not taking any medication or dietary supplements, with the exception of 
contraception.
• Must not have donated blood or participated in a trial involving blood collection in 
the past two months prior to the start of the study.
• Must not be pregnant
Volunteers were asked to attend the Clinical Investigation Unit (C IU ) before the start of 
the study for collection of a blood sample (10 ml) for full blood screening to screen for 
possible blood disorders. The participants, whose full blood screening results confirmed 
their suitability for the study, were asked to avoid consumption of ITC-containing 
vegetables for at least one day before and throughout the study period. The
participants were asked to consume 300 ml of liquidised broccoli for 10 consecutive
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mornings and blood samples were withdrawn at regular tim e intervals over 24 h periods 
on two occasions: after intake of the first and the last portion of broccoli.
Sex Age Body weight (kg)
Participant 1 Female 27 55
Participant 2 Female 33 60
Participant 3 Male 46 70
Participant 4 Male 26 90
Participant 5 Male 59 118
Participant 6 Female 37 60
Table 4.1: Details of volunteers participating in the study 
4 .2 .3  Blood collection
Biood samples were taken through a cannula inserted into a vein in the forearm on the 
first day of the study (visit 1). The first sample of blood (15  ml) was taken before the 
ingestion of broccoli to measure the baseline plasma concentration of SFN, and further 9 
blood samples (15m l each) were collected following intake of broccoli at 0 .5 , 1.0, 1.5, 
2.0, 3.0, 4 .0 , 6 .0 , 8 .0  h post-dosing. On the second day of the study (visit 2 ), a single 
blood sample (24h post-treatm ent, 15 ml) was taken from a vein in the forearm through 
a vena puncture. Visits 3 and 4 were the same as visits 1 and 2 (Fig. 4 .1 ).
Blood co l lec t ion  
visit 2
Broccol i  consumpt i on
3 4  5 6 7 8
St udy  durat ion ( d a y )
10  11
Blood  co l le c t i on  
'  V i s i t  4
Figure 4.1: Experimental design of the study into the pharmacokinetic fate of SFN in 
humans following single and repeated ingestion of broccoli. Healthy volunteers (n=6) 
consumed liquidised broccoli (300 ml) for 10 consecutive mornings and samples of their blood 
were collected for up to 24 h following ingestion of the first (visits 1 and 2) and the last (visits 3 
and 4) portion. A sample of blood prior to ingestion of broccoli was also obtained.
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4 .2 .4  Sam ple p rep ara tio n
Human plasma samples were prepared for analysis by LC-MS/MS following a method 
described by Janobi et al. (2006 ). Aliquots of the plasma (0 .5  ml) were defrosted on ice 
and mixed with ice-cold trifluoroacetic acid (10  % v /v ) to precipitate plasma proteins. 
The samples were centrifuged at 10,000 x g for 10 min, the supernatant was decanted, 
filtered through a 0 .22  pm syringe filter (Millex, Millipore corp.) and 1 pi was injected for 
analysis. Quality control (5 .0  and 40 .0  ng/m l) and standard (1 .0 -5 0 .0  ng/m l) solutions 
of SFN in blank human plasma were also carried through the same sample clean-up 
procedure. Calibration curves were constructed by plotting the peak area of SFN 
standards versus their theoretical concentration.
SFN content in the consumed by the volunteers broccoli preparation was determined by 
adapting method described by Gasper et al. (2005). Aliquots of liquidised broccoli (1 .0  
ml) were sonicated for 5-7 sec to disrupt any remaining plant tissue, diluted 1000-fold  
with solvent (95  %  water, 5 % acetonitriie and 0.1 %  of formic acid), filtered through a 
0.22 pm syringe filter (Millex, Millipore corp.), and 1 pi was injected for analysis. 
Standards (1 .0 -5 0 .0  ng/m l) of SFN were prepared in the same solvent used for dilution 
of broccoli preparation.
4 .2 .5  D eterm in ation  o f  SFN in hum an piasm a by LC -M S /M S
Plasma levels of SFN were determined by high-performance liquid chromatography 
(HPLC)-Chip/MS system, featuring the HPLC-Chip/MS cube interface. Separation of SFN 
from matrix constituents was achieved using an Agilent 1200 (Agilent Technologies, 
Germany) LC system equipped with an in-line filter and employing a reusable custom- 
made chip, containing a pre-column and 150 mm x 75 pm ACE 5 AQ analytical column 
supplied by Agilent (Agilent Technologies, Germany). Mobile phase consisted of solvent
A (water containing 0 .1%  formic acid) and solvent B (90  %  acetonitriie in water
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containing 0 .1%  formic acid). The sample was loaded onto the chip pre-column and then 
flushed (8  pi) under isocratic conditions (5%  of organic solvent B) using a capillary pump 
operating at a flow rate of 4 pl/m in. The analyte was eluted under isocratic conditions 
(65%  of organic solvent B) using a nano pump operating at a flow rate of 0 .6  pl/min. 
Under these conditions, the retention time of SFN was 1.2 minutes in a total run time of 
3 minutes.
SFN was detected on-line using an Agilent 6410 triple quadrupole mass spectrometer 
(Agilent Technologies, Germany) equipped with an electrospray ionisation source 
sprayer, operating in the positive ionisation mode. The sprayer voltage was set to 1900  
V, gas tem perature and pressure were set at 300°C  and 4 l/m in respectively. The 
analyte was detected by monitoring the specific transitions in the positive MRM scan 
mode. The collision energy (CE) and fragm enter voltage (Table 4 .2 ) necessary to 
maximise the yield of the characteristic transitions (product ions) of the protonated SFN 
[M + H]^ precursor ions were optimised by direct infusion of SFN (0 .2  pg/m l) dissolved in 
a solvent comprising 1:1 water:acetonitrile and acidified with formic acid (0 .1  % v /v ). 
Data were acquired and qualitatively analysed using the Agilent MassHunter Workstation 
and the Qualitative Software respectively. The acquired data were quantified using the 
Agilent MassHunter Quantitative Software (Agilent Technologies, Germany).
Precursor ion 
(m /z )
Product ion 
(m /z )
Fragm entor
(V )
Collision energy  
(V )
178.1
119.1
110.0
10
114.1 8
72.1 21
Table 4.2: Optimal MS/MS parameters for detection of SFN in positive MRM mode
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4 .2 .6  D ata  analysis
The pharmacokinetic parameters were calculated using a PK Solutions ™ software 
package (version 2 .0 , Summit research Services, Ohio, USA). Because of the long
terminal phase (mean t ^^2 > 33 h following single and repeated ingestion of broccoli),
pharmacokinetic parameters of SFN were calculated from the better defined Area Under
the Curve (AUC)q_2 4 , rather than from AUCq-oo to avoid introducing an inaccuracy in
extrapolating the terminal phase to time infinity. AUCq_24 was calculated using the
trapezoidal rule utilising the data determined experimentally. Apparent volume of 
distribution (Vd) was calculated from the equation Vd = FD/ AUCq_24 kg|, where kg| is
the elimination rate constant, F is the bioavailability and D is the dose. Plasma clearance 
(CIp) was determined using the equation CIp = FD/ AUCQ.2 4 . Since bioavailability of SFN
in humans following ingestion of broccoli can not be calculated from the available data, it 
was assumed that absorption of SFN was rapid and complete, i.e. F = l .  Such assumption 
is based on the previous findings that the bioavailability (F) of low doses of SFN (0 .5  
mg/kg) in rats was close to 1. Finally, C^g^^ and were determined graphically
from the plasma concentration versus time plots.
4 .2 .7  S tatistical evaluation  of pharm acokinetic p aram eter
Data were analysed individually and statistically evaluated using the paired t-test. 
Comparisons were performed between the pharmacokinetic parameters calculated from  
the data obtained for all six volunteers after single and following repeated intake of
broccoli. The statistical significance is expressed as follows:
P>0.05 not significant
P<0.05 significant ( * )
P<Q.Q1 very significant ( * * )
85
Chapter 4: Pharmacokinetics of SFN in humans
4 .3  Results
4 .3 .1  D evelopm ent and  validation o f LC -M S /M S  m ethod  fo r SFN detection in  
hum an plasm a
The compound-dependent parameters of an Agilent 6410 triple quadruple mass 
spectrometer for the MRM scan were optimised using direct infusion of SFN (0 .2  pg/m l). 
SFN spectra (Q1 scan) in the positive mode were acquired over the mass range m /z  
100-250 (Fig. 4 .2 ). The protonated SFN ion [M +  H]'*' of m /z  178.1 (precursor ion) was 
fragmented to produce SFN-specific product ions of m /z 72, 114 and 119 for monitoring
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04 -
0.2 -
1M.00000 209.20000
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Courts vs.Mass-to-Charge (nVz)
Figure 4.2: Mass spectrum  o f SFN acquired in the  fu ll-scan mode
in the multiple reaction monitoring (MRM) mode using the product ion scan operating in 
the positive mode (Fig. 4 .3 ). SFN was separated from the m atrix constituents under 
isocratic conditions at a flow rate of 0.6 pl/min using the LG system equipped with an in­
line filter and employing a reusable custom-made chip, combining a pre-column and an 
ACE 5 AQ analytical column designed to retain the hydrophilic and weakly 
hydrophobic molecules. SFN eluting under these conditions produced a good peak shape, 
high sensitivity and a short run time of 3 min. At the retention tim e for SFN (1 .2  min), 
there were no interfering peaks on the chromatograms obtained from blank human 
plasma extracts (Fig. 4 .4 ).
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Figure 4.3: Collision-induced dissociation of SFN. Fragmentation of the (M+H)^ ion of SFN
(m/z 178,1) to SFN-specific product ions of m/z 178 114.1, 178 119.1 and 178 72 at
collision energy set to 5 (A) and 10 V (B)
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Figure 4.4: A representative chromatogram of extracted blank human plasma. No
significant matrix interferences for SFN transitions (product ions) of m /z  178 72 (A), 178 ->
114.1 (B) and 178 119.1 (C) were observed at the retention time for SFN (1.2 min).
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The limit of quantification (LOQ), defined as the lowest concentration that produces an 
instrument response with a signal to noise ratio of 5, was 1 pg/injection (Fig. 4 .5 ). The 
calibration curve for SFN (Fig. 4 .6 ), constructed using the least square linear regression 
analysis of 7 data points, displayed very good linearity over the tested concentration 
range (1 -5 0  ng/m l, using the injection volume of 1 pi). The inter-assay variation at two 
different concentrations (5 and 40 ng/m l) was 9 .7  and 7.4 % CV respectively (n = 4 ), 
whereas the intra-assay variation for the same concentrations was 6.3 and 2.5 % CV 
respectively (n = 4 ).
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Figure 4.5: Representative LC-MS/MS chromatograms of SFN in spiked human plasma at 
the limit of quantification. 1 pi o f 1 pg/ml SFN standard in blank human plasma was injected 
for analysis. SFN transitions (product ions) of m /z 178 -> 119.1 (A), 178 114.1 (B) and 178
72 were monitored in positive MRM mode.
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Figure 4.6: Calibration curve for the determination of SFN in human plasma.
4 .3 .2  Pharm acokinetics o f SFN hum ans fo iiow ing s ingie an d  rep ea ted  ingestion  
o f broccoii
The SFN content of liquidised broccoli was 1.3 mg per 100 g (3 .9  mg per consumed 
portion). Analysis of the time-course changes in the plasma levels of SFN in humans, 
plotted using a logarithmic plot (Fig. 4 .7 ), following both single and repeated ingestion 
of broccoli, showed that the plasma profile fitted best a two-compartment 
pharmacokinetic model, as was the case with rats (Chapter 3). The maximum plasma 
concentration of SFN (Tmax) after ingestion of a single portion of liquidised broccoli was 
attained in 1.0 to 1.5 h in all six volunteers. Similarly, plasma SFN concentration peaked 
at 1.0 to 1.5 h following repeated ingestion of liquidised broccoli. After both single and 
repeated intake of broccoli, plasma levels rapidly declined reaching 50%  at around 3 h 
and falling to about 10-15 % from the peak levels by about 8 h, and remained fairly 
constant between 8 and 24 h (Fig. 4 .7 ), indicating a relatively long terminal phase. 
However, despite the relatively long terminal phase, the maximum plasma levels of SFN 
following single or repeated ingestion of broccoli did not significantly differ (Table 4 .3 ), 
suggesting lack of a cumulative effect.
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Figure 4.7: SFN plasma concentrations in human volunteers following single and 
repeated ingestion of broccoli versus time curves. Healthy volunteers (n=6) consumed 
liquidised broccoli (300 ml) for 10 consecutive mornings and blood samples were collected for up 
to 24 h following ingestion of the first (single intake) and the last (repeated intake) portion. A 
sample of blood prior to ingestion of broccoli was also obtained. Results are mean ± SD of 
duplicate determinations.
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Single broccoli intake
Parameter Volunteer1
Volunteer
2
Volunteer
3
Volunteer
4
Volunteer
5
Volunteer
6
Mean 
± SD
Cmax
(ng/ml) 14.07 11.32 12.41 10.37 10.65 14.07 12.15 ± 1.65
Tmax (h ) 1.0 1.0 1.5 0.5 1.5 1.5 1.2 ± 0.4
kab(h') 2.3 2.3 1.7 2.4 2.1 1.9 2.1 ± 0.3
ke,(h-^) 0.025 0.011 0.027 0.011 0.020 0.054 0.025 ± 0.016
ti/2 (h) 27.4 62.9 25.3 62.3 34.4 12.8 37.5 ± 20.6
CIp (m l/h) 55.4 54.4 58.5 65.8 80.1 52.0 61.0 ± 10.5
Vd (1) 2.19 4.94 2.14 5.91 3.98 0.96 3.35 ± 1.90
AUCo-24 
(ng ml'  ^h) 70.39 71.69 66.61 59.31 48.71 75.03 65.29 ± 9.74
Repeated broccoli intake
Parameter Volunteer Volunteer Volunteer Volunteer Volunteer Volunteer
Mean
1 2 3 4 5 6 ± SD
(ng/ml) 15.54 12.84 13.16 9.68 9.33 13.93 12.41 ± 2.44
Tmax (h ) 1.0 1.0 1.5 1.0 1.5 1.0 1.2 ± 0.3
kab(h-^) 3.7 4.6 1.7 2.2 3.0 2.0 2.9 ± 1.2
kel(h') 0.041 0.016 0.027 0.010 0.032 0.030 0.026 ± 0.011
ti/2 (h) 17.0 43.7 25.4 67.8 21.5 23.2 33.1 ± 19.3
CIp (m l/h) 63.4 53.8 54.7 64.3 71.7 57.6 60.9 ± 6.8
Vd (1) 1.56 3.42 2.00 6.26 2.22 1.93 2.90 ± 1.76
AUCo-24 
(ng ml'  ^h) 61.56 72.00 71.25 60.97 54.36 67.73 64.65 ± 6.87
Table 4.3: Pharmacokinetic parameters of SFN in humans following single and repeated  
ingestion of liquidised broccoli. Healthy volunteers (n=6) consumed liquidised broccoli (300 
ml) for 10 consecutive mornings and blood samples were collected for up to 24 h following 
ingestion of the (single intake) and the last (repeated intake) portion. A sample of blood prior to 
ingestion of broccoli was also obtained.
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4 .4  D iscussion
An analytical LC-MS/MS method that allows determination of SFN present at low 
concentrations in human plasma was developed, validated and employed to determine 
its pharmacokinetic behaviour following single and repeated ingestion of commercially 
available broccoli.
In the current study SFN was rapidly absorbed attaining peak plasma concentration 
levels between 60 and 90 min following either single or repeated ingestion of broccoli. 
This concords with previous studies in humans, where plasma ITCs, measured as total 
dithiocarbamates (ITCs and their thiol conjugates) (Ye et al., 2002) or as SFN (Gasper at 
al., 2005 and Janobi et al., 2006) reached peak levels by 1.0 to 2 .0  hour after ingestion 
of raw or lightly microwaved broccoli. However, the rate of absorption appears to vary 
considerably and can be significantly less rapid. ITCs, measured as total plasma 
dithiocarbamates, peaked between 2 to 6 h after ingestion of Broccoli sprouts (Conaway 
et al., 2000). The discrepancy in the absorption rate between the studies by Conaway et 
al. (2000) and Ye et al. (2002) can not be attributed to differences in methodology and 
study design because the amount of ITCs ingested by each volunteer (about 0 .2  mmol) 
and the methodology (both studies used cyclocondensation method) for determining 
total plasma ITCs is sufficiently similar between the latter study and the study by Ye et 
al. (2002). The cyclocondensation method lacks discrimination between individual ITCs 
and their mercapturates (Conaway et al., 2000 and Ye et al., 2002). The increase in 
time it takes to reach the Cmax may be due to inter-individual differences in the GST 
phenotype. Human G STAl, GSTA2, and to a lesser extent GSTM, can bind to and 
sequester glutathione conjugates of ITCs (Meyer et al., 1995). Consequently, in GSTA 
and GSTM-positive individuals such sequestered GS-ITC conjugates could be released 
from the cells into plasma after a time lag.
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In the rat study (Chapter 3 ), the pharmacokinetic behaviour of SFN was dose-dependent 
(Chapter 3), with the decline in plasma levels becoming steeper at lower dose levels. 
The average intake of SFN in the current study was approximately 0 .07 m g/kg, which is 
nearly an order of magnitude lower than the lowest (0 .5  m g/kg) dose administered to 
rats; however, the decline in plasma SFN levels in humans was considerably less steep 
compared with the rat, raising several possibilities: 1) the intact glucosinolates were 
present in the broccoli preparation, 2) most of the absorbed SFN dose may be bound to 
plasma proteins, limiting its availability for metabolism, and/or a substantial part of the 
SFN dose may be absorbed from the gut after a time lag following dissociation of the 
reversible complexes with food constituents. As for the first possibility, the absorption of 
SFN, formed from its precursor glucoraphanin as a result of myrosinase activity of the 
colon bacteria (Rungapamestry et al., 2007) has been shown to be delayed by a few 
hours (Ye et al., 2002 and Rouzaud et al., 2004). Consequently, presence of intact 
glucosinolates In the broccoli preparation could distort the pharmacokinetic behaviour of 
SFN at the absorption/distribution phase. Glucoraphanin content of broccoli preparation 
remains to be determined in order to establish whether its was fully converted to SFN. 
However, the broccoli florets used in the current study were liquidised to maximise 
myrosinase-dependent formation of SFN from its glucosinolate precursor, so that most 
of SFN in such broccoli preparation had been formed and was available for immediate 
absorption (Rungapamestry et al., 2007). The second possibility is supported by the 
observation that the Vd of SFN in humans was significantly lower compared with rats, 
implying that most of the absorbed dose could be bound to plasma proteins. SFN, being 
highly reactive towards thiol groups of proteins, readily forms reversible 
dithiocarbamates (Thornalley, 2002; Kassie et al., 2000 and Zhang, 2001) and is likely 
to bind to plasma albumin. Thus the amount of "free" SFN capable of entering cells and 
available for metabolism would be limited to the rate of spontaneous dithiocarbamates 
dissociation. It  should also be noted that the elimination of SFN may be enhanced by
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binding non-enzymatically to thiols such as homocysteine, cysteine, cysteineglycine and 
glutathione, which are present in plasma at micromolar levels. However, given that most 
plasma thiols exist either in the oxidised form or are bound to plasma proteins and are 
unavailable for binding (Mansoor et al., 1992, Andersson et al., 1993 and Di Giuseppe et 
al., 2004), the extent of such binding is unlikely to be high. Finally, ITCs readily form 
reversible complexes with thiol groups of macromolecules (Thornalley, 2002). Such non­
specific binding to food constituents may limit immediate availability of ITCs for 
absorption. The bound fraction of ITC dose is likely to be absorbed after a time lag, 
following dissociation ITC-macromolecule complexes (Johnson, 2002).
Maximal concentration of SFN achieved in human plasma after either single or repeated 
ingestion of broccoli did not exceed 80 nmol/l. This level is considerably lower than was 
previously reported in humans after ingestion of various broccoli preparations (Gasper at 
al., 2005 and Janobi et al., 2006). The observed discrepancy is likely to be due to a 
number of factors influencing the glucosinolate content of broccoli. Up to a third of 
glucosinolates can be lost during storage (Song and Thornalley, 2007). Broccoli used in 
the current study was purchased from a supermarket and is likely to have been stored 
for some time prior to sale, whereas broccoli used in the previous human trials was 
freshly harvested or of a variety selected for its high glucosinolate content. Furthermore, 
a number of additional factors significantly influence the glucosinolate content and the 
extent of their conversion to isothiocyanates, such as the cultivar, age of the plant, 
weather, soil and processing conditions of broccoli (Howard et al., 1997; Song and 
Thornalley, 2007). Consequently, the glucosinolate and SFN content of broccoli vary 
widely. The SFN content of Broccoli used in the current study was 1.3 mg per 100 g, but 
could be as high as 49 m g/100 g (Howard et al., 1997). In  the present study, broccoli 
was obtained from a local supermarket in order to simulate the levels of intake by the 
vast majority of consumers.
—
Chapter 4: Pharmacokinetics of SFN in humans
There was no significant difference between the pharmacokinetic profiles of SFN 
following a single and repeated ingestion of broccoli. Although SFN plasma levels did not 
significantly decrease between 8 and 24 h, suggesting that it may accumulate after 
repeated intake, this phenomenon was not observed. Considering that the rate of either 
in vivo or in vitro dithiocarbamate dissociation to release "free" ITC that can enter the 
cell is slow (Ye et al., 2002 ), binding to plasma proteins such as albumin, which contains 
a single residue of free cysteine (Sugio et al., 1999), can be regarded as possible 
mechanism of ITC accumulation. Moreover, the low Vd of SFN (about 3 I) in humans was 
consistent with its plasma localisation as a result of extensive protein binding. I t  appears 
that the dose of SFN (0 .07  mg/kg for a 70 kg individual) employed in the current study 
was insufficient for clear manifestation of the accumulation effect.
It  is not clear whether the pharmacokinetic behaviour of SFN in humans may be dose-
dependent, as was noted in rats, and/or species-specific. The apparent Vd of SFN in rat
(Chapter 3) was clearly dose-dependent and large (25  I at 0 .5  mg/kg dose level),
whereas in humans following either single or repeated Broccoli intake it was significantly
smaller (3 I). At higher dose levels achieved after consumption of Broccoli sprouts, the
apparent Vd of total ITCs in human was about 60 I, indicating possible distribution
throughout the total body water (Ye et al., 2002). However, the cyclocondensation
method used by Ye et al., (2002) to determine plasma ITC levels does not allow the
differentiation between individuals ITCs and their mercapturates; thus it is impossible to
relate the apparent Vd of total dithiocarbamates to that of SFN, Subsequent studies on
metabolic fate of SFN in humans after ingestion of various broccoli preparations used
more sensitive LC/MS/MS methodology specific for SFN, but, unfortunately, no PK
parameters were calculated (Gasper et al., 2005; Song at al., 2005 and Janobi at al.,
2006), although the SFN plasma levels after ingestion of "standard" broccoli appear to
decline slower compared to "high" glucosinolate broccoli (Gasper et al., 2005),
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suggesting that the pharmacokinetic behaviour of SFN in humans may be dose- 
dependent. Additional studies are required to establish whether pharmacokinetic 
behaviour of SFN in humans is dose-dependent.
Biphasic elimination of SFN in humans following intake of broccoli, characterised by a 
long terminal phase, is most likely a consequence of protein binding, limiting its 
metabolism and excretion. Non-linear and dose-dependent (Ji and Morris, 2003 and Ji et 
al., 2005) pharmacokinetic behaviour in rats has also been reported for PEITC, which 
has an aromatic substituent, and collectively these observations indicate that the 
isothiocyanate group is responsible for this effect rather than the substituent. A recent 
study conducted in our laboratory (N. Konsue, personal communications) indicated that 
maximum PEITC plasma concentrations (Cmax) in rats were higher after repeated oral 
administration.
In summary, the results of the present study show that SFN does not appear to 
accumulate in humans after repeated consumption of Broccoli, most likely reflecting its 
low SFN content. The overall pharmacokinetic behaviour of SFN in humans, following 
either single or repeated ingestion of broccoli, and in rat appear to be similar, although, 
in view of significant differences in dose levels, it is not possible to reach a definite 
conclusion.
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5.1 In troduction
Previous studies have demonstrated that SFN is an effective suppressor of chemically- 
induced tumour development in rodents (Zhang et al., 1994; Chung et al., 2000; Fahey 
et al., 2002, Hecht et al., 2002; Changjiang et al., 2006; Dinkova-Costova, 2006 and 
Shen et al., 2007). Of the various chemopreventive mechanisms of ITCs operating at 
different stages of tumourigenesis, the ability of these phytochemicals to suppress 
generation and/or to enhance detoxification and elimination of mutagens is of 
paramount importance at the initiation stage. Both, inhibition of cytochromes P450 
(Barcelo et al., 1996, Jiao et al., 1996, Maheo et al., 1997 and Zhou et al., 2006) and 
marked induction of Phase I I  enzymes such as QR and GST (Zhang et al., 1992; Zhang 
et al., 1994; Gerhauser et al., 1997; Fahey et al., 1997; Gao and Talalay, 2004; Maheo 
et al., 1997; Rose et al., 2000; Brooks et al., 2001; Misiewicz et al., 2004; Munday and 
Munday, 2004; Ritz et al., 2006 and Dinkova-Kostova et al., 2007) have been reported 
previously following exposure to SFN. Even when administered at dose levels that 
approximate human intake, sulforaphane augments activity of antioxidant enzymes such 
as QR (Yoxall et al., 2005) and GST (Zhang and Talalay, 1998).
While SFN is one of the most extensively researched ITCs, surprisingly few studies 
evaluated the effect of erucin on XMEs. I t  appears that both compounds are equipotent 
inducers of GST and OR activities when administered to rodents (Zhang at al., 1992 and 
Munday and Munday, 2004). Considering that in the Western diet, most cruciferous 
vegetables, the major source of the glucosinolate precursor of SFN, are usually 
consumed cooked, erucin has an important advantage over SFN in that rocket salad 
{Eruca sativa), the principal source of the glucosinolate precusor of erucin glucoerucin 
(Vaughn and Berhow, 2004 ), is ingested raw. Thermal processing of vegetables leads to 
a substantial loss of glucosinolates, but more importantly, inactivates plant myrosinase,
the enzyme that converts the glucosinolates to the active ITCs and, consequently, ITC
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bioavailability is substantially reduced, as only 10-20%  of all glucosinolates are 
converted to ITCs by mammalian gut bacteria (Conaway et al., 2000 and Shapiro et al., 
2001).
Since previous in vitro (Zhang at al., 1992 and Jakubikova et al., 2005) and in vivo 
(Zhang at al., 1992 and Munday and Munday, 2004) studies focussed only on 
modulation of Phase I I  enzyme systems, the aim of this study was to evaluate the 
potential of erucin to modulate cytochrome P450 enzymes as well as Phase I I  enzymes 
in the liver, the principal site of xenobiotic metabolism, and the lung, the target tissue in 
ITC-mediated chemoprevention (Higdon et al., 2007), when administered to rats at 
dietary relevant doses. Moreover, the effect of erucin on activity and expression of XME 
is compared to that of sulforaphane.
Moreover, as isothiocyanates, with either aliphatic or aromatic side chain, can be 
metabolically converted to intermediates that can inactivate the cytochrome P450 
(Goosen et al., 2000, 2001; Moreno et al., 1999), the ability of erucin to act as a 
mechanism-based inhibitor was evaluated and compared with sulforaphane. Finally, the 
ability of erucin to modulate the CYPlA-associated metabolic activation of the  
heterocyclic amine IQ  to mutagens was evaluated using the Ames mutagenicity assay.
5.2  Methods
5 .2 .1  Test com pound form ulation  and  storage
The control grroup of animals received tap water containing the solvent vehicle only 
(DMSO, 0 .05%  v /v ). Stock solutions of erucin and sulforaphane were prepared in DMSO 
(300m g/m l w /v ) and diluted with tap water to achieve final concentrations of 30m g/l 
and 150m g/l (v /v ) for erucin, corresponding to approximate daily doses of 3 and 15
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mg/kg respectively, and 150m g/l for sulforaphane, approximating daily dose of 15 
mg/kg. All aqueous solutions of ITCs were prepared in advance and stored at -  20°C as 
aliquots that were defrosted as required at 4°C overnight prior to administration.
5 .2 .2  A nim al rece ip t a n d  s tudy  design
The commercial source and the conditions at which the animals were maintained during 
acclimatisation and study periods are described in section 2 .2 .1 . Twenty male Wistar 
albino rats (about 180g) were randomly assigned to 4 groups of 5 animals as follows:
Group A: Control, tap water and normal standard rodent diet 
Group B: Low dose of erucin -  30m g/litre in tap w ater and standard rodent diet 
Group C: High dose of erucin -  150m g/litre in tap w ater and normal rodent diet 
Group D: High dose of SFN -  150m g/litre of tap w ater and normal rodent diet
After the acclimatisation period of 4 days, the animals were maintained on the 
respective treatm ent regimes for 10 days. At the end of the study, animals were killed 
by cervical dislocation and their terminal body weights were recorded. Livers and lungs 
were excised and placed in ice-cold solution of KCI (1 .1 5 % , w /v ). The tissues were 
processed and stored as described in section 2 .2 .6 .
5 .2 .3  D eterm in ation  o f  XM E activ ities
The dealkylations of methoxy-, ethoxy-, pentoxy-resorufin and 7-benzyloxyquinoline 
were determined using the microsomal fraction as described in sections 2 .2 .7  and 2 .2 .8 . 
The following assays were performed in the cytosol: QR using MTT [3 -(4 ,-5 -  
dim ethylthiazo-2-yl)-2,5-diphenyltetrazolium  bromide] as substrate, glutathione S- 
transferase activity using as accepting substrates CDNB, DCNB and NBD-CI, and total 
glutathione (sections 2 .2 .1 0 -2 .2 .1 2 ). Protein concentration in both fractions was
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determined as described in section 2 .2 .6 . Finally, changes in enzyme protein expression 
were identified and quantified by Western blot analysis (section 2 .2 .13 ).
5 .2 .4  In h ib itio n  o f  C Y P lA l b y  erucin and  SFN
The methodology of assessing whether erucin and SFN could function as competitive 
and/or NADPH-dependent inhibitors of C YP lA l in Aroclor-1254 induced rat hepatic 
microsomes is described in Chapter 2 (sections 2 .2 .7 .1  and 2 .2 .7 .2 ). The ability of 
oxidised and reduced glutathione to prevent inhibitory effect of these compounds on rat 
CYPlA l activity was determined as detailed in section 2 .2 .7 .2 .
5 .2 .5  Am es m u tag en ic ity  studies
Mutagenic activity elicited by IQ was monitored using the Ames mutagenicity assay In 
the presence of an activation system containing 10 %  (v /v ) hepatic 59 preparations 
from control, erucin- and Aroclor 1254-treated rats, and employing Salmonella 
typhimurlum  YG1024 as the indicator strain, as detailed in section 2 .2 .14 . The Aroclor 
1254-induced hepatic S9 fraction was prepared from the livers of W /A rats Injected 
intraperitonealy with a single dose of Aroclor 1254 (0 .5  g/kg of body weight) dissolved in 
corn oil (0 .2  g /m l), and killed on the 5‘  ^ day after dosing.
5 .2 .6  In h ib itio n  o f cytochrom e P 450  by erucin and  SFN
The methodology for assessing whether erucin and SFN could function as competitive 
and/or NADPH-dependent inhibitors of C YP lA l in Aroclor-1254 induced rat hepatic 
microsomes is described in Chapter 2 (sections 2 .2 .7 .1  and 2 .2 .7 .2 ). The ability of 
oxidised and reduced glutathione to reverse inhibitory effect of erucin and SFN on rat 
C YPlA l activity was determined as detailed in section 2 .2 .7 .2 .
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5.3  Results
5.3 .1  Effects o f  erucin an d  sulforaphane on w a te r-in tak e  an d  body w eigh t
The animals remained in good health throughout the duration of the study; no clinical or 
behavioural signs of systemic toxicity were apparent among the different treatm ent 
groups. The body weight and water consumption were recorded daily (on weekdays 
only). Addition of test compound to the drinking water did not deter the animals from 
drinking; consequently, although the water consumption fluctuates (Fig. 5.1 A), the 
fluctuation pattern does not significantly differ among the groups. All animals 
progressively gained weight (Fig. 5.1 B) at the expected rate, with no significant 
differences between the groups.
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Figure 5.1: Body weight gain (A) and intake of water (B) supplemented with erucin or 
sulforaphane by rats. Male Wistar albino rats were administered erucin (30 or 150 m g/l), SFN 
(150 mg/i) or solvent vehicle DMSO, 0.05% v/v) in drinking water for 10 days. Results are 
presented as the means for five animals, but error bars have been omitted for clarity.
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5 .3 .2  M odulation o f  ra t hepatic  XMEs activ ity  and  expression by  d ie tary  doses 
o f erucin and  sulforaphane
Treatment of rats with either compound failed to modulate the hepatic dealkylations of 
methoxy-, ethoxy- or pentoxy resorufin and of 7-benzoyloxyquinoline (Fig. 5 .2). 
Immunoblot analysis employing antibodies to rat C YP lA l recognised a singie band, 
presumably CYP1A2, whose levels were modestly (30 % ) elevated by the highest
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Figure 5.2: Effect of treatm ent with erucin on activities of rat hepatic cytochrome P450  
enzymes. Male Wistar albino rats were administered erucin (30 or 150 mg/l), SFN (150 mg/l) or 
solvent vehicle (DMSO, 0.05% v/v) in drinking water for 10 days. EROD (A), MROD (B), PROD (C) 
and 7-BQ (D) activities were determined in microsomal fraction using ethoxy-, methoxy- or 
pentoxyresorufin and 7-benzyloxyquinoline as respective probes. Results are presented as mean ± 
SD, where n = 5. *P<0.05.
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dose of erucin. SFN also significantly elevated (100% ) CYP1A2 expression at the highest 
dose level (Fig. 5.4  A). A single band was also recognised by the antibodies to C Y P IB I, 
expression of which increased to a similar extent following treatm ent of the animals with 
the higher dose of erucin and SFN (Fig. 5.4  A). Treatm ent with erucin failed to modulate 
the levels of the CYP2B1 and CYP3A2 proteins, detected as single bands by the 
respective anti-rat serum (Fig. 5.4 A).
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Figure 5.3: Effect of treatment with erucin 
on rat hepatic phase I I  enzyme activities.
Male Wistar albino rats were administered erucin 
(30 or 150 m g/l), SFN (150 mg/l) or solvent 
vehicle (DMSO, 0.05% v/v) in drinking water for 
10 days. The activities of GSTs, analysed using 
CDNB (A), DCNB (B) or NBD-CI (C) as accepting 
substrates, QR (D) and total glutathione (E) 
were determined in the cytosolic fraction. 
Results are presented as mean ± SD, where 
n=5. *, P<0.05, * * , P<0.01 and * * * ,  P<0.001.
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Figure 5.4: Modulation of rat hepatic cytochrome P450 (A ) and Phase I I  (B ) enzymes by 
treatm ent w ith ITCs. R ats  w e re  expo sed  to  e ru c in  o r SFN fo r  10  days  th ro u g h  th e ir  d rin k in g  
w a te r . H e p a tic  m ic ro s o m a l (A ) and  cytoso lic  (B ) p ro te in s  w e re  reso lve d  by S D S -P A G E  b e fo re  being  
tra n s fe rre d  e le c tro p h o re tic a lly  to  H y b o n d -P  p o ly v in y lid e n e  d iflu o rid e  m e m b ra n e s . Im m u n o b lo t  
analys is  w as c a rried  o u t using an tib o d ie s  to  c y to c h ro m e  P 4 5 0  p ro te in s , fo llo w e d  by th e  
a p p ro p ria te  p e ro x id a s e -la b e lle d  seco n d a ry  a n tib o d y . Each lan e  w as  load ed  w ith  5 (C Y P 2B 1 , 
CYP 3A 2, G STa and  GST ij) o r 4 0  pg (C Y P IA , C Y P IB I ,  G S Tn and  Q R ) o f to ta l p ro te in . M o le c u la r  
m a rk e rs  w e re  run c o n c u rre n tly  to  aid band id e n tif ic a tio n . T h e  v a lu e s  in ita lics  show  o p tica l d en s ity  
p erc e n ta g e  o f each  band  re la t iv e  to  co n tro l.
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Total glutathione levels and cytosolic glutathione S-transferase activity in the liver, 
determined using CDNB or DCNB as substrates, were unaffected by either, erucin or SFN 
treatm ent; however, when NBD-CI was used as a substrate, activity was significantly 
enhanced by SFN treatm ent only. Both compounds augmented quinone reductase 
activity (Fig. 5 .3 ). Im munoblot analysis indicated that erucin, at both dose levels, as well 
as SFN, up-regulated the levels of GSTa, GSTp, and, in particular, QR, while GSTtt was 
unaffected (Fig. 5 .4  B).
5 .3 .3  M odulation o f  pu lm onary  XM E activ ities  an d  expression in  ra ts  trea ted  
w ith  d ie ta ry  doses o f  erucin and  sulforaphane
In the lung, neither isothiocyanate modulated the O-dealkylation of the alkoxyresorufins 
(Fig. 5 .5 ); 7-benzyloxyquinoline demethylase was not detectable in this tissue. 
Immunoblot studies revealed that erucin, at both doses, as well as sulforaphane 
elevated pulmonary C Y P lA l apoprotein levels (Fig. 5.7 A). Similarly, the higher erucin 
dose and sulforaphane increased the band recognised by antibodies to C Y P IB I by 80 
and 70%  respectively. No changes were evident in the expression of CYP2B1 or CYP3A2 
(Fig. 5.7 A).
Neither GST activity, monitored with CDNB or NBD-CI, nor total glutathione levels were 
influenced by the isothiocyanate treatm ent. Quinone reductase activity, which was 
higher in the lung compared with the liver, was clearly elevated by the treatm ents with 
erucin or sulforaphane (Fig. 5 .6 ). The increase in quinone reductase activity was 
paralleled by a similar rise in protein levels determined by immunoblot, which more 
than doubied in animals treated with the high erucin dose and sulforaphane respectively, 
in comparison with controls (Fig. 5.7 B). Erucin, at the higher dose, similar to 
sulforaphane, raised the levels of GSTa by 25-30%  whereas GSTti and GSTp were 
unaffected (Fig. 5.7 B).
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Figure 5.5: Effect of treatment with erucin and sulforaphane on rat pulmonary 
cytochrome P450 enzyme activities. Male WIstar albino rats were administered erucin (30 or 
150 mg/l), SFN (150 mg/l) or solvent vehicle (DMSO, 0.05% v/v) in drinking water for 10 days. 
EROD (A) and PROD (B) activities were determined in microsomal fraction using ethoxy- or 
pentoxyresorufin as respective probes. Results are presented as mean ± SD for five rats. 
*P<0.05.
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Figure 5.6: Effect of treatment with erucin and sulforaphane on rat pulmonary phase I I  
enzyme activities. Male Wistar albino rats were administered erucin (30 or 150 mg/l), SFN (150 
mg/l) or solvent vehicle (DMSO, 0.05% v/v) in drinking water for 10 days. The activities of GSTs, 
analysed using CDNB (A) or NBD-CI (B) as accepting substrates, QR (C) and total glutathione 
levels (D) were determined in the cytosolic fraction. Results are presented as mean ± SD, where 
n=5. P<0.05 and * * , P<0.01.
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Figure 5.7: Modulation of rat pulmonary cytochrome P450 (A ) and Phase I I  (B ) enzymes 
by treatm ent w ith erucin and sulforaphane. Rats were exposed to erucin or sulforaphane 
through their drinking water for 10 days. Pooled pulmonary microsomal (A) and cytosolic (B) 
proteins were resolved by SDS-PAGE before being transferred electrophoretically to Hybond-P 
polyvinylidene difluoride membrane. Immunoblot analysis was carried out using antibodies to 
cytochrome P450 proteins, followed by the appropriate peroxidase-labelled secondary antibody. 
Each lane was loaded with 5 (CYP2B1, GSTn and GSTp), 20 (CYP3A2, GSTa and QR) or 40 pg 
(CYPIA and CYPIBI,) of total protein. Molecular markers were run concurrently to aid band 
identification. The values in italics show optical density percentage of each band relative to 
control.
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5 .3 .4  In a c tiv a tio n  o f  EROD b y  erucin and  SFN
To investigate whether the observed decrease in B(a)P-medlated up-regulatlon of 
CYPlA l by ITCs was associated with their potential to act as competitive and/or 
mechanism-based inhibitors of this enzyme, the inhibitory activity of erucin and SFN (25  
and 50 pM) on C YPlA l-m ediated 0-deethylation of ethoxyresorufin (0 -2  pM), was 
determined in vitro using hepatic microsomes from Aroclor-1254 induced rats. 
Michaelis-Menten constant (K m) and V^ax values (Table 5 .1 ), obtained from the linear 
Lineweaver-Burk plot (Fig 5 .8 ), were not influenced by erucin, indicating lack of direct 
inhibitory effect of these phytochemicals on C YP lA l enzyme activity.
The potential of erucin and SFN to function as mechanism-based inactivators of C Y P lA l, 
was evaluated in hepatic microsomes prepared from Aroclor 1254-induced rats by 
monitoring the rate of C YPlA l-m ediated 0-deethylation of ethoxyresorufin following 
pre-incubation of ITCs in the presence of NADPH. Mechanism-based enzyme inactivation 
is characterised by a metabolic conversion of the inactivator to a reactive intermediate in 
the presence of NADPH. After 0 .5  h pre-incubation of hepatic microsomes with erucin or 
SFN (0 -100  pM), EROD activity declined in a concentration-dependent manner, with only 
20 and 30%  of residual EROD activity detected at 100 pM erucin and SFN respectively 
(Figs. 5.9 A and B). The ITC concentration required to achieve a 50 %  inhibition of EROD 
activity was about 25 pM.
In further studies, hepatic microsomes, prepared from Aroclor 1254-induced rats, were 
pre-incubated for different time periods, up to 1 h, at 37 °C in the presence of erucin or 
SFN (0 or 25 pM) and NADPH, to determine whether NADPH-dependent EROD inhibition 
by ITCs is time-dependent. Although both erucin and SFN significantly inhibited EROD 
activity in a tim e-dependent manner (EROD activity was about 50 %  at 30 m in), erucin 
displayed a stronger inhibitory activity compared with SFN (Fig. 5.9 C).
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Figure 5.8: Lineweaver-Burk plot of EROD activity in hepatic microsomes in the presence 
of erucin (A) or SFN (B). The rate of ethoxyresorufin 0-deethyiation was monitored in Aroclor 
1254-induced mcrosomes in the absence and presence of erucin (10 and 25 pM), employing 
multiple ethoxyresorufin concentrations (0-2 pM). Each point represents the mean ± SD of 
triplicate determinations.
The potential of reduced and oxidised glutathione to prevent ITC-m ediated inhibition of 
0-deethyiation of ethoxyresorufin was evaluated using Aroclor 1254-induced rat liver 
microsomes pre-incubated in the presence of erucin or SFN (25 pM), NADPH and
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reduced or oxidised glutathione (0-200pM ) for 0 .5  h. Reduced glutathione prevented 
inhibition of microsomal EROD by erucin and SFN in a concentration-dependent manner, 
restoring activity to control values at glutathione concentrations of 100 to 200 pM (Fig. 
5.10 A). In contrast, oxidised glutathione failed to prevent ITC-mediated loss of EROD 
activity under similar experimental conditions (Fig. 5 .10 B).
T reatm en t (p m o l/m in /m g  pro te in ) Km (p M )
Control 
10 pM erucin 
25 pM erucin
3031 ± 173 
2929 ± 165 
2878 ± 169
0.29 ± 0.06 
0.27 ± 0.05 
0.28 ± 0.06
Treatm en t ^max(p m o l/m in /m g  p ro te in ) Km (p M )
Control 3031 ± 173 0.29 ± 0.06
10 pM SFN 2972 ± 227 0.27 ± 0.08
25 pM SFN 3058 ± 183 0.32 ± 0.07
Table 5.1: Effect of erucin (A) and SFN (B) on EROD kinetics in Aroclor 1254-induced rat 
hepatic microsomes. The rate of ethoxyresorufin 0-deethyiation was monitored in the absence 
and presence of SFN (10 and 25 pM) over multiple substrate concentrations (0-2 pM). Km and 
Vmax values were determined by non-iinear curve fitting. The values represent mean ± SD of 
triplicate determinations.
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Figure 5.9: Effect of pre-incubation on the inhibition of the hepatic O-deethylation of 
ethoxyresorufin by erucin and sulforaphane. Microsomes from Aroclor 1254-treated rats, 
supplemented with NADPH, were pre-incubated for 30 minutes in the presence of erucin (A) or 
sulforaphane (B) (0-100 pM), and reaction was initiated by addition of ethoxyresorufin. The 100 % 
activity after a 30-minute pre-incubation in the two studies was 2.74 + 0.20 and 3.18 ± 0.21 
nmol/min per mg protein. C. Microsomes from Aroclor 1254-treated rats, fortified with NADPH, 
were pre-incubated for various periods of time (0-60 minutes) in the absence or presence of 
erucin or sulforaphane (25 pM), and reaction was initiated with the addition of the substrate. 
Results are presented as mean ± SD of triplicate determinations. * , P<0.05; * * ,  P<0.01, * * * ,  
P<0.001.
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Figure 5.10: Effect of glutathione on the erucin- and sulforaphane-mediated inhibition of 
the O-deethylation of ethoxyresorufin. Microsomes from Aroclor 1254-treated rats, fortified 
with NADPH, were pre-incubated for 30 minutes in the presence of erucin or sulforaphane (25 pM), 
and reduced (A) or oxidised (B) glutathione (0-200 pM); reaction was initiated with the addition of 
ethoxyresorufin. The 100 % activity after a 30-minute pre-incubation in the two studies was 2.33 
± 0.08 and 3.25 ± 0.17 nmol/min per mg protein. Results are presented as mean ± SD of triplicate 
determinations. * , P<0.05; * * ,  P<0.01, * * * ,  P<0.001.
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5 .3 .4  E ffect o f  p re -tre a tm e n t w ith  erucin and  SFN on m utagen ic ity  o f  IQ
The bioactivation of the heterocyclic amine IQ to genotoxic intermediates in the Ames 
test was determined in the presence of hepatic post-mitochondrial preparations from  
control, Aroclor 1254-, erucin- and sulforaphane-pretreated rats. A concentration- 
dependent mutagenic response, induced by IQ , was evident in the presence of all 
activation systems, but the Aroclor 1254 system was clearly the most efficient; 
treatm ent with either isothiocyanate caused a modest decrease in mutagenic response 
(Fig. 5 .11).
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Figure 5.11: Effect of erucin treatment on the rat hepatic activation of IQ to mutagenic 
intermediates in the Ames test. Rats were exposed to erucin, at two dose levels, or SFN 
through their drinking water for 10 days. Mutagenic activity was determined in the presence of 
activation systems containing hepatic 89 (10%, v/v) derived from control, Aroclor 1254- (positive 
control) and erucin-treated rats. Salmonella typhimurium YG1024 and IQ (100-1000 ng/plate). 
Mutagenic activity of IQ (1000 ng/plate) was 7596 ± 1240 revertant colonies per plate in the 
presence of Aroclor 1254-induced activation system. The spontaneous reversion rate of 48 ± 8 has 
already been subtracted. Results are presented as mean ± SD for triplicate plates.
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5 .4  Discussion
The aim of this study was to evaluate the potential of the aliphatic isothiocyanate erucin 
to modulate glutathione 5-transferase and quinone reductase, two pivotal enzymes in 
the detoxication of reactive intermediates and prevention of oxidative stress, and 
cytochromes P450, the most important enzyme system in the generation of these 
intermediates. The choice of Phase I  enzymes monitored in this project was based on 
the following considerations: the role in bioactivation of pro-carcinogens, the possibility 
of interactions with drugs and the impact on the biotransformation of xenobiotic 
compounds.
Activities and expression levels of C Y P lA l, C Y P IB I and CYP2B1 enzymes were 
monitored in this project because of their role in bioactivation of pro-carcinogens. The 
CYPl family is involved in bioactivation of polycyclic aromatic hydrocarbons, aromatic 
and heterocyclic amines to highly mutagenic chemical species (reviewed by Nebert et 
ai., 2004 and Ma and Lu, 2007). CYP2B1 is involved in bioactivation of human 
environmental and dietary carcinogenic N-nitrosamines (Parkinson, 1996). Finally, since 
about 60%  of ail prescription drugs are hydroxyiated by human CYP3A4 (Guengerich, 
1999), effect of ITCs on rat CYP3A2 enzyme was determined to evaluate the potential of 
interactions with drugs in humans as a resulf of altered biotransformation of xenobiotics.
Since the liver is the principal site of metabolism and the lung is a target tissue in ITC- 
associated chemoprevention (Higdon et al., 2007), this project focussed on these two 
rodent tissues. The effects of erucin on hepatic and pulmonary enzymes, following 
exposure to dietary doses, were compared with those of sulforaphane. Previous studies 
in mice have indicated the potential of erucin and sulforaphane, at least at high doses 
administered by gavage, to stimulate quinone reductase and glutathione 5-transferase
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activities in the liver and other tissues (Zhang et ai., 1992), but this is the first study 
evaluating the potential of this isothiocyanate to modulate cytochrome P450 enzymes. 
Both isothiocyanates were given to rats in the drinking w ater at dose levels 
corresponding to the estimated human total ITC intake (Howard et ai., 1997). Since the 
human consumption levels of erucin or giucoerucin have not been defined, the doses 
employed in these studies were based on the consumption of sulforaphane, a 
structurally similar isothiocyanate. A 250g serving of fresh broccoli will release 93-187  
mg of sulforaphane (Howard et ai., 1997), so that the intake for a 70 kg individual would 
be 1 .3 -2 .7  m g/kg. The lower dose of erucin employed in the current study of 
approximately 3 mg/kg represents such dietary level of intake.
None of the cytochrome P450 activities studied was modulated by treatm ent with either 
ITC in the liver or lung. Hepatic and pulmonary C Y P lA l protein levels, determined 
immunoiogicaliy, were, however, elevated by both compounds. C Y P IB I could not be 
monitored at the activity level as a selective substrate is not available, but immunoblot 
analysis indicated that treatm ent with SFN and erucin at the higher dose, elevated the 
levels of this enzyme in the liver. In the lung, both isothiocyanates led to an increase in 
the single band detected by the C Y P IB I antibodies. Neither compound had any effect on 
expression of either hepatic or pulmonary CYP2B or CYP3A2 protein. I t  is important to 
note that no statistical evaluation was performed on the western blots since only a single 
pooled sample was analysed per each group. Therefore, only variation in the 
immunoiogicaliy detected amount of protein greater than 10-15%  relative to control was 
interpreted as an indication of a likely treatment-induced change.
As isothiocyanates, with either aliphatic or aromatic side chain, can be metabolicaiiy 
converted to intermediates that cause cytochrome P450 inhibition, the ability of erucin
to act as a mechanism-based inhibitor was evaluated and compared to sulforaphane.
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The Km values for the O-deethylation of ethoxyresorufin in hepatic microsomes of 
Aroclor 1254-induced rats in the presence or absence of ITCs did not significantly differ, 
indicating lack of competitive inhibition of C YP lA l enzyme by erucin or SFN, at least at 
concentrations up to 25 pM. Interestingly, SFN also failed to modulate C Y P lA l activity in 
microsomal preparations (Langouet et ai., 2000), but not in rat hepatocytes (Jiao et ai., 
1996, Maheo et ai., 1997 and Zhou et ai., 2006), suggesting a possibility that SFN 
metaboiite(s), generated in the whole cells, rather than parent compound itself, was the 
inhibitor of this enzyme. Mechanism-based inhibition is characterised by a tim e- and 
concentration-dependent inhibition that requires presence of NADPH. This type of 
inhibition is usually irreversible and, since inactivated enzyme has to be replaced by 
newly synthesised protein, has longer-lasting effects than competitive inhibition (Murray, 
1997). Of the two isothiocyanates, erucin was marginally more potent at suppressing, in 
a tim e- and concentration-dependent manner, the 0-deethyiation of ethoxyresorufin. 
The fact that inhibition was prevented by reduced, but not oxidised, glutathione 
concords with the generation of an electrophilic m etaboiite(s). A more reactive 
isocyanate, derived from the cytochrome P450-mediated isothiocyanate oxidation has 
been postulated as the possible entity that interacts and inactivates cytochromes P450 
(Lee, 1994). Such reactive metabolites were also identified in case of BITC, which 
inactivated rat C Y P lA l and CYP1A2 following metabolism to a reactive benzyl cyanate 
and benzyiamine that covalently attached to and inactivated the enzymes (Goosen et 
ai., 2001; Moreno et ai., 1999). Moreover, o-naphthyiiosothiocyanate was converted by 
rat liver microsomes, in the presence of NADPH, to metabolites that bound irreversibly 
to microsomal proteins (Ei-Hawari and Plaa, 1977). Although both ITCs acted as 
mechanism-based inhibitors of CYPIA, they are unlikely to be metabolized by these 
enzymes. Aliphatic ITCs such as SFN and erucin are small molecules that are most likely 
to be the substrates for microsomal CYP2E1. However, neither the activity nor
expression of this cytochrome P450 was influenced by SFN in preliminary studies and,
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therefore, were not determined in the current studies (C.Ioannides, personal 
communications).
Erucin, at both dose levels, as well as SFN, significantly increased hepatic quinone 
reductase activity as previously described for sulforaphane (Yoxaii et ai., 2005). For both 
tissues. Western blot analysis indicated that this was due to increased cytosolic 
concentrations of quinone reductase protein. In  accordance with the present 
observations, AITC also induced the activity of pulmonary QR in rat (Munday and 
Munday, 2002). On the other hand, exposure of rats to phenethyi isothiocyanate failed 
to enhance this activity in the lung (Guo et ai, 1992), highlighting the importance of the 
side chain, since SFN and erucin, as well as AITC, have an aliphatic side chain whereas 
in the case of phenethyi isothiocyanate it is aromatic. Glutathione S-transferase activity 
was monitored using three substrates; CDNB is a substrate for a number of the cytosolic 
transferases (Habig et al., 1974). The much higher activity in the liver compared with 
the lung reflects the higher capacity of the form er tissue to detoxicate eiectrophiies. 
Both compounds failed to influence activity in either liver or lung. DCNB is a substrate 
associated with the p-famiiy, but no activity was detectable in lung as a result of poor 
expression in this tissue (Sherrat and Hayes, 2002). Hepatic activity, whaterever the 
accepting substrate, was not influenced by erucin treatm ent although a modest rise in 
apoprotein levels was evident. Finally, NBD-Ci has been reported to be selective for the 
a-ciass (Ricci et ai 1994), and the very low activity in the lung demonstrates the poor 
expression of this class in this tissue (Sherratt and Hayes 2002 ). A rise in GST activity 
was not seen with any of the three accepting substrates studied, whereas GSTa and 
GSTp were up regulated at the protein level. Considering that ITCs have been previously 
shown to generate metabolites that are cytochrome P450 inactivators (Goosen et ai., 
2001 and Nakajima et ai., 2001 ), it may be speculated that a hepatic m etaboiite(s) of
erucin and SFN may be sufficiently stable to escape the endoplasmic reticulum and
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inhibit cytosolic GST activity. In lung, similarly no change in activity was manifested by 
treatm ent with either isothiocyanate, but GSTa levels increased, GSTti was not 
modulated by either isothiocyanate in either tissue. Thus, the effects of isothiocyanates 
on the GST system are both compound and tissue specific. In terms of effectiveness as 
Phase I I  enzyme inducers, erucin was as potent as SFN, which is not surprising since 
erucin is extensively oxidised to form SFN and, likewise, sulforaphane is reduced to 
erucin in rat (Kassahun et ai., 1997).
In order to assess whether the erucin treatm ent had any impact on the ability of liver 
microsomes to bioactivate chemical carcinogens, the metabolic conversion of the 
heterocyclic amine 2-am ino-3-m ethylim idazo-[4,5-/]quinoiine (IQ ) to mutagens was 
investigated using the Ames mutagenicity assay. This compound was used as model 
carcinogen as previous studies showed that sulforaphane inhibits the genotoxicity and 
DNA-adduct formation of heterocyclic amines in cell cultures (Barcelo et ai., 1998 and 
Bacon et ai., 2003). Erucin treatm ent caused a modest decrease in the bioactivation of 
IQ  but no clear concentration-dependent effect was evident. Sulforaphane simiariy had a 
modest effect in agreement with a previous in vivo study (Yoxaii et al., 2005).
In summary, the present studies have demonstrated that following intake of erucin, at a 
dose corresponding to human intake, the only enzyme modulated of those studied was 
quinone reductase; an increase was seen in both liver and lung. No cytochrome P450 
enzyme activity was perturbed by the erucin treatm ent implying that attenuated 
generation of genotoxic intermediates is unlikely to be a chemopreventive mechanism at 
dietary dose levels. These observations allow the conclusion that erucin may exert a 
chemopreventive effect by affording protection against the carcinogenicity of quinones, 
such as those formed by the oxidation of polycyclic aromatic hydrocarbons. At higher
doses, which may be achieved by the consumption of dietary supplements, the
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expression of other enzymes was modulated, at least at the protein level. In  general, no 
marked differences were observed between erucin and sulforaphane. However, as the 
major source of erucin is rocket salad which is largely consumed uncooked, it may prove 
a more effective chemopreventive agent than sulforaphane as it is likely to achieve a 
higher bioavailabiiity, because the principal sources of glucoslnolate precursor of SFN are 
vegetables which are commonly consumed cooked, resulting in loss of the glucoslnolate 
and their lower conversion to the isothiocyanate. Finally, the ability of dietary 
isothiocyanates to up-reguiate C Y P IB I expression in the liver and lung has been 
detected for the first time.
123
Chapter 6: Modulation of xenobiotic-metabolising enzymes by isothiocyanates___________
Chapter 6
Tissue and species differences in 
the modulation of xenobiotic 
metabolising enzymes by erucin 
and sulforaphane
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6.1 In troduction
Modulation of cytochrome P450 and Phase I I  detoxification enzymes expression is 
central to the chemopreventive effects of ITC during the initiation stage of 
carcinogenesis (Hecht, 2000 and Fimognari and Hrelia, 2007). Since down-regulation of 
cytochrome P450 enzymes leads to suppression of bioactivation, it is necessary to clarify 
whether erucin, like SFN, modulates expression of Phase I  enzymes, as the focus of 
previous studies was the modulation of QR and GST (Zhang at ai, 1992 and Jacubikova 
et ai., 2005). Previous in vitro studies have investigated the effect of SFN on expression 
of cytochrome P450 enzymes in rat (Jiao et al., 1996; Maheo et al., 1997 and Zhou et 
al., 2007) and human liver parenchymal cells (Maheo et ai., 1997) and microsomes 
(Langouet et ai., 2000 ), as well as phase I I  enzymes in rat and human liver hepatocytes 
(Maheo et ai., 1997), human retinal pigment epithelial ceils (Gao and Talaiay, 2004) and 
various ceil lines (Zhang et al., 1992, Brooks et ai., 2001, Basten et ai., 2002, Bacon et 
al., 2003, Misiewicz et al., 2004 and Ritz et al., 2006). The present studies aim to 
compare modulation of xenobiotic-metabolising enzyme expression and activity by 
erucin and SFN in rat and human liver slices as well as in two rat tissues, lung and liver, 
following their incubation under identical conditions. Moreover, given that an increased 
global expression/activity of GSTs is thought to compensate for the lack of activity of a 
non-functioning class of GST in individuals with null polymorphism (Sapone et ai., 2006), 
it is important to investigate the effect of these aliphatic ITCs on expression of distinct 
classes of GSTs since these data remain incomplete.
The use of precision-cut tissue slices generates metabolic and toxicoiogicai data that is 
indicative of in vivo responses (Berthou et al., 1989) and, therefore, is an ethical 
alternative to animals. The advantages of precision-cut tissue slices over isolated cells 
include preservation of normal tissue architecture, ceil heterogenicity and ceii-cell 
interactions within their original matrix. The technique, developed by Krumdieck,
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Brendel and Sipes (Krumdieck et al,, 1980; Brendel et al., 1987; Sipes et ai., 1987) can 
be employed in the preparation of precision-cut slices of uniform thickness and diameter 
from a number of tissues including liver, kidney, lung, prostate, spleen and heart (Azri et 
al., 1990; Stefan la k et al., 1992; Ball et al., 1996; Parrish et al., 1992, 1995, 2002), 
allowing one to investigate metabolic, toxicoiogicai and pharmacological profiles of test 
compounds in target tissues. More importantly, use of precision-cut tissue slices 
prepared from a variety of species such as laboratory animals (Sivapathasundaram et 
al., 1994; Price et al., 1995 and Hashemi et al., 1999) and humans (Renwick et al., 
2000) facilitates cross species comparisons.
The current studies investigate the effects of different concentrations of erucin on 
expression of xenobiotic-metabolising enzymes (XME) in precision-cut slices generated 
from rat liver, the m ajor site of xenobiotic metabolism, and lung, a target tissue for 
chemopreventive activity of ITC (Higdon et al., 2007). The potential of erucin to alter 
activity/levels of m ajor enzyme systems, including cytochrome P450 enzymes, QR and 
GSTs is compared with that of SFN. Moreover, the present study, utilising precision-cut 
slices prepared from rat and human liver, explores whether the effect of erucin and SFN 
on XME expression and activity differs between these two species.
6 .2  Methods
The methodology for preparation and incubation of precision-cut rat liver and lung slices 
is described in Chapter 2 (section 2 .2 .3 ). Liver and lung slices were incubated with 
sulforaphane or erucin (1 -50  pM) for 24 h. Control slices were incubated with dimethyl 
sulphoxide (DMSO), the solvent vehicle (final concentration 0 .1%  v /v ). At the end of the 
incubation period, tissue slices were homogenised and resolved into microsomal and 
cytosolic fractions used in the determination of Phase I  and I I  enzyme activities, total 
protein and total glutathione levels as described in sections 2 .2 .6 -2 .2 .1 4 . Changes in
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enzyme protein expression were determined by Western blot analysis (section 2 .2 .13 ). 
The functional and metabolic viability of the tissue slices was monitored by measuring 
the extent of lactate dehydrogenase leakage in the incubation medium and the rate of 
biotransformation of the diagnostic substrate 7- ethoxycoumarin (7-EC) as described in 
sections 2 .2 .4  and 2 .2 .5  of the Chapter 2.
6 .2 .1  H um an liv e r
Portions of human livers (about 200g each) from donors who suffered a lethal brain 
injury were obtained from the Human Tissue Bank, UK. The first liver (Donor 1) came 
from a Caucasian male, aged 26, smoker, who was maintained on ventilation for four 
days prior to death. The second liver (Donor 2) was obtained from a non-smoking 
Caucasian female, aged 54, who was maintained on artificial ventilation for two days 
prior to death. Both livers were HIV, hepatitis B and C-negative. The tim e from the  
moment of donors' death to the beginning of the incubation of the liver slices did not 
exceed 12 h on both occasions.
6 .3  Results
6 .3 .1  Assessm ent o f  m etabo lic  tissue s lice v iab ility : m etabolism  o f  7-EC
Rat liver and lung slices were incubated with 7-HC for up to 6 h. The slice protein 
content remained unchanged in both tissues throughout the incubation period. The
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Figure 6.1: Protein content of rat 
tissue slices. Rat liver and lung 
slices were incubated in RPMI 1640 
containing 7-ethoxycoumarin (50 
pM) for up to 6 h. The slices were 
individually homogenised in PBS. The 
results are expressed as means ±  
SD, where n=3, with each analysis 
carried out in duplicate. Ail slices 
were generated from a single rat.
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protein content of the lung slice homogenates was 60%  of that of the liver slices. The 
protein concentration of the slice homogenates was expressed as mg/slice (Fig. 6 .1 ). 
The concentrations of the glucuronide and sulphate conjugates of 7-HC in the culture 
medium increased in a tim e-dependant manner, while the levels of free 7-HC remained 
low but constant throughout the incubation period. The rate of the biotransformation of 
7-H C  by the liver slices was 3-fold greater than the metabolic activity of the lung slices 
(Fig. 6 .2).
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Figure 6.2: Cumulative metabolism of 7-ethoxycoumarin by rat lung (A) and liver (B) 
slices. The siices were incubated in modified RPMI 1640 with 7-ethoxycoumarin (50 pM) for up to 
6 h. Metabolites of 7-ethoxycoumarin were determined in the media for each incubation period. 
Resuits are expressed as means ± SD of duplicate analysis of each of three slices per time point. 
All slices were generated from a single rat.
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6 .3 .2  Effect o f  erucin on expression an d  ac tiv ity  o f  xenob iotic-m etaboiis ing  
enzym es in precis ion-cut ra t iive r siices
In liver slices, no significant differences in the activities of the microsomal MROD, PROD 
or 7-BQ demethylase were recorded following incubation with erucin (0 -5 0  pM) for 24 h. 
Hepatic EROD, however, was significantly inhibited at the highest concentration (SOpM) 
of erucin (Fig. 6 .3 ). In contrast. Western Blot analysis revealed a modest elevation of 
hepatic CYP3A2 and pronounced concentration-dependent rise in CYPIA and C YPIB I 
apoprotein levels, while the protein levels of CYP2B1 remained unaffected (Fig. 6 .5 ).
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Figure 6.3: Effect of erucin on activities of Phase I  enzymes in cultured rat liver slices.
Liver slices were incubated in modified RPMI 1640 culture medium containing erucin (0 to SOpM) 
for 24 h. EROD (A), MROD (B), PROD (C) and 7-BQ (D) activities were determined in microsomal 
fraction using ethoxyresorufin, methoxyresorufin, pentoxyresorufin and 7-benzoxyquinoline as 
respective probes. Values represent the means ± SD where n=3. *, P<0.05.
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Figure 6.4: Effect of erucin on activities of 
Phase I I  enzymes in cultured rat liver 
slices. Liver slices were incubated in modified 
RPMI 1640 culture medium containing erucin (0 
to 50pM) for 24 h. The activities of GSTs, 
analysed using CDNB (A), NBD-CI (B) and DCNB 
(C) as substrates, QR (D) and total glutathione 
(E) were determined in the cytosolic fraction. 
Values represent the means ± SD where n=3. *, 
P<0.05, * * ,  P<0.01 and * * * ,  P<0.001.
QR activity in rat liver slices was induced in concentration-dependent fashion, with a 74 
% increase achieved at 25 pM; at the highest concentration of 50 pM, activity decreased 
to control levels (Fig. 6 .4 ). Immunoiogicaliy, there was a pronounced 
concentration-dependent increase in QR protein level, reaching a maximum of 3.5-fold  
at the 10 pM concentration. The magnitude of the induction diminished at the highest 
erucin concentrations (Fig. 6 .5 ).
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Figure 6.5: Modulation of hepatic cytochrome P450 enzymes (A ) and phase I I  enzymes 
(B) by treatm ent w ith erucin. L iver slices w e re  in c u b a te d  in m o d ifie d  R P M I 1 5 4 0  c u ltu re  
m e d iu m  co n ta in in g  eru c in  (0  to  5 0  p M ) fo r  2 4 h . H e p a tic  m ic ro s o m a l (A ) and  cy to so lic  p ro te in s  (B ) 
w e re  reso lved  by 10  %  ( w /v )  S D S -P A G E  and th e n  tra n s fe rre d  e le c tro p h o re tic a lly  to  H y b o n d -P  
p o ly v in y lid e n e  d iflu o rid e  m e m b ra n e s . Im m u n o b lo t  a n a ly s is  w a s  ca rried  o u t using e ith e r  a n t i- ra t  
seru m  to  c y to c h ro m e  P 4 5 0  (A ) o r to  phase I I  e n z y m e s  (B ) ,  fo llo w e d  by th e  a p p ro p r ia te  
p e ro x id a s e -la b e lle d  s e c o n d a ry  a n tib o d y . Each lane w as  load ed  w ith  10  (C Y P 2 B 1 , C Y P 3A 2, G STa  
and G S Tp) or 4 0  pg (C Y P IA , C Y P IB I ,  G STn and  Q R ) o f to ta l p ro te in . M o le c u la r m a rk e rs  w e re  run  
co n c u rre n tly  to  aid band  id e n tif ic a tio n . T h e  va lues  in ita lic  show  o p tica l d e n s ity  p e rc e n ta g e  o f each  
band re la tiv e  to  co n tro l.
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Of the GST enzymes, global hepatic GST activity, determined with the broad-spectrum  
diagnostic substrate CDNB, was modestly elevated (about 20% ) but the statistical 
significance was achieved only at concentration of 2.5  pM. The activity of GSTo, 
determined using the marker substrate NBD-CI, increased by 40% , while GST/j activity, 
determined using DCNB as the marker substrate, was without change (Fig. 6 .4 ). At the 
protein level, GSTa and GST/j levels were modestly elevated, while GSTn protein did not 
change (Fig. 6 .5 ).
Total cytosolic GSH content was analysed using GSH reductase-coupled 5, 5'-dithiobis- 
2-nitrobenzoic acid (DTNB) assay. Treatm ent with erucin significantly elevated total 
glutathione level in a concentration-dependent fashion. However, the glutathione levels 
started to fall at 25 pM and were halved at the highest concentration (Fig. 6 .4 ).
6 .3 .3  E ffect o f  erucin on expression and  a c tiv ity  o f  xenob io tic -m etabo iis ing  
enzym es in precis ion -cu t ra t iung siices
Following incubation of rat lung slices with a range of erucin concentrations (0 -5 0  pM), 
there was no significant change in the activities of monitored cytochrome P450 enzymes, 
except at the highest concentration (50pM ), at which PROD activity was inhibited by 
almost 50 % (Fig. 6 .6 ). CYP3A2 activity was not detectable when 7-benxyloxyquinoline 
was used as a probe. Western blot analysis showed a modest decrease in pulmonary 
CYP2B1 protein levels, which diminished by 23 %  at 50 pM (Fig. 6 .8 ). C YP lA l 
apoprotein levels were elevated by erucin in a concentration-dependent manner (up to 
2-fold) before returning to control values at 50 pM. Similarly, treatm ent with erucin 
caused a marked and concentration-dependent increase in pulmonary C Y P IB I 
apoprotein. There was no m ajor change in CYP3A2 apoprotein levels (Fig. 6 .8 ).
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Figure 6.6: Effect of erucin on activities of Phase I  enzymes in cultured rat lung slices.
Lung slices were incubated in modified RPMI 1640 culture medium containing erucin (0 to 50pM) 
for 24 h. EROD (A) and PROD (B) activities were determined in microsomal fraction using ethoxy- 
and pentoxyresorufin as respective probes. Values represent the means ± SD where n=3, each 
replicate comprised up to 12 slices. *, P<0.05, **,  P<0.01.
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Figure 6.7: Effect of erucin on
activities of Phase I I  enzymes in 
cultured rat lung slices. Lung slices were 
incubated in modified RPMI 1640 culture 
medium containing erucin (0 to 50pM) for 
24 h. The activities of GST, analysed using 
CDNB as substrate (A), QR (B) and total 
glutathione (C) were determined in the 
cytosolic fraction. Values represent the 
means ± SD, where n=3; each replicate 
comprised up to 12 slices. *, P<0.05, * * ,  
P<0.01 and * * * ,  P<0.001.
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Figure 6.8: Modulation of pulmonary cytochrome P450 enzymes (A ) and phase I I  
enzymes (B ) by treatm ent w ith erucin. The slices were cut from rat lungs stabilised with 
agarose (0.75 % w/v) and incubated in the modified RPMI 1640 culture supplemented with erucin 
(0 to 50pM) for 24 h. Pooled pulmonary microsomal (A) and cytosolic proteins (B) were resolved 
by 10 % (w/v) SDS-PAGE and then transferred electrophoretically to Hybond-P polyvinylidene 
difluoride membrane. Immunoblot analysis was carried out using either anti-rat serum to 
cytochrome P450 (A) or to phase I I  enzymes (B), followed by the appropriate peroxidase-labelled 
secondary antibody. Each lane was loaded with 10 (CYP2B1, CYP3A2, GSTn), 20 (GSTa, GST/j and 
QR; or 40 pg (CYPIA and CYPIB I) of total protein. Molecular markers were run concurrently to aid 
band identification. The values in italic show optical density percentage of each band relative to 
control. The values in italics show percentage of optical density of each band relative to control.
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The activities of pulmonary QR and GST, when CDNB was used as an accepting 
substrate, were significantly elevated (Fig. 6 .7 ). GST activity was not detectable when 
either DCNB or NBD-CI served as accepting substrate. Immunologically, QR and GSTo 
protein levels increased in a concentration- dependent manner, declined at the highest 
erucin concentration. Treatm ent with erucin had no effect on GST fj and GST n protein 
expression (Fig. 6 .8 ).
The total cytosolic glutathione level in lung slices was 10 %  of hepatic levels. There was 
a concentration-dependent increase in the pulmonary glutathione levels, but at the 
highest dose level concentration of glutathione fell to 60 %  of the control values (Fig. 
6.7).
6 .3 .4  Effect o f  SEN on expression and  a c tiv ity  o f  xenob io tic -m etabo lis ing  
enzym es in precis ion -cu t ra t  live r slices
When rat liver slices were incubated with SFN (0 -5 0  pM) for 24 h, the only change in 
microsomal EROD, MROD, PROD and 7-BQ demethylase activities was observed at the 
highest concentration, at which the activities of all monitored cytochromes P450 
diminished, but statistical significance was attained only for MROD and PROD (Fig. 6 .9 ). 
In contrast, treatm ent with SFN induced expression of hepatic C Y P lA l, C Y P IB I and, to 
a lesser extent, CYP3A2 protein in a concentration-dependent manner, as analysed by 
Western Blot. However, effect of induction declined at the highest concentrations of SFN. 
Treatment with SFN had no effect on expression of hepatic CYP2B1 (Fig. 6 .11 ).
SFN markedly induced hepatic QR, both at the activity (Fig. 6 .10 ) and, in particular, at 
the protein level (Fig. 6 .11 ). Maximal induction of QR was observed at 5 and 10 pM, but 
further increase in SFN concentration diminished magnitude of induction. Global GST 
activity rose in a concentration-dependent manner, but the statistical significance was
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achieved only at 10 and 25 pM SFN concentrations. GSTo and GSTp activities were 
induced by SFN by approximately 40 and 75 %  respectively (Fig. 6 .10 ). The effect of 
SFN on the expression of hepatic GSTs varied depending on the GST class. GSTo and 
GSTp protein levels were elevated, while GSTn levels did not appear to alter (Fig. 6 .11 ). 
Following 24 h incubation of rat liver slices with SFN, the total cytosolic glutathione 
levels were elevated in a concentration-dependent manner, but dropped to 59 % of the 
control value at 50 pM (Fig. 6 .10).
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Figure 6.9: Effect of sulforaphane on rat hepatic cytochrome P450 enzyme activities. Rat
liver slices were maintained on sulforaphane-supplemented RPMI 1640 culture media for 24 h. 
Activities of EROD (A), MROD (B), PROD (C) and 7-BQ demethylase were determined in 
microsomal fraction. Values are presented as means ± SD, where n=3; each replicate comprised 
of up to 12 slices. *, P<0.05 versus control. '*P<0.05.
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Figure 6.10: Effect of sulforaphane on 
activities of Phase I I  enzymes in 
cultured rat liver slices. Liver slices 
were incubated in modified RPMI 1640 
culture medium containing erucin (0 to 
50pM) for 24 h. The activities of GSTs, 
analysed using CDNB (A), CNBODI (B) and 
DCNB (C) as substrates, QR (D) and total 
glutathione (E) were determined in the 
cytosolic fraction. Values represent the 
means ± SD where n=3. * , P<0.05, 
P<0.01 and * * * ,  P<0.001.
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Figure 6.11: Modulation of hepatic cytochrome P450 enzymes (A ) and phase I I  enzymes 
(B) by exposure to sulforaphane. Liver slices were incubated in modified RPMI 1640 culture 
medium containing sulforaphane (0 to 50 pM) for 24h. Hepatic microsomal (A) and cytosolic 
proteins (B) were resolved by 10 % (w/v) SDS-PAGE and then transferred electrophoretically to 
Hybond-P polyvinylidene difluoride membrane. Immunoblot analysis was carried out using either 
anti-rat serum to cytochrome P450 (A) or to phase II enzymes (B), followed by the appropriate 
peroxidase-labelled secondary antibody. Each lane was loaded with 10 (CYP2B1, CYP3A2, GSTa 
and GST/v) or 40 pg (CYPIA, CYPIBI, GSTr? and QR) of total protein. Molecular markers were run 
concurrently to aid band identification. The values in italic show optical density percentage of each 
band relative to control. Molecular markers were run concurrently to aid band identification. The 
values in italic show optical density percentage of each band relative to control. The values in italic 
show percentage of optical density of each band relative to control.
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6 .3 .5  E ffect o f  SFN on expression and  a c tiv ity  o f  xenob iotic-m etabolis ing  
enzym es in precis ion-cut ra t  lung slices
In the lung slices incubated with SFN for 24 h, EROD activity was inhibited by 33 and 44  
%  at the highest concentration levels. Activity of pulmonary PROD was without change 
(Fig. 6 .12 ). At the apoprotein level, SFN induced expression of the microsomal C Y P lA l, 
C YPIB I and CYP3A2 levels, the effect being more marked in the case of C Y P lA l. At the 
two highest concentrations (25 and 50 pM), C YP IB I protein levels were markedly 
decreased. Modulation of pulmonary CYP2B1 by SFN was not observed (Fig. 6 .14 ).
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Figure 6.12: Effect of sulforaphane on activities of Phase I  enzymes in cultured rat lung 
slices. Lung slices were incubated on SFN-supplemented (0 to 50pM) modified RPMI 1640 cuiture 
medium for 24 h. EROD (A) and PROD (B) activities were determined in microsomal fraction using 
ethoxy- and pentoxyresorufin as respective probes. Values represent the means ± SD where n=3, 
each replicate comprises up to 12 slices. *, P<0.05, * * ,  P<0.01.
Similar to erucin, SFN significantly increased QR and, to a lesser extent, total GST 
activities in lung slices (Fig. 6 .13). Immunologicaly, there was a marked and 
concentration-dependent increase in QR and a less pronounced rise in GSTa protein, 
whereas GST n and GST^ were unaffected by this treatm ent (Fig. 6 .14 ).
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Figure 6.13: Effect of sulforaphane on rat pulmonary Phase I I  enzyme activities and 
total glutathione levels. Lung slices were incubated in modified RPMI 1640 culture medium 
containing SFN (0 to SOpM) for 24 h. The activities of GST, analysed using CDNB as an accepting 
substrate (A), QR (B) and total glutathione (C) were determined in cytosolic fraction. Values 
represent the means ± SD, where n=3; each replicate comprised 12 slices. * , P<0.05, 
P<0.01 and * * * ,  P<0.001.
Total GSH levels in lung slices after exposure to SFN (0 -50  pM) for 24h were moderately 
elevated in a concentration-dependent fashion. GSH concentrations fell to control levels 
in lung slices exposed to the highest SFN concentrations (25 and 50 pM).
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Figure 6.14: Modulation of pulmonary cytochrome P450 enzymes (A ) and phase I I  
enzymes (B ) by sulforaphane. The slices were cut from rat lungs stabilised with agarose (0.75 
% w/v) and incubated in the modified RPMI 1640 culture supplemented with SFN (0 to 50pM) for 
24 h. Pooled pulmonary microsomal (A) and cytosolic proteins (B) were resolved by 10 % (w/v) 
SDS-PAGE and then transferred electrophoretically to Hybond-P polyvinylidene difluoride 
membrane. Immunoblot analysis was carried out using either anti-rat serum to cytochrome P450 
(A) or to phase II enzymes (B), followed by the appropriate peroxidase-labelled secondary 
antibody. Each lane was loaded with 10 (CYP2B1, CYP3A2, GSTn), 20 (GSTa, GSTp and QR/ or 40 
pg (CYPIA and CYPIBI) of total protein. Molecular markers were run concurrently to aid band 
identification. The values in italic show optical density percentage of each band relative to control. 
The numbers in italics show percentage of optical density of each band relative to control.
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6 .3 .6  Effect o f  erucin on expression and  activ ity  o f xenobiotic-m etabolis ing  
enzym es in precis ion-cut hum an liv e r slices
When slices prepared from the human liver were incubated with erucin (0 -5 0  pM) for 
24 h, no significant changes in activities of hepatic EROD, MROD or 7-BQ demethylase 
were observed. At the highest concentration, however, activity of hepatic MROD was 
significantly reduced (Fig. 6 .15 ). Activity of human PROD was not determined due 
to limited amounts of available human liver. The expression of human CYPIA, CYP2B1 
and CYP3A4 was su pressed only at the highest concentration of erucin (50  pM), while 
hepatic C YP IB I apoprotein levels remained unchanged (Fig. 6 .17 ).
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Figure 6.15; Effect of erucin on 
activities of human Phase I  enzymes 
(Donor 1 and 2). Slices were generated 
from livers of two donor and incubated in 
modified RPMI 1640 culture medium 
containing erucin (0 to 50 pM) for 24 h. The 
activities of EROD, MROD and 7-BQ 
demethylase were determined in the 
microsomal fraction using ethoxyresorufin
(A), methoxy resorufin (B) and 7- 
benzyloxyquinoline (C) as substrates. 
Results are presented as mean ± SD, 
where n=3; each replicate comprised 12 
slices. * , P<0.05, * * ,  P<0.01 and * * * ,  
P<0.001.
In slices prepared from a second human liver, incubation with erucin similarly led to a 
significant decrease in the activities of both microsomal enzymes studied, EROD and 7-
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BQ demethylase, at the highest concentration (50pM ) only (Fig. 6 .15 ). Modulation of 
MROD and PROD activities by erucin in the second human liver was not evaluated due 
to limited amounts of this tissue. The Western Blot analysis revealed reduction in 
microsomal CYP2B1 and CYP3A4 protein levels (40 and 70%  respectively) following 
treatm ent with the highest concentration of erucin. In  contrast, C YP lA l and CYPCIB I 
expression in liver of the second donor was modestly up-regulated (up to 60% ) by 
erucin (Fig. 6 .17 ).
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Figure 6.16: Effect of erucin on activities of human Phase I I  enzymes (Donor 1 and 2).
Slices were incubated in modified RPMI 1640 cuiture medium containing erucin (0-50pM) for 24 h. 
The activities of GST, monitored using CDNB (A) or NBD-CI as substrate, QR and total glutathione 
levels were determined in the cytosolic fraction. Results are presented as mean ± SD, where n=3; 
each replicate comprised up to 12 slices. *, P<0.05.
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Figure 6.17: Modulation of hepatic cytochrome P450 enzymes (A ) and phase I I  enzymes
(B) by exposure to erucin (Donors 1 and 2 ). Slices from two human livers were incubated in 
the modified RPMI 1640 culture medium containing erucin (0 to 50 ( jM ) for 24h. Hepatic 
microsomal (A) and cytosolic proteins (B) were resolved by 10% (w/v) SDS-PAGE and then 
transferred electrophoretically to Hybond-P polyvinylidene difluoride membranes. Immunoblot 
analysis was carried out using either rat antibodies to cytochrome P450 (A) or to phase II 
enzymes (B), followed by the appropriate peroxidase-labelled secondary antibody. Each lane was 
loaded with 10 (GSTs), 20 (CYPIA and CYP3A4) or 40 pg (CYPIA, CYPIBI and QR) of total 
protein. Molecular markers were run concurrently to aid band identification. The values in italics 
show optical density percentage of each band relative to control. The values in italics show 
percentage of optical density of each band relative to control.
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In the human liver, treatm ent with erucin had no effect on activity of QR and GST, 
the latter being monitored using either CDNB or NBD-CI as a marker substrate 
(Fig,6 .16 ). GST activity was not detectable in either of human livers when DCNB was 
used as a probe. Western blot analysis of the phase I I  enzymes expression revealed that 
erucin, unexpectedly, failed to up-regulate expression of QR or GST. Once again, the 
highest concentrations of erucin were associated with suppressed expression of QR, 
GSTn and GST^u, whereas GSTa protein levels were not affected (Fig. 6 .17 ).
In contrast, in slices generated from the second human liver, erucin enhanced activities 
of GST, determined using either broad-spectrum CDNB or GSTa-specific NBD-CI as 
marker substrates, with the most marked increase observed at 5 and 10 pM. Further 
increase in erucin concentration, however, was associated with reduction in GST activity 
(Fig. 6 .16). Neither QR nor GST/v activities were detectable. Similarly, erucin modestly 
up-regulated expression of QR and all GST isoformes except GST n, although GSTa 
protein levels fell below control values at the highest erucin concentration (Fig. 6 .17 ).
Total glutathione levels in slices prepared from the 1^  ^ liver were unaffected by treatm ent 
with erucin (Fig. 6 .16 ). In the liver of the 2"  ^ donor, however, a concentration- 
dependent increase in total glutathione concentration was evident after 24 h incubation 
with erucin. Marked glutathione depletion at the highest concentration of erucin was 
observed in both human livers (Fig. 6 .16).
3 .3 .7  E ffect o f  sulforaphane on expression an d  a c tiv ity  o f  xenob io tic - 
m etabolising enzym es in precis ion-cut hum an liv e r  slices
SFN had no effect on activity of cytochromes P450 monitored in either human liver 
following 24 h incubation, except at the highest concentration (50  pM), which was 
associated with a significant decrease in activities of most phase I  enzymes (Fig. 6 .18 ). 
Effect of SFN on MROD activity in the 1^ *^  human liver, as well as modulation of PROD in
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either human livers, was not determined due to shortage of this tissue. At the protein 
level, SFN had no effect on expression of cytochrome P450 enzymes in the human 
liver. In the 2"  ^ human liver, however, C YP lA l and C YP IB I expression was modestly 
up-regulated (up to 40% ) by treatm ent with SFN, while CYP2B1 and CYP3A4 apoprotein 
levels remained mostly unaffected (Fig. 6 .20 ). Protein levels of all four monitored 
cytochromes P450 fell in both human livers in response to treatm ent with the highest 
SFN concentration, as in rat (Fig. 6 .20).
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Figure 6.18: Effect of sulforaphane on 
activities of human Phase I  enzymes 
(Donor 1 and 2). Slices were generated 
from livers of two donor and incubated in 
modified RPMI 1640 culture medium 
containing sulforaphane (0 to 50 pM) for 24 
h. The activities of EROD, MROD and 7-BQ 
demethylase were determined in the 
microsomal fraction using ethoxy resorufin
(A), methoxy resorufin (B) and 7- 
benzyloxyquinoline (C) as substrates in 
microsomal fraction. Values are means ± 
SD, where n=3; each replicate comprised 
12 slices. *, P<0.05 and * * ,  P<0.01.
None of the phase I I  enzymes studied was influenced by SFN at the activity level at 
concentrations less than 50 pM (Fig. 6 .19 ). In contract, in the 2"  ^ human liver, global 
hepatic GST and GSTa activities almost doubled at 10 pM. (Fig. 6. 19). After 24 h 
incubation with SFN, activities of QR in the 1®^  liver and GST^u in both human livers were 
undetectable. Immunologicaly, SFN, like erucin, had no effect of expression of either
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phase I I  enzyme in the human liver, but, in the 2"*^  human liver, this ITC modestly 
up-regulated expression of GSTa, GSTp and QR enzymes, with the highest increase 
achieved at 5 and 10 pM. No concentration-dependent change in human GSTn 
expression was detected in the 2"  ^ liver (Fig. 6 .20 ). Use of the highest concentration of 
SFN (50 pM) resulted in declining protein levels and activity of phase I I  enzymes 
(Figures 6 .19 and 6 .20 ).
B
S' E
Hi
u E c
1.80 
1 . 2 0  H 
0.60 
0 . 2 0 -r
0 .1 5 -
0.10
0.00 I
0 1 2.5 5 10 25 50
Sulforaphane concentration (pM)
1 g
5 0 0 n
4 0 0tJ(0
I I 3 0 0
(9 Ü
Û ^  2 E °-
2 0 0 -
i c 1 0 0
0 a a Ù. ù_ Û.
O 1 2 .5  5 10 25 50
Su lfo raphane concentration (p M )  
c = i  D o n o r  1  , = '  D o n o r  2
ill
S i -
20
15
10
5-
0 1 2.5 5 10 25 50
Sulforaphane concentration (pM)
II
I
100
80
60
40H
20
0
0 1 2.5 5 10 25 50
Sulforaphane concentration (pM)
Figure 6.19: Effect of sulforaphane on activities of human Phase I I  enzymes (Donor 1
and 2). Slices were incubated in modified RPMI 1640 culture medium containing erucin or 
sulforaphane (0 to SOpM) for 24 h. The activities of GST, with CDNB or CNBOD as substrate), QR 
and total glutathione were determined in cytosolic fraction. Values represent the means ± SD, 
where n=3; each replicate comprised 10 slices. *, P<0.05 and * * ,  P<0.01.
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Figure 3.20: Modulation of hepatic cytochrome P450 enzymes (A ) and phase I I  enzymes
(B) by exposure to sulforaphane (Donor 1 and 2). Slices from the liver of a male donor were 
incubated in modified RPMI 1640 culture medium containing sulforaphane (0 to 50 pM) for 24h. 
Each lane was loaded with 10 (GSTs), 20 (CYPIA and CYP3A4) or 40 pg (CYPIA, CYPIBI and QR) 
of total protein. Hepatic microsomal (A) and cytosolic proteins (B) were resolved by 10 % (w/v) 
SDS-PAGE and then transferred electrophoretically to Hybond-P polyvinylidene difluoride 
membranes. Immunoblot analysis was carried out using either anti-rat antibodies to cytochrome 
P450 proteins (A) or to phase II  enzymes (B), followed by the appropriate peroxidase-labelled 
secondary antibody. Molecular markers were run concurrently to aid band identification. The 
values in italics show percentage of optical density of each band relative to control.
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Total glutathione levels in the human liver remained mainly unaltered, whereas in the 
2"  ^ human liver, treatm ent with SFN increase total glutathione concentration in a 
concentration dependent manner (Fig. 6 .19 ). At the highest concentration, SFN 
markedly decreased glutathione levels in both human livers (Fig. 6 .19 ).
3 .3 .8  IT C  tox ic ity  to tissue slices
Initially, slices were exposed for 24 h to ITC concentrations ranging from 0 to 100 pM. 
However, the necrotic macroscopic appearance and significant loss of the metabolic 
activity in slices suggested that the concentrations of ITC exceeding 50 pM could be 
toxic. To investigate whether these phytochemicals are toxic to the cultured tissues, 
extent of the lactate dehydrogenase (LDH) leakage into the incubation medium was 
measured after 24 h incubation with either SFN or erucin. The results of the latter 
experiment confirmed that both SFN and erucin were marginally toxic to rat liver tissue 
at concentration of 50 pM and highly toxic at concentration of 100 pM. The lung slices 
tended to leak less intracellular LDH into the medium after 24 h incubation but, 
compared with liver slices, appeared to be more susceptible to ITC-induced toxicity; mild 
toxicity was apparent at concentrations of 25 pM SFN (Fig. 6 .21 ).
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Figure 6.21: Toxicity of erucin (A) and sulforaphane (B) to rat liver slices. LDH leakage 
was measured in the liver and lung slices incubated in modified RPMI 1640 containing a range of 
concentrations (0 to 100 pM) of erucin or sulforaphane for 24 h. LDH release Is expressed as 
percentage of total LDH. Results are presented as mean ± SD of duplicate measurements from 
each of three slices per concentration. P<0.05 '*P<0.05; **P<0.01; ***P<0.001.
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6 .4  Discussion
A major mechanism underlying ITC-associated chemopreventive activity is alteration of 
the carcinogen metabolism in favour of detoxification and elimination, achieved by 
suppressing their generation, through impairment of cytochrome P450-mediated 
activation, and by enhancing their detoxication by up-regulating protective enzyme 
systems such as quinone reductase and the glutathione S-transferases (reviewed by 
Hecht, 2000 and Fimognari and Hrelia, 2007). I t  is assumed that similar mechanisms 
operate in humans exposed to these compounds through diet. The use of precision-cut 
tissue slices allows, for the first tim e, an investigation of the effects of erucin and SFN on 
carcinogen-metabolising enzyme systems in human tissue, in comparison with rat 
following exposure to these compounds under identical conditions. The obvious 
advantage of this approach is a direct assessment of outcome from exposure of the 
human tissue(s) to the test compounds that eliminates the necessity to extrapolate 
experimental observations from animals to humans.
Other important advantages of this experimental technique include preservation of the 
tissue architecture and cell heterogeneity, both are important factors when studying 
modulation of the XMEs in vitro. In control adult rat most hepatic cytochromes P450, 
including CYP1A2, CYP2B1 and CYP3A2, are distributed non-uniformly, being localised 
predominantly in the centrilobuiar hepatocytes, whereas C Y P lA l shows a significantly 
less zone-specific pattern of expression and is heterogeneously expressed by 
hepatocytes throughout the parenchyma (Murray and Burke, 1995). CYP2B is also 
abundant in the midzonal hepatocytes (Heinonen et al., 1996). The predominant classes 
of cytosolic GSTs in adult rat liver are alpha and mu, both being uniformly expressed by 
hepatocytes (Tee et al., 1992). The rat bile duct epithelial cells express GST class mu 
and pi. In the rat lung, CYP2B and CYP3A are expressed by Clara cells of the bronchial 
epithelium and type I I  alveolar epithelial cells, whereas CYPIA is localised in Clara cells
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of the bronchial epithelium (Murray and Burke, 1995). All three m ajor classes of the rat 
cytosoic pulmonary GSTa are localised in Clara cells and ciliated cells of the bronchial 
epithelium (Murray and Burke, 1995).
One of the m ajor disadvantages of the tissue slice system is the short duration of their 
maintenance in culture media, thus limiting the timescale of in vitro studies to a 
maximum of 72 h (Hashemi et al., 1999; Hashemi et al., 2000 and Umachandran and 
loannides, 2006). However, the duration of exposure, known to influence the inducing 
potential of ITCs on phase I I  enzymes (Munday and Munday, 2002 ), is an important 
factor to be considered when extrapolating the in vitro findings to an in vivo situation. 
Tissue slices provide valuabie data on biologicai and toxicoiogical effects of test 
compounds in target organs, however, it is essentiai to ensure that they remain viable 
during incubation in a culture medium.
6.4 .1  B iotransform ation  o f  7-ethoxycoum arin
Viability of cultured tissue can be monitored using a variety of biochemical markers, 
including intracellular ATP content, MTT (3 -[4 ,5 -d im ethy lth iazo l-2 -y i]-2 ,5 - 
diphenyltetrazolium bromide) reduction, retention, enzyme leakage (De Kanter et al, 
1999; Monteil et al., 1999; Price et ai., 1995) and a biotransformation of a marker 
substrate such as 7-ethoxycoumarin (Steensma et al., 1994).
Biotransformation of 7-ethoxycoumarin (7-EC) is a sensitive indicator of the metabolic 
capability of slices as both Phase I and I I  enzymes activities are monitored during 
incubation. 7-Ethoxycoumarin is metabolised by the microsomal Phase I enzymes to 7- 
hydroxycoumarin (7 -H C ), which is subsequently enzymatically conjugated with sulphate 
and glucuronide (Barr et al., 1991a, 1991b and Steensma et al., 1994). The rate of 
metabolism of the diagnostic substrate 7- hydroxycoumarin (7-H C ) was determined to
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ensure the quality and validity of the subsequent experiments involving the use of 
precision-cut liver and lung slices as an in vitro model employed to study the effect of 
erucin and SFN on activity and expression of xenobiotic-metabolising enzymes (XMEs). 
The formation of the hydroxylated product 7-HC and its sulphate and glucuronide 
conjugates from a parent compound 7-EC during incubation for up to 6 h approximated 
the levels previously reported for this model substrate for rat liver (Price et al., 1995, 
Hashemi and loannides, 1999, 2000 and De Kanter et al., 1999) and lung slices (Price et 
al., 1995 and Umachandran et al., 2004), allowing the conclusion that the tissue slices 
were metabolically viable under the experimental conditions of this and subsequent 
studies.
6 .4 .2  Species an d  tissue differences in the m odulation  XM E enzym e activ ities  
and expression b y  erucin and  SFN
Slices of both rat tissues and human liver were incubated with the isothiocyanates for 24 
h, the tim e period required to achieve maximal induction (Pushparajah et al., 2007).
Neither compound modulated the activity of any cytochrome P450 studied in rat lung 
and liver, as well as in both human livers, except at the highest concentrations used (50  
pM), in which case the activities of most human and rat cytochromes P450 significantly 
fell. Such effect is most likely to be a manifestation of cytotoxicity caused by exposure to 
high concentrations of ITCs as will be discussed later in this chapter. Western blot 
analysis, on the other hand, revealed a pronounced and concentration-dependent rise in 
C YPlA l and, to a lesser extent, C YP IB I apoprotein in rat liver and lung. In the liver of 
Donor 2, C YP lA l and C YP IB I apoprotein was modestly elevated, but no similar changes 
in expression of these enzymes were evident in slices from the liver of Donor 2. Thus 
there are marked inter-individual differences in modulation of C Y P lA l and C YP IB I 
expression by both compounds.
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The CYPIA subfamily consists of two members: C Y P lA l and CYP1A2, the activity of 
which is commonly determined using ethoxy- and methoxy resorufin as respective 
marker substrates. However, in hepatic microsomes of control rats, ethoxy resorufin is 
primarily deethylated by CYP2C6 (Burke et al., 1994) and CYP2C11 (Nakajima et al., 
1990). EROD and MROD activities in both rat tissues were without change at non-toxic 
concentrations of ITCs, although inhibition of EROD by SFN was previously detected at > 
5 pM in primary rat hepatocytes (Maheo et al., 1997). In contrast, the expression of rat 
pulmonary and hepatic C Y P lA l was markedly up-regulated in the concentration- 
dependent manner by both compounds. Considering that C Y P lA l, unlike CYP1A2, is not 
constitutively expressed in rat and human liver (Casarett et al, 2001 ), the protein 
recognised by the polyclonal anti-rat C Y P lA l/2  serum in control rat and human liver is 
most likely to be CYP1A2. CYP1A2, on the other hand, is not expressed in extrahepatic 
tissues of most mammals, thus pulmonary protein detected by the polyclonal anti-rat 
C Y P lA l/2  serum is C Y P lA l. Although the polyclonal rat C Y P lA l/2  antibodies, used in 
the western blot analysis, have the same affinity for both rat enzymes, only a single 
band was detected because separation of rat C YP lA l and CYP1A2, which have molecular 
weights of 59 and 58 kDa respectively, is difficult to achieve. A lack of change in the rat 
EROD activity despite a marked increase in C YP lA l protein suggests loss of catalytic 
activity due to the mechanism-based inhibition of this enzyme by both compounds as 
has previously been discussed in chapter 5. The activities of human EROD in both livers 
and MROD in the liver of donor 1 were not influenced by treatm ent with non-toxic 
concentrations of either erucin or SFN. Interestingly, the basal EROD activities in the 
liver of Donor 1, a smoker, did not differ from that of Donor 2, a non-smoker. The lack 
of inhibiting activity on CYPIA has previously been demonstrated with SFN using 
bacteria expressing human enzymes (Langouet et al., 2000 ). Immunoblot using the 
polyclonal anti-rat C Y P lA l/2  serum that cross-reacts with human CYPIA protein, 
revealed a modest elevation of C Y P lA l/2  protein in the liver of the 2"  ^ donor. C Y P lA l/2 ,
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visualised as a single band of approximately 58 kDa, was not induced by either ITC in 
the liver of the donor, indicating genetic variability.
Due to lack of CYPlB l-selective diagnostic substrate, the activity of this enzyme was not 
monitored. Both ITCs markedly induced expression of this enzyme in rat liver and, to a 
lesser extent, in lung. In contrast, human C YP IB I was marginally induced only in the 
liver of the 2"^ donor, clearly demonstrating species differences. The overall pattern and 
magnitude of rat C Y P IB I expression following treatm ent with erucin and SFN resembles 
that of C Y P lA l. The similarities are not surprising since expression of mammalian  
C YPlA l and C Y P IB I is regulated by a common ligand-activated transcription factor, the 
aryl hydrocarbon receptor (AhR) (reviewed by Nebert et al., 2004). Although SFN is 
thought to act as a monofunctional inducer that selectively induces Phase I I  enzymes 
without concurrent induction of AhR-dependant Cytochrome P450 enzymes (Miao et al., 
2004 and Higdon et al., 2007 ), current results indicate that there is a cross-talk between 
ARE-regulated and AhR-dependent gene regulation pathways. Indeed, SFN up-regulated 
rat C YP lA l apoprotein (Yoxall et al., 2005) in vivo.
Activities of CYP2B1 and CYP3A were determined using pentoxyresorufin and 
7-benzyloxyquinoline as respective diagnostic substrates. Both compound failed to alter 
either activity or expression of CYP2B1, rat CYP3A2 and human CYP3A4 in any of the 
tissues studied at non-toxic concentrations. In contrast, SFN inhibited hepatic PROD in 
rat primary hepatocytes (Maheo et al., 1997) and CYP3A4 catalytic activity and mRNA 
levels in human liver parenchymal cells (Maheo et al., 1997 and Zhou et al., 2007), but 
was without effect on the human enzymes expressed by bacteria (Langouet et al., 
2000), the conflicting outcomes probably arising due to differences in experimental 
protocols. The anti-rat CYP3A2 serum, used in the western blot analysis, recognises and
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strongly binds to rat CYP3A2 and human CYP3A4, but cross-reacts weakly with CYP2B 
and CYP2C, which appeared as an additional faint band on some blots.
NADPH: quinone oxidoreductase-1 (QR) is a Phase I I  enzyme that protects the cell from 
quinone-semiquinone redox cycling and generation of ROS through obligatory two- 
electron reduction of exogenous compounds, such as those generated by the oxidation 
of polycyclic aromatic hydrocarbons and endogenous quinones (Brunmark and Cadenas, 
1989). In the studies with the rat tissue slices, both compounds up-regulated activity 
and expression of pulmonary and hepatic QR, in accordance with observations made 
previously both, in vitro (Zhang at al., 1992, Gerhauser et al., 1997 and Ritz et al., 
2006) and in vivo (Zhang at al., 1992, Yoxall et al., 2005 and Chapter 5). The inducing 
effect of erucin and SFN on rat hepatic and pulmonary QR activities and expression was 
concentration-dependent. As a QR inducer, SFN was only marginally more potent than 
erucin, indicating that the oxidation state of sulphur has little impact on the ability of 
these isothiocyanates to modulate Phase I I  enzymes. However, when human liver slices 
from two different donors were used, only a weak rise in protein levels was noted in only 
one of the two human livers studied, in marked contrast to the observations made in rat. 
These findings suggest that human QR may be resistant to induction by these aliphatic 
isothiocyanates. However, the aromatic isothiocyanate, phenethyl isothiocyanate, also 
failed to induce this enzyme or increase protein levels in three human livers, whereas 
increases were observed in rat slices incubated under identical conditions (N Konsue, 
personal communication). Collectively, these data illustrate an important species 
difference between rat and human with implications for the chemopreventive activity of 
theses isothiocyanates, as it would imply that chemopreventive potential might be less 
pronounced in human compared with rat. The lack of induction of human QR by erucin 
and SFN observed in current studies OR is surprising given that QR mRNA was induced 
in human colonic adenocarcinoma cells (Jacubikova et al., 2005) by erucin while SFN
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similarly up-regulated expression of QR in human retinal pigment epithelial cells (Gao 
and Talalay, 2004) and in various human cell lines (Brooks et al., 2001 and Misiewicz et 
al., 2004). The differences may be consequence of the use of tissue slices as an In vitro 
model, resembling the in vivo environment more closeiy than immortaiised cell lines or 
isolated cells, or/and human polymorphism. The non-functioning QR gene found in 20%  
of Caucasians and almost 50%  of other ethnic proup (Gaedigk et al., 1998). 
Furthermore, human Nrf2, the transcriptional factor involved in activation of ARE- 
controlled genes encoding phase I I  enzymes, is aiso poiymorphic. This could influence its 
expression and function (Marzec et al., 2007) and may influence QR inducibility. A more 
definitive conclusion would require the analysis of more human liver samples.
Conjugation with polar glutathione moieties is a m ajor pathway of detoxification and 
excretion of mutagens. Glutathione S-transferase (GST) activity was monitored using 
three substrates. CDNB is a substrate for several cytosolic transferases, whereas DCNB 
is a substrate predominantly metabolised by the p-family and NBD-CI has been reported 
to be selective for the o-class (Ricci et al., 1994 and Sherrat and Hayes, 2002). Both 
compounds stimulated (GST) activity in rat liver, with all three substrates, with DCNB 
being the most sensitive, followed by NBD-CI, implying a rise in the p- and o-class 
enzymes, and the immunological studies revealed modest increase in the protein levels 
of these classes, but not in the Ti-dass. Of the pulmonary GST enzymes, rat GST activity, 
measured with the CDNB, was modestly elevated by both ITCs to the same degree, 
however, neither phytochemical influenced expression of the pulmonary GST/y, indicating 
that in rat, the effect of ITCs on GST is tissue and class-specific. When human liver slices 
were investigated, glutathione S-transferase activity was not detectable when DCNB was 
used as substrate; even in rat slices the lowest activity was obtained with this substrate. 
Incubation of liver slices for 24 hours leads to loss of glutathione S-transferase activity, 
particularly when assessed using DCNB (Hashemi et al., 1999), which may fall below the
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levels of detection. The response seen in the two human livers following incubation with 
the two isothiocyanates differed. Neither compound modulated glutathione S-transferase 
activity, whatever the substrate used, or protein expression following Western blot 
analysis when studies were performed with liver slices from Donor 1. In the liver from 
Donor 2, however, both isothiocyanates caused moderate elevation of glutathione S- 
transferase activity, accompanied by a similar rise in the levels of immunologically 
determined GSTo and GSTp with no concentration-dependent changes in GSTti, similar 
to what was noted in rat liver slices. Enhanced expression of the human GST G STA l/2  
and GSTMl in vitro has been reported previously for SFN (Maheo et al., 1997, Bacon et 
al., 2003 and Ritz et al., 2006). The varied response obtained in the two human livers 
may be attributed to either genetic differences or to factors linked to the tim e of liver 
removal relative to the time of death and/or transport of the tissue. The latter is unlikely 
as, in fact, the basal hepatic glutathione S-transferase activity in Donor 1 was much 
higher than that of Donor 2. Clearly, more human livers need to be analysed for a 
clearer picture to emerge. Similarly, both compounds increased total glutathione levels 
in rat liver but only in human liver from Donor 2. The ability of isothiocyanates to 
enhance glutathione synthesis in animals has already been documented with 
sulforaphane (Zhang, 1992), but this is the first time that this has been demonstrated 
with erucin.
6 .4 .3  Cytotoxicity  o f  erucin and  SFN and  e ffec t on to ta l GSH levels
The activities of most cytochromes P450 decreased in both rat tissues and human liver 
at the highest concentrations of erucin and SFN (25 and 50 pM). Moreover, the increases 
in activity of the various enzymes observed in rat and human slices at lower 
concentrations were no longer evident at the highest isothiocyanate concentration used. 
Such a pattern of XME modulation by ITCs is consistent with cytotoxicity as supported by 
the observations that these and higher concentrations increased leakage of lactic
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dehydrogenase. Furthermore, the highest concentrations of ITCs depleted tissue 
glutathione.
Cytotoxic effects of erucin and SFN on liver and lung slices were evaluated using a 
simple colorimetric assay based on quantifying lactate dehydrogenase (LDH) activity 
released from damaged cells into the medium. The extent of LDH leakage, expressed as 
percentage of total liver slice LDH content, is a commonly used m arker of parenchymal 
cell membrane integrity, however, no clear relationship between the degree of LDH 
leakage and slice viability has been established (Barr et al., 1991a and 1991b and Elkins 
et al., 1996). Although the LDH leakage from control slices was quite high (up to 40% ) 
by 24 h of incubation, the slices retained their metabolic activity.
Both compounds were toxic to cultured rat and lung slices at 50 pM, and highly cytotoxic 
at 100 pM. Although the LDH leakage was not monitored in human liver slices, it is 
reasonable to expect manifestation of toxicity at high concentrations of ITCs, such as 
falling activities and/or cessation of induction of some enzyme, as indeed was the case 
with both human livers.
GSH is the major cellular scavenger of free radicals and electrophiles. At 50 pM, both 
ITCs profoundly decreased total cellular glutathione levels in the human liver as well as 
in both rat tissues. Rapid intracellular accumulation has been reported previously with 
SFN in Hepa lc lc 7  ceils (Zhang and Talalay, 1998). Since ITCs are highly reactive 
towards glutathione, 95 -98  % of intracellular SFN exists as glutathione conjugates 
(Zhang, 2000) that are then rapidly exported out of the cells (Zhang and Callaway, 2002  
and Callaway et al. 2004). Therefore it is not surprising that exposure of rat and human 
tissue slices to excessively high concentrations of SFN (>  25 pM) results in profound 
glutathione depletion and associated cytotoxicity. Erucin appears to sequester cellular
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glutathione to the same degree as SFN. In contrast, after 24 h incubation of rat liver and 
lung slices with lower concentrations of erucin or SFN, glutathione levels were increased 
in a concentration-dependent manner. SFN substantially increased GSH levels previously 
in lymphoblastoid (Misiewicz et al., 2004) and in HepG2-C8 (Kim et al., 2003) cells. 
Such rebound up-regulation of glutathione synthesis in response to treatm ent with non­
toxic concentrations of ITCs was only apparent in the liver from second donor. In 
contrast, glutathione levels in the human liver of the donor did not recover by 24 h, 
indicating inter-individual differences in response to glutathione depletion among 
humans.
6 .4 .4  Conclusion
Neither erucin nor SFN modulated the activities of cytocromes P450, suggesting that 
suppression of bioactivation of human mutagens by dietary levels of erucin and SFN is 
unlikely to be a relevant mechanism of their anticarcinogenic activity. On the other 
hand, the likelihood of food-drug interactions that can lead to undesired side effects in 
humans taking medications may also be significantly decreased. Erucin and sulforaphane 
elevated glutathione S-transferase expression in isoform-specific manner in both rat and 
human liver. However, quinone reductase, either at the activity or protein level, was 
inducible by these compounds only In rat, and very poorly, or not at all, in human liver.
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7.1 In troduction
Humans are exposed repeatedly throughout the course of life to low levels of 
carcinogenic nitrosamines, heterocyclic amines (HA) and polycyclic aromatic 
hydrocarbons (PAH) present in foods such as smoked, grilled, fried or barbecued meat 
and fish, tobacco smoke and environment. Such carcinogens require cytochrome P450- 
mediated metabolic bioactivation to form highly reactive chemical species that covalently 
bind to the cellular DNA. Chemical mutagens and carcinogens are highly hydrophobic in 
nature and require metabolic modification to a more polar derivative that can be safely 
eliminated from  the body. The first step of their metabolism involves hydroxylation by 
cytochrome P450 enzymes. Depending on the specific cytochrome P450 involved, the 
hydroxylation reaction is the first metabolic step leading to either detoxification or 
bioactivation. A large number of human carcinogens, including polycyclic aromatic 
hydrocarbons (PAHs) and heterocyclic amines (HA), are bioactivated by the CYPl, a 
highly inducible cytochrome P450 family (Ma and Lu, 2007). CYPl expression is 
regulated by a ligand-activated transcriptional factor, the aryl hydrocarbon receptor 
(AhR). Many AhR ligands are CYPl substrates, some of which, such as the classical PAH 
B(a)P, potently induce expression of this enzyme (McFadyen et al., 2003 and Nebert et 
al., 2004). CYPl family consists of two subfamilies, CYPl A and CYPIB. The latter, 
composed of a single enzyme C Y P IB I, is poorly expressed in the liver, but is present in 
extrahepatic tissues. The former subfamily consists of two enzymes, C Y P lA l and 
CYP1A2. CYP1A2 is liver-specific, whereas C YP lA l is poorly expressed in the liver but 
occurs in extrahepatic tissues (Nebert et al., 2004). C Y P lA l induction has been 
associated with increased risk of cancer in animals (Gelboln, 1980) and humans 
(Proctor, 2001).
One of the putative mechanisms of suppressed tumour initiation in experimental animals
by dietary erucin and SFN is acknowledged to be inhibition of the CYPlA-associated
— —
Chapter 7: Effect of isothiocyanates on metabolism of carcinogens______________________
metabolic bioactivation of chemical carcinogens (Juge et al., 2007). However, SFN up- 
regulated C Y P lA l apoprotein (Yoxall et al., 2005). Moreover, both erucin and SFN 
markedly induced C Y P lA l apoprotein in the in vivo and in vitro studies described in 
Chapters 5 and 6 respectively, indicating that these ITCs may modulate cellular 
signalling pathways involved in the regulation of CYPIA enzyme expression. I t  was, 
therefore, hypothesised that these phytochemicals may interfere with B(c)P-induced up- 
regulation of C Y P lA l enzyme by B(a)P by possibly antagonising its binding to the AhR. 
The purpose of the present studies was to investigate whether concomitant treatm ent 
with ITC and B(a)P may antagonise B(a)P-mediated C Y P lA l induction and, 
consequently, the extent of bioactivation of carcinogens.
7 .2  Methods
7.2 .1  E ffect o f  concom itant tre a tm en t w ith  IT C s  an d  B (a )P -m e d ia ted  
upreguiation o f  C Y P lA l expression
The possibility of ITCs interacting with B(a)P was evaluated in precision-cut rat liver 
slices prepared and maintained as described in sections 2 .2 .2 .1 , 2 .2 .2 .3  and 2 .2 .2 .4 . 
Liver slices were incubated in modified RPMI 1640 containing either a mixture of BaP (1 
or 5 pM) with erucin/SFN (5 - 50 pM) or the ITCs alone for 24 h. The appropriate 
controls were incubated with the solvent vehicle (0 .1 % , v /v ), dimethyl sulfoxide 
(DMSO). The toxicity of the ITC /B(a)P mixtures to liver slices was assessed by 
monitoring the LDH leakage (section 2 .2 .3 ). Tissue slices were homogenised and 
resolved into microsomal and cytosolic fractions (section 2 .2 .5 ), and the former was 
used in the determination of C YP lA l activity section 2 .2 .7 ) and apoprotein levels 
(section 2 .2 .13 ). Total protein was determined as described in section 2 .2 .6 .
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7 .2 .2  E ffect o f  p re -tre a tm e n t w ith  ITC s on m utagen ic ity  o f  u rin a ry  IQ
The antimutagenic potential of each of the two test compounds, SFN and erucin, was 
assessed in rats maintained on water containing the test compounds or solvent vehicle 
for "long" (10  days) or "short" (1 day) period of time prior to exposure to a single dose 
of IQ. Body weight was recorded at the beginning (day 1) and at the end of the study 
(terminal body weight). At the end of the study, the animals were killed by cervical 
dislocation; the livers were removed, snap-frozen in liquid nitrogen and subsequently 
stored at -80°C  until processed for analysis as described in section 2 .2 .5 . The urine, 
collected prior to and post IQ administration, was analysed using the Ames mutagenicity 
test carried out in the presence of an activation system (10%  of Aroclor 1254-indused  
59) and employing Salmonella typhimurium  strain YG1024, characterised by over­
expression of 0-acetylase as described in section 2 .2 .14 .
7 .2 .2 .1  Test compound form ulation  and storage
Stock solutions of erucin and sulforaphane were prepared in DMSO (300 m g/m l) and 
diluted with tap water to achieve final concentrations of 30m g/l and 150m g/l (v /v ), 
corresponding to approximate daily doses of 3 and 15 mg/kg for each of the ITCs. The 
tap water for control animals was supplemented with the solvent vehicle only (DMSO, 
0.05%  v /v ). All aqueous solutions of test compounds and solvent vehicle were prepared 
in advance and stored at -20°C  as aliquots that were defrosted as required at 4°C 
overnight prior to administration. The heterocyclic amine 2-am ino-3-m ethylim idazo- 
[4,5-f]quinoline (IQ ) was dissolved In corn oil at a concentration of 1 .25m g/m l and 
stored at 4°C.
7 .2 .2 .2  Anim al m aintenance
The commercial source and conditions at which the animals were maintained during 
acclimatisation and study periods are described in section 2 .2 .1 .
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7 .2 .2 .3  Design of study into the effects of "Mona"-term p re -tre a tm en t w ith  ITCs 
on the lO -m ed ia ted  urinary excretion of m utaaens
The experimental design of the study is summarised in Figure 7.1. Twelve male W/A rats 
were examined and randomly assigned to 3 groups of 4 animals each. Following an 
acclimatisation period of three days, the animals were maintained on water containing 
test compounds or solvent vehicle for 14 days as detailed below:
• Group A Control, DMSO (0 .05% , v /v ) in tap water
• Group B Low dose (30m g/l) of erucin or SFN in drinking water containing
DMSO (0 .0 5 % , v /v )
• Group C High dose (150m g/l) of erucin or SFN in drinking water in water
containing DMSO (0 .05% , v /v )
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Figure 7.1: Experimental design of the 14 day (long-term ) study into the effects of 
erucin or sulforaphane on the IQ-m ediated excretion of mutagens in urine. Male Wistar 
albino rats (n=4) were maintained on either erucin (30 and 150 mg/I) or SFN (30 and 150 mg/l)- 
supplemented water for 14 days; controls received water containing solvent vehicle (DMSO, 0.5 % 
v/v). Eleven days after the treatment commenced, a single dose of IQ (5 mg/kg of body weight) 
was administered by oral gavage to all animals. Urine was collected daily, starting 24h before and 
finishing 72 h after the IQ administration and urinary excretion of mutagens determined using the 
Ames mutagenicity assay.
On the 10^ '^  day of treatm ent (24h prior to the IQ administration), all animals were 
transferred into metabolic cages where they were housed singly for the last 4 days of
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the study. On the day of the treatm ent, all animals received a single dose of IQ (5 
mg/kg body weight) administered by oral gavage. Urine was collected on a daily basis 
starting 24h before and finishing 72 h after IQ administration
7 .2 .2 .4  Design of study into the  effects o f 's h o rt '- te rm  p re -tre a tm en t w ith  
ITCs on lO -m ed ia ted  urinary  excretion of m utaaens
The experimental design of this short-term study is outlined in figure 8.2. Twelve male 
W/A rats were randomly assigned to 3 groups of 4 animals each. Following an 
acclimatisation period of three days, all animals were transferred into metabolic cages 
where they were housed singly throughout the study (4 days), and received the 
following treatments:
• Group A Control, DMSO (0 .05% , v /v ) in tap water
• Group B Erucin (150m g/l) in drinking water containing DMSO 
(0 .05% , v /v )
• Group C SFN (150m g/l) in drinking water in water containing DMSO 
(0 .05% , v /v )
Acclim atisation T rea tm en t w ith  ITC
IQ administration 
;
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Figure 7.2: Experimental design of the "short'-term  study into the effects of ITCs on the 
IQ-m ediated urinary excretion of mutagens. Male Wistar albino rats (n=4) were maintained 
on erucin (150 mg/I) or SFN (150 mg/l)-supplemented water for 4 days. Twenty four h after the 
treatment commenced, a single dose of IQ (5 mg/kg of body weight) was administered by oral 
gavage to all animals. Urine was collected daily and excretion of mutagens determined using the 
Ames mutagenicity assay.
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After a 24 pre-treatm ent with the ITCs, all animals received a single dose of IQ (5  
mg/kg body weight), administered by oral gavage. Urine was collected on a daily basis 
starting 24h before and finishing 72 h after the IQ administration.
7 .2 .2 .5  D eterm ination  of XME activities
Rate of ethoxy- and methoxyresorufin dealkylation was determined in hepatic 
microsomal fraction (section 2 .2 .7 ). Activity of cytosolic glutathione S-transferase was 
monitored using CDNB as the accepting substrate (section 2 .2 .1 2 ). Protein concentration 
in both fractions was determined as described in section 2 .2 .6 .
7.3  Results
7.3 .1  E ffect o f  IT C /B (a )P  m ixtu re  on LDH ieakage
Lactate dehydrogenase (LDH) leakage into the incubation medium after a 24 h 
incubation of liver slices with erucin/SFN and B(a)P alone, as well as with their mixtures, 
was monitored as an indicator of cytotoxicity (the data on toxicity of individual ITCs is 
presented in Chapter 6, section 6 .3 .2 ). There was no change in the extent of LDH 
leakage from liver slices incubated with B(a)P alone (0 -1 0 0  pM) for 24 h (Fig. 7 .3 ). 
Following 24 h treatm ent of liver slices with mixtures of erucin (0 -5 0  pM) and B(a)P (1 
and 5 pM), a weak, but statistically significant toxicity was observed at 50 pM erucin 
combined with either 1 or 5 pM B(a)P (Fig. 7.4  A). Similarly, LDH leakage in hepatic 
slices treated with mixtures of SFN (0 -50  pM) and B(a)P (1 and 5 pM) was only 
increased at the highest SFN level irrespective of B(a)P concentration (Fig. 7 .4  B).
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Figure 7.3: Leakage of LDH from rat iiver slices incubated with BaP. LDH leakage was 
measured In liver slices incubated in modified RPMI 1640 supplemented with BaP (0-100 pM) for 
24 h. LDH release is expressed as percentage of total LDH. Values are presented as means ± SD 
of duplicate determinations of triplicate slices per concentration.
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Figure 7.4: Leakage of LDH from rat liver slices incubated concurrently w ith  BaP and 
erucin (A ) or SFN (B). LDH leakage was measured In liver slices incubated in modified RPMI 
1640 containing a mixture of BaP (1 and 5 pM) and either erucin or SFN (5 - 50 pM) for 24 h. LDH 
release is expressed as percentage of total LDH. Values are presented as means ± SD of duplicate 
determinations of triplicate slices per concentration. *, P<0.05.
7 .3 .2  E ffect o f  erucin and  SFN on B (a )P -m e d ia ted  upreguiation  o f  C Y P lA l 
expression in iiv e r slices
Initially, rat liver slices were incubated for 24 h with B(a)P (0 -20  pM) alone to establish 
the concentration levels optimal for C YP lA l induction. Hepatic C Y P lA l activity, 
determined using ethoxyresorufin as a diagnostic substrate, was induced by B(a)P in a 
concentration-dependent manner, increasing almost 6- and 16-fold at 1 and 5 pM 
respectively. The B(a)P-mediated C YP lA l induction was linear up to B(a)P concentration 
of 5 pM. Therefore, B(a)P concentration of 1 pM was selected for detecting a possible 
synergistic or additive effect of ITC on B(a)P-mediated EROD induction, whereas 5 pM 
was optimal for evaluating the possibility of an antagonistic effect (Fig. 7 .5 ).
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Figure 7.5: Effect of B(a)P concentration on induction of hepatic C Y P lA l. Livers slices  
f ro m  control rats  w e re  incu b a ted  in m od if ied  R PM I 1 5 4 0  con ta in in g  B (a )P  ( 0 - 2 0  p M )  fo r  2 4  h. 
EROD a c t iv i ty  w a s  d e te r m in e d  in m ic ro so m al frac tio n .  Results  a re  p re s e n te d  as m e a n s  ±  S D  of  
tr ip licate  d e te rm in a t io n s ,  each rep l icate  com prised  a pool o f  6 - 1 0  slices. * ,  P < 0 . 0 5 ;  * * ,  P < 0 . 0 1 .
When liver slices were incubated with either ITC alone (0 -5 0  pM) for 24 h, hepatic EROD 
activity was significantly inhibited by both compounds only at the highest concentration 
(SOpM) (Fig. 7 .6 ) ,  while Western blot analysis revealed a concentration-dependent  
increase in C Y P lA l  apoprotein levels (Fig. 7 .7 ) .  In contrast, concurrent trea tm en t of rat 
liver slices with erucin or SFN (0 -5 0  pM) and BaP (1 and 5 pM) diminished the inducing 
potential of the latter (Fig. 7 .6 ) .  The antagonistic effect of both ITC was clearly 
concentration-dependent (Figures 7 .6 ) .  Both ITCs caused a similar concentration-  
dependent decrease in the B(a)P-mediated increase in C Y P lA l  protein expression (Fig 
7.7 A and B). The change in expression of C Y P lA l  was plotted taking into account 
amounts of loaded protein (Fig 7 .7  C), since a linearity has already been established 
between protein concentration and optical density of the protein band (Pushparajah et 
al., 2007) .
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Figure 7.6: Effect of erucin (A) and SFN (B) on BaP-mediated increase in EROD activity.
Slices from the liver of control rats were Incubated In modified RPMI 1640 containing either 
mixtures of BaP (1 and 5 pM) and erucin (5-50 pM) or the test compounds alone for 24 h. Hepatic 
EROD activity was determined In microsomal preparation. Results are presented as mean ± SD of 
triplicate determinations. Each replicate comprised a pool of 6-10 slices. P<0.05; * * ,  P<0.01. 
P<0.001.
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Figure 7.7: Effect of erucin (A) or SFN (B) on B(a)P-medfiated increase in hepatic 
CYPlAl apoprotein. Slices from livers of control rats were Incubated In modified RPMI 1640 
containing either a mixture of B(a)P (5 pM) and ITC (0 - 50 pM) or ITC alone for 24 h. Microsomal 
proteins were resolved by 10 % (w/v) SDS-PAGE and then transferred electrophoretlcally to the 
Hybond-P polyvinylldene difluorlde membrane. Immunoblot analysis was carried out using rat 
CYPlAl antibodies followed by the appropriate peroxidase-labelled secondary antibody. Each lane 
was loaded with 5 (B(a)P alone and B(a)P-erucln groups) or 40 pg (control and erucin only 
groups) of total protein. Molecular markers were run concurrently to aid band Identification. The 
values In Italics above the Immunoblots show optical density (percentage) of each band relative to 
respective control (solvent vehicle-treated slices). C. Graphical presentation of quantitive changes 
In the apoprotein levels taking into account protein levels loaded.
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7 .3 .3  E ffect o f  a 'lo n g " -te rm  tre a tm en t w ith  erucin o r  SFN on u rin a ry  excretion  
o f m utagens in  ra ts  exposed to IQ
The animals remained in good health throughout the duration of the study; no clinical or 
behavioural signs of systemic toxicity were apparent among the different treatm ent 
groups. Since a single 250 g rat consumed at least 25 ml of water daily, ITC intake was 
calculated to be 0 .75 and 3 .75 mg per rat or 3 and 15 mg per kg for the low and higher 
dose levels respectively. Neither compound had any significant impact on water 
consumption, body weight gain or relative liver weight (Table 7 .1 ).
Treatment
group
Dose
(m g/kg /day)
Average daily 
water intake 
(m l/day)
Average daily 
body weight 
gain (g)
Relative liver 
weight (%  of 
body weight)
Control 27.4 ± 1.9 4.1 ± 0.2 4.1 ± 0.2
Low erucin 3 30.3 ± 6.9 4.2 ± 0.3 3.8 ± 0.3
High erucin 15 25.7 ± 4.1 4.2 ± 0.7 3.9 ± 0.1
B
Treatment
group
Dose
(m g/kg /day)
Average daily 
water intake 
(m l/day)
Average daily 
body weight 
gain (g)
Relative liver 
weight (%  of 
body weight)
Control 27.4 ± 0.3 4.4 ± 2.9 3.9 ± 0.3
Low SFN 3 27.8 ± 0.4 4.2 ± 0.3 3.6 ± 0.3
High SFN 15 31.5 ± 3.1 4.2 ± 0.7 3.6 ± 0.4
Table 7.1: Daily water consumption, body weight gain and relative liver weight of rats 
pre-treated with erucin (A) or SFN in water and exposed to IQ . Male Wistar albino rats 
were treated with ITC (30 and 150 mg/I) or solvent vehicle (DMSO, 0.05% v/v) in drinking water 
for 14 days. Eleven days after the treatment commenced, a single dose of IQ (5 mg/kg) was 
administered by oral gavage to all animals. Results are presented as mean ± SD, where n=4.
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Effect of pre-treatm ent of rats with ITCs (low and high dose) for 11 days prior to expose 
to IQ (5 m g/kg) on excretion of the indirect-acting urinary mutagens was determined 
using the Ames mutagenicity test in the presence of an Aroclor 1254-induced activation 
system. Both ITCs suppressed the indirect-acting mutagenicity of urine, but a clear 
concentration-dependent effect was evident only in the case of erucin (Fig. 7.8 A). 
Excretion of the indirectly-acting mutagens in urine in the first 24 h after IQ  
administration was significantly suppressed in animals maintained on the higher dose of 
either compound, whereas at iower dose statistical significance was attained only for 
erucin (Fig. 7.8  A). Treatm ent with lower dose of SFN decreased the indirect-acting 
mutagenicity of urine, but statistical significance was not achieved as a result of wide 
variations and small size (n = 4 ) of groups (Fig. 7.8 B). Significant suppressing effect of 
erucin persisted up to 72 h after IQ administration (Fig. 7 .8  A). Suppressing effect of 
SFN on excretion of indirect-acting mutagens was evident only in the first 24 h after 
administration of IQ  (Fig. 7 .8  B). No direct-acting mutagenicity was detected, i.e. in the 
absence of the activation system (results are not shown).
To investigate whether the observed ITC-induced decrease in urinary mutagenicity 
following exposure to IQ  was associated with a change in CYPl-m ediated metabolism of 
this model HA, the rate of hepatic 0-deethylation (EROD) and 0-dem ethylation (MROD) 
of ethoxy- and methoxyresorufin, catalysed by C Y P lA l and CYP1A2 enzymes 
respectively, were determined. Neither ITC modulated microsomal EROD or MROD (Fig. 
7.12 A and B), suggesting that other mechanisms may be involved. Activity of GST, 
determined using CDNB as a marker substrate, was marginally elevated by the higher 
doses of both compounds, but statistical significance was not reached due to small size 
and wide variations between the groups (Fig. 7 .12 C).
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Figure 7.8: Effect of 11 day pre-treatm ent w ith erucin (A ) and SFN (B ) on urinary 
excretion of mutagens in rats following IQ  administration. Male Wistar albino rats (n=4) 
were treated with ITC (30 and 150 mg/I) or solvent vehicle (DMSO, 0.05% v/v) in drinking water 
for 14 days. Eleven days after the treatment commenced, a single dose of IQ (5 mg/kg of body 
weight) was administered by oral gavage to all animals. Urine was collected daily, starting 24h 
before and finishing 72 h after the IQ administration. Urinary mutagenic activity was determined 
by the Ames mutagenicity test employing S. typhimurium strain YG1024 in the presence of Aroclor 
1254-induced activation system. Results are presented as mean ± SD of triplicate determinations. 
The spontaneous reversion rates of 20 ± 3 and 38 ± 6 for erucin and SFN respectively have 
already been subtracted. *, P<0.05; * * ,  P<0.01.
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Figure 7.9: Effect of erucin and SFN on rat hepatic EROD, MROD and GST. Male Wistar 
albino rats were treated with ITC (30 and 150 mg/I) or solvent vehicle (DMSO, 0.05% v/v) in 
drinking water for 14 days. Eleven days after the treatment commenced, a single dose of IQ (5 
mg/kg) was administered by oral gavage to all animals. Hepatic EROD (A) and MROD (B) were 
determined in the microsomal fraction, whereas GST (C) activity was determined in the cytosolic 
fraction using CDNB as an accepting substrate. Results are presented as mean ± SD, where n=4, 
each sample assayed in duplicate. *, P<0.05; * * ,  P<0.01.
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7 .3 .4  E ffect o f  sh o rt-te rm  p re -tre a tm e n t w ith  erucin o r  SFN on u rin ary  
excretion o f  m utagens in ra ts  tre a te d  w ith  IQ
To investigate whether a duration of ITC pre-treatm ent prior to IQ  exposure can 
influence urinary mutagenicity, rats were pre-treated with ITC for one day prior to IQ  
administration. The animals remained in good health; no clinical or behavioural signs 
of systemic toxicity were apparent among the different treatm ent groups. Neither 
compound had any significant impact on water consumption, body weight gain or 
relative liver weight (Table 7 .2 ).
Treatment
group
Dose
(m g/kg /day)
Daily water 
intake (m l/day)
Daily body 
weight gain (g)
Relative liver 
weight (%  of 
body weight)
Control 
High erucin 
High SFN
15
15
23.9 ± 0.9
20.9 ± 3.6 
22.5 ± 6.0
4.9 ± 0.7 
5.5 ± 0.9 
5.1 ± 0.6
4.2 ± 0.1
4.3 ± 0.2
4.4 ± 0.3
Table 7.2: Daily water consumption, body weight gain and relative liver weight of rats 
pre-treated for 24h with erucin (A) or SFN prior to IQ administration. Male Wistar albino 
rats were maintained on erucin (150 mg/I), SFN (150 mg/I) or solvent vehicle (DMSO, 0.5 % v/v)- 
supplemented water for 4 days. Twenty four h after the treatment commenced, a single dose of IQ 
(5 mg/kg) was administered by oral gavage. Results are presented as mean ± SD, where n=4.
Analysis of urine in the presence of an Aroclor 1254-induced activation system revealed 
that neither erucin nor SFN influenced excretion of the indirect-acting mutagens (Fig. 
7.13), whereas no mutagenicity was detected in the absence of the activation system 
(results not shown).
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Figure 7.10: Effect of short-term pre-treatment with erucin or SFN on urinary excretion 
of mutagens after IQ administration to rats. Male Wistar albino rats (n=4) were treated with 
ITCs (150 mg/I) or solvent vehicle (DMSO, 0.05% v/v) in drinking water for 4 days. Twenty four h 
after the treatment commenced, a single dose of IQ (5 mg/kg) was administered by oral gavage 
to all animals and urine was collected daily. Urinary mutagenic activity was determined by the 
Ames mutagenicity test employing S. typhimurium strain YG1024 in the presence of Aroclor 1254- 
induced activation system. Results are presented as mean ± SD of triplicate determinations. The 
spontaneous reversion rate of 54 ± 7 has already been subtracted.
7 .4  Discussion
7 .4 .1  In te rac tio n s  o f  ITC s w ith  B (a )P
Inhibition of Phase I enzymes and, consequently, interruption of the bioactivation 
pathway(s) of parent carcinogens by dietary ITCs has been associated with decreased 
DNA damage, mutation frequency and, ultimately, inhibition or retardation of 
tumourigenesis (Juge et al., 2007). The reverse is also true, especially in case of the 
C Y P lA l, induction of which has been associated with increased risk of cancer in animals 
(Gelboln, 1980) and humans (Proctor, 2001).
Neither C YP lA l apoprotein nor activity were down-regulated by the individual ITCs. In  
contrast, both ITCs antagonised in a concentration-dependent manner the AhR-mediated
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induction of C Y P lA l enzyme activity and expression by B(a)P in liver slices following 
their concurrent incubation for 24 h. B(a)P is a potent inducer of its own metabolism and 
bioactivation to genotoxic metabolites mostly by C Y P lA l, induction of which has been 
linked to an increased risk of cancer in animals (Gelboln, 1980) and humans (Proctor,
2001). Curbing its up-regulation by inducers such as B(a)P and, consequently, 
bioactivation of human carcinogens such a PAHs and HAs, therefore represents a novel 
mechanism that may contribute to the pleiotropic anticarcinogenic effects of erucin, SFN 
and, possibly other ITCs. Given that induction of C YP lA l by B(a)P is AhR-controlled, it is 
possible that ITCs disrupt activation by B(a)P and/or interfere with downstream events 
involving formation of active transcription factor and binding to the promoter of XRE 
region of AhR-controlled battery of genes. Recently SFN has been shown to bind to the 
steroid and xenobiotic receptors (SXR) directly and disrupt the SXR-coactivator 
interactions necessary for the activation of the gene transcription in primary human 
hepatocytes (Zhou et al., 2007).
Alternatively, the inhibiting effect of ITCs on B(a)P-mediated up-regulation of C YPlA l 
could be explained by direct mechanism-based inactivation of this enzyme as described 
in Chapter 5. However, the latter mechanism does not explain a decrease in C YP lA l 
apoprotein levels. Moreover, ITC-induced loss of C Y P lA l activity, prevented even by 
relatively low levels of reduced GSH (0 .2  mM) is unlikely to take place in hepatocytes 
where physiological GSH concentration is significantly higher (Chapter 5).
7 .4 .2  E ffect o f  'lo n g -"  and  "short"-term  p re -tre a tm e n t w ith  ITC s on excretion  
o f urinary  m utagens in IQ -tre a te d  rats
H eterocyclic-am ines^re^anotherx-im portant class of CYPlAzbioactivated chemicals, 
associated with increased risk of human cancers (Ikeda et al., 1983, Robbana-Barnat et 
al., 1996, De Stephani et al., 1997 and SInha et al., 2000) and established carcinogens
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in animals (Adamson et al., 1994), which are formed in protein-rich food such as red 
meat, poultry and fish during heat processing, especially grilling, broiling or frying. The 
mutagenic activity of the heterocyclic amines, such as 2-am ino-3-m ethylim idazo-[4,5- 
fjquinoline (IQ ) (Fig. 7 .11 ), arises as a consequence of metabolic activation of the 
parent compounds, which are oxidised by microsomal CYP1A2, with minor contribution 
from C YPlA l to form the A/-hydroxyamino derivatives that are subsequently conjugated 
with sulphate and acetate to generate esters that spontaneously break-down to form the 
nitrenium ion, the presumed ultimate carcinogen that interacts with DNA (Davis et al., 
1993). IQ was chosen as a model mutagen for several reasons: 1) it is a food mutagen 
and thus likely to be consumed concurrently with ITCs formed in cruciferous vegetables, 
2) previous studies have shown a SFN-mediated decrease in IQ-induced genotoxicity 
and/or mutagenicity (Barcelo et al., 1998; Bacon et al., 2003 and Yoxall et al., 2005) 
and 3) it is highly mutagenic in the Ames mutagenicity assay thus enabling the 
determination of IQ -m ediated mutagenicity in rat urine.
Since the mechanism of ITC-mediated chemoprevention is partially based on impairment 
of the metabolic pathways of chemical carcinogens that produce genetoxic metabolites 
and enhanced detoxification of their reactive intermediates (Fahey and Talalay, 1999), 
the aim of the current studies was to investigate whether erucin can modulate the 
metabolism of IQ  as exemplified by urinary excretion of pro-mutagens. Mutagenic 
activity was determined using the Ames assay employing Salmonella typhimurium  
bacteria strain YG1024, genetically modified to over-express 0-acetyl transferase, the 
enzyme involved in the bioactivation of IQ (McArdle et al., 1999). The effects of long- 
and short-tern pre-treatm ent of rats with erucin or SFN prior to IQ  administration on
excretion of urinary mutagens was evaluated at the dose levels reflecting human intakes 
(Howard et al., 1997). Direct-acting urinary mutagenic activity, i.e. in the absence of the 
activation system, was not detected in either long- or short-term  study. Treatm ent of
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urine with aryl sulphatase or (3-glucuronidase failed to increase the IQ-induced 
mutagenic response in previous studies (McArdle et al., 1999), therefore this 
methodology was not applied to the current studies.
"Long-term" pre-treatm ent of rats with low and high dose of erucin prior to IQ  
administration resulted In a significant and dose-dependent reduction in excretion of 
indirect-acting mutagens in urine collected during the first 24h after IQ  administration. 
Marked suppressing effect of erucin persisted up to 72 h after IQ  administration, but 
only at the high dose group. SFN was a less potent suppressant of the indirect-acting 
mutagenicity, decreasing it only in the first 24 h after IQ  administration and only at the 
high dose. Indirect mutagenic activity reflects the levels of unchanged IQ that is 
converted by the CYPIA, present in the activation system, to the hydroxylamine, the 
proximate mutagen responsible for the mutagenic effect in the Ames assay. The only 
other metabolites that may contribute to indirect mutagenic activity are N-acetyl IQ  and 
demethylated IQ , but both are minor metabolites (Barnes and Weisburger, 1985). In  
contrast, the ring hydroxylated metabolites of amino-compounds can not be activated 
despite having an intact exocyclic amino group (Tong et al., 1986 and loannides et al., 
1989) and the A/-conjugates of IQ such as the sulphamate lack mutagenic activity 
(Turesky et al., 1986). Since the indirect-acting urinary mutagens most likely represents 
the unchanged parent compound, the decrease in their excretion can be caused by 
induction of liver C Y P lA l and, more importantly CYP1A2, the latter being the principal 
enzyme involved in cytochrome P450-mediated detoxification, as well as bioactivation 
pathways of IQ  metabolism (McArdle et al., 1999 and Yoxall et al., 2004). However, 
activities of either EROD or MROD in the current studies did not differ between the 
treated and control animals. IQ itself is a very weak inducer of the CYPl family 
(Rodrigues et al., 1989) and it is extremely unlikely to influence this enzyme systems 
following administration of a single oral dose. The CYPIA enzyme activities were only
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determined In the liver, the principal site of IQ  metabolism, the contribution of other 
organs to the metabolism of IQ , which could be conceivably differentially modulated by 
isothiocyanates, has not been accounted for. Another feasible explanation is that a 
change in the activity of other enzyme systems, such as sulfotransferases or UGTs can 
shift the IQ metabolism so as to favour the competing detoxification pathways. This 
mechanism is supported by the observation that the extent of Phase I I  enzyme induction 
in rats can be enhanced by increased duration of ITC treatm ent (Munday and Munday,
2002). Furthermore, the protective effect of ITC in the current studies was only apparent 
after "long"-term, but not 24 h pre-treatm ent with ITC prior to IQ  administration. 
Activity of sulfotransferases and UGTs were not determined and it remains to be 
established whether direct conjugation with sulphur and/or glucuronide of the exocyclic 
amino group (Turesky et al., 1986 and Armbrecht et al., 2007 ), which are likely to 
promote its detoxification, may be enhanced. Glucuronide and sulphur conjugates (Fig. 
7.11) of the exocyclic amino group are expected to increase the direct mutagenicity
NH,
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Figure 7.11: Structures of IQ  and its major metabolites. Adapted from Armbrecht at al. 
(2007)
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following treatm ent of urine with (3-glucuronidases or aryl sulphatases respectively, 
which was not the case (McArden et al., 1999), suggesting that these metabolites are 
not good substrates and/or may be resistant to the activity of these enzymes (Turesky 
et al., 1986). Ring hydroxylation by cytochrome P450 enzymes followed by glucuronide 
and sulphur conjugation (Fig. 7 .11) are also among the important detoxification 
pathways of IQ (Armbrecht et al., 2007) that may be enhanced by ITCs. I t  is 
conceivable that ITCs excreted in urine act as mechanism-based inactivators of CYPIA in 
59 preparations used in the activation system. The latter mechanism is unlikely for at 
least two reasons. Firstly, the urinary concentrations of ITC even at the high dose level 
does not exceed 2 pM (Chapter 3) and was further reduced 20-fold when urine was 
incorporated into the top agar for plating, whereas effective CYPIA inhibition (50 % ) can 
be achieved in vitro at concentrations of erucin and SFN of 25 pM. Secondly, the 
chemopreventive effect of ITCs against IQ-associated mutagenicity was evident only 
after "long"-term administration, but not after 1-day pre-treatm ent. Considering that 
most of ITC dose is excreted within first 24 h after administration, duration of ITC  
pretreatment should not affect CYPIA inhibition if such mechanism was operative. To 
gain a better understanding of the mechanism of ITC-m ediated attenuation of IQ  
mutagenicity, it is necessary to investigate the metabolic profile of IQ before and after 
ITC administration. Finally, it can not be ruled out that the observed decrease in the 
urinary excretion of indirect-acting following long-term pre-treatm ent of rats with ITC  
prior to exposure to IQ is attributed to the enhancement of the metabolic pathway(s) 
leading to bioactivation of this mutagen and formation of DNA and/or protein adducts 
and thus promoting mutagenic effects of IQ. Further studies are required to ascertain 
whether ITCs are capable of promoting IQ-induced DNA damage.
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7 .4 .3  Conclusion
Both ITCs, erucin and SFN, attenuated B(a)P-mediated induction of CYPIA, possibly as a 
result of mechanism-based inactivation of this enzyme by ITC and/or antagonism of 
B(a)P binding to the AhR. Moreover, the current studies demonstrate that "long"-term, 
but not short-term administration of ITCs diminishes urinary excretion of indirect-acting 
mutagens in rats exposed to a single dose of IQ , although the mechanism of the 
modulating effects remains to be elucidated.
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8.1 Effects o f erucin and SEN on phase I I  enzym es and g lu ta th ione  levels
Diets rich in Brassica vegetables have been linked to reduced incidence of various 
human cancers (Higdon et a!., 2007 and Sapone et al., 2007). The observed beneficial 
health effects of these plants are ascribed to ITCs, the most abundant class of 
phytochemicals present in these vegetables. They occur in the form of glucosinolate 
precursors that are converted to their respective ITCs by the endogenous plant enzyme 
myrosinase following disruption of the plant material (Talalay and Fahey, 2001). 
Numerous in vitro and animal studies have confirmed the beneficial chemopreventive 
activity of these phytochemicals.
The most extensively investigated ITCs include AITC, BITC, PEITC and SFN, most of 
which are inducers of phase I I  enzymes such as QR, GST and UGTs, and inhibitors of 
cytochromes P450 (Hecht, 2000). Among these, SFN is arguably the most extensively 
investigated ITC, whereas erucin has received much less attention. One of the 
postulated mechanisms of the anticarcinogenic activity of ITCs involves impairment of 
the metabolic activation of chemical carcinogens and enhanced detoxification of their 
reactive metabolites. Consequently, the carcinogens are bio-transformed through 
metabolic pathways that lead to inactive products that the body can readily eliminate 
(Thornalley, 2002 and Juge et al., 2007). At the dietary relevant doses (Howard et al., 
1997), which were the focus of the current in vivo studies, only hepatic and pulmonary 
QR activity was elevated by erucin. When rats were treated with low doses of erucin, no 
detectable change in GST activity was achieved, although the GSTa and GSTji protein 
levels were marginally up-regulated. Immunoblots can be more sensitive than 
biochemical assays and can identify changes in the protein expression that are too small 
to be detected at the catalytic activity level. However, the sensitivity of immunoassays 
depends on the source and quality of antibodies and reagents. Alternatively, the GST 
isoenzymes may be catalytically inactive; such possibility is supported by previous
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studies reporting ITC-induced inactivation of GSTs following irreversible binding of 
substrate, rendering the enzyme catalytically inactive (Zhang et al., 1995). The 
elevation of rat GST apoprotein was isoenzyme-specific, as neither compound modulated 
GSTti expression (Chapter 5 ), the latter being in agreement with the current studies in 
precision-cut slices (Chapter 6).
8 .1 .1  A re d ie ta ry  achievable  plasm a levels o f  SFN su ffic ien t fo r  Its  In vitro  
biological ac tiv ity
In  vivo exposure to SFN modestly enhanced GST activity when assessed by NBD-CI, but 
the effect was only evident at a dose-level of 15 m g/kg, which is higher than human 
dietary exposure. Following oral administration of SFN to rats at the dietary dose of 0.5  
mg/kg, the peak plasma concentration achieved was < 0 .3  p M  (Chapter 3), which is 
below the lowest dose (3 m g/kg) employed in the present study (Chapter 5). The 
minimal concentration of erucin and SFN required to achieve a clear induction of both rat 
and human phase I I  enzymes in liver slices was 2.5 pM (Chapter 3), which can be 
attained in humans following Broccoli intake (Ye at al., 2002 and Gasper et al., 2005). 
However, it should be emphasised that the broccoli used in previous studies was 
selected for high glucosinolate concentration and/or was grown for the purpose of the 
study. Concentration of glucosinolates and consequently ITCs in commercially supplied 
Brassica vegetables can vary up to 10 fold at each step of the food production chain 
(Dekker et al., 2000). The broccoli used in the study described in Chapter 4 was 
purchased from a local supermarket to match the levels of SFN that can be reached by 
the general population. However, even after repeated consumption of large quantities of 
raw broccoli, the maximal plasma concentration of SFN (80  nM) was below the levels 
compatible with a measurable change in biological activity in rat and human tissue slices 
(Chapter 6). Moreover, the intake of ITCs, including SFN, by the general population may 
be further reduced substantially as a result of storage and cooking (Song and
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Thornalley, 2007 and Rungapamestry et al., 2007). In this respect erucin, the principal 
source of which, the rocket salad, is consumed raw, has an important advantage over 
SFN. Currently it is not known whether plasma levels of erucin compatible with its 
biological activity can be attained by consumption of Brassica vegetables, because their 
glucoerucin content and consequently human intake have not yet been defined.
8 .1 .2  Role o f GSTs in  tum ourigenesis
Since induction of GSTs by ITCs is one of the putative mechanisms of their 
anticarcinogenic activity, it is important to consider the complexity of the role of GSTs in 
tumourigenesis.
GSTs are unusual in that they are present at very high intracellular concentrations and 
are characterised by surprisingly low catalytic efficiency (Meyer et al., 1995). Most 
abundant mammalian cytosolic GSTs belong to class a, p and n. Their expression is 
regulated by complex mechanisms through multiple pathways including the ARE, XRE, 
GST P enhancer I  glucocorticosteroid-responsive element and AhR and, therefore is 
species-, age- and sex-specific (Hayes and Pulford, 1995). The biological role of GST is 
not confined to metabolic conjugation and subsequent clearance of xenobiotic 
substrates. The human GSTp and GSTn are involved in cellular signalling regulating cell 
survival and death presumably by means of direct interaction with proteins at the site 
independent of their catalytic site, binding to and sequestering signalling proteins. 
Although induction of GSTs is thought to be beneficial to health, elevated levels of GSTs 
can lead to resistance to apoptosis initiated by a variety of stimuli (Townsend and Tew,
2003).
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8 .1 .3  Erucin and  SFN as substrates fo r GSTs
The major elimination pathway of SFN both in rodents (Kassahun et al., 1997 and 
Bheemreddy and Jeffery, 2007) and in humans (Janobi et al., 2006) is the mercapturic 
acid pathway, the first step of which entails GST-catalysed conjugation with glutathione. 
Moreover, the enzymatic rate of ITC conjugation with glutathione is high (Zhang et al., 
1995; Kolm et al., 1995 and Meyer et al., 1995). I t  is therefore necessary to consider 
whether ITCs can enhance their own metabolism through induction of GST activity, 
increasing the rate of conjugation with glutathione and consequently elimination.
The induction of GSTs by erucin and SFN in both rat and human tissue slices was 
isoenzyme-specific, with GST class a and p, but not n being up-regulated (Chapter 6). 
Human GSTMl and GSTPl are the most efficient catalysts of GSH conjugation with ITCs, 
whereas the GSTAl, GSTM2 and GSTM4 are significantly less efficient (Zhang et al., 
1995 and Kolm et al., 1995). However, GSTAl and, to a lesser extent, GSTA2 and GSTM 
favour direct binding to GS-ITC conjugates over binding of GSH and ITC alone, 
sequestering the conjugates and thus promoting the conjugation of ITCs with GSH by 
other classes of GSTs (Meyer et al., 1995). Expression of rat and human GSTp was 
modestly up-regulated (Chapter 6) and, since GSTM l appears to be the main contributor 
to ITC metabolism in humans due to high catalytic efficiency towards these compounds 
and high hepatic concentration of this isoenzyme, it may be speculated that erucin and 
SFN have the potential to induce their own metabolism; however, paradoxically, GSTM- 
null subjects excreted SFN metabolites at a faster rate than their GSTM-positive 
counterparts (Gasper et al., 2005), although it was hypothesised that diminished risk of 
cancer in GSTM l and GSTTl-null individuals is associated with slower rate of ITC  
metabolism and clearance (Higdon et al., 2007). In view of significant polymorphism in 
GST expression in humans, the overall ITC metabolism is likely to depend on the 
individual's phenotype. Marked inter-individual variations in response to treatm ent with
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erucin and SFN were evident following incubation with human liver slices, expression of 
GSTs being modestly elevated in only one of the two donors (Chapter 6).
8 .1 .4  E ffect o f  erucin an d  SFN on g iu tath ione ieveis
GSH is the major cellular thiol and is regarded as the first line of cellular defence against 
genotoxic chemical carcinogens and ROS. Therefore, a rise in GSH levels will boost cell 
antioxidant capacity, diminishing damage that could be inflicted by electrophiles to 
cellular macromolecules such as DNA, proteins and lipids (Fahey and Talaley, 1999 and 
Mu rata et al., 2000). Both SFN and erucin elevated GSH levels following incubation with 
rat liver and lung slices (Chapter 6), as has been shown for SFN in previous in vitro 
studies (Brooks et al., 2001; Ye and Zhang, 2001; Kim et al., 2003 and Misiewicz et al.,
2004). Although the extent of the ITC-induced increase in total GSH levels was similar in 
rat liver and lung slices, this effect is probably of greater importance in the lung, where 
basal levels of glutathione are much lower (Chapter 6). Such up-regulation of 
glutathione synthesis may be an adaptive response to a tem porary decline in cellular 
GSH following exposure to non-toxic (up to 25 pM) concentrations of ITCs (Chapter 6). 
Owing to high enzymatic and non-enzymatic rate of reaction with GSH, ITCs utilise 
cellular GSH to form mercapturates (Zhang, 2000 and Zhang, 2001 ), their principal 
metabolites both in rodents (Kassahun et al., 1997 and Rungapamestry et al., 2006) and 
in humans (Janobi et al., 2006). In contrast, concentrations of erucin and SFN exceeding 
25 pM were cytotoxic and seemed to evoke more profound depletion of cellular 
glutathione levels which did not rebound by 24 h of incubation (Chapter 6).
Of the two human livers, modest elevation of total GSH levels in response to non-toxic
concentrations of either ITC was only apparent in the liver from the second donor,
indicating inter-individual differences in response to glutathione depletion among
humans. GSH levels in the second human liver were induced by ITCs in parallel with the
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other phase I I  enzymes, presumably because the genes encoding glutathione synthesis 
enzymes such as y-glutamylcysteine synthetase, the rate-lim iting enzyme in glutathione 
biosynthesis, are also ARE-responsive and are therefore co-coordinately up-regulated 
with other phase I I  enzymes (Zhang et al 1992; Bonnesen et al., 2001; Brooks et al., 
2001 and Morimitsu et al., 2001).
In contrast to the in v/fro outcome, neither compound influenced hepatic or pulmonary 
GSH concentrations when administered to animals at low dose levels (Chapter 5). The 
lack of detectable change in GSH levels in vivo most likely reflects insufficient 
concentration of ITCs in rat plasma (Chapter 3) as already discussed in section 8 .1 .1 .
8 .1 .5  M odulation o f  QR a c tiv ity  by erucin and  SFN
Both compounds markedly up-regulated expression and activity of rat pulmonary and 
hepatic QR both in vitro and , more importantly, in vivo (Chapters 5 and 6, Zhang et al., 
1992; Matusheski and Jeffery, 2001; Munday and Munday, 2004 and Yoxall et al.,
2005), an enzyme that may stabilize p53 protein, resulting in increased apoptosis in 
cancerous cells (Asher et al., 2001), and which also facilitates the detoxication of 
quinones (Dinkova-Kostova and Talalay, 2000). Since this enzyme system is responsible 
for the detoxification of quinones, it may be inferred that erucin and sulforaphane have 
the potential to antagonise the carcinogenicity of polycyclic aromatic hydrocarbons in rat 
tissues through such a mechanism. Intriguingly, when human liver slices from two 
different donors were used, neither ITC influenced expression and/or activity of QR in 
the first liver, whereas only a weak rise in protein levels was noted in the second, in 
marked contrast to the observations made in rat. The possible mechanism(s) and 
implication of the observed differences in the inducibility of rat and human QR are 
discussed in section 8.6.
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8 .2  Effect o f erucin and SFN on activ ity  and expression o f phase I  enzym es
Inhibition of phase I  enzymes, particularly of the CYPl family is associated with 
suppressed bioactivation of carcinogens to genotoxic metabolites and is viewed as one of 
the mechanisms underlying anticarcinogenic activity of ITCs (Fimognari and Hrelia, 2007  
and Juge et al., 2007 ), although the suppression of CYPlA-mediated deactivation 
pathways is frequently overlooked. Modulation of cytochromes P450 activity by erucin 
and SFN was not observed either in vivo, after oral administration to rats for two weeks 
at low dose levels, or in vitro, following exposure of rat and human tissue slices for 24 h 
to non-toxic concentrations (Chapter 5 and 6). However, the expression of CYPIA and 
CYPIB I proteins was up-regulated both in vivo and in vitro, indicating catalytic 
incompetence of these enzymes. In concord with a previous study (Yoxall et al., 2005), 
SFN was a mechanism-based inhibitor of rat hepatic EROD, as was erucin, but the ITC- 
mediated loss of EROD activity was completely prevented by reduced GSH even at 
concentration (0 .2  m M), i.e. below the physiological levels (about 5 mM) found in rat 
hepatocytes (Chapter 5). Moreover, the inhibiting effect was only apparent at relatively 
high ITC concentrations (>  25 pM) that are significantly higher than dietary achievable 
levels in humans as has already been discussed above. Consequently, it is unlikely that 
this mechanism is operative under conditions that prevail in vivo.
The observation that CYPIA apoprotein, but not the activity, was induced by ITCs is 
consistent with mechanism-based inactivation of this enzyme (Chapters 5 and 6). 
Contrary to the notion that SFN is a monofunctional inducer that selectively up-regulates 
expression of phase I I  enzymes through the ARE pathway without concurrent induction 
of AhR-regulated CYPIA family of enzymes (Zhang et al., 1992 and Miao et al., 1994), 
both compounds enhanced CYPIA and CYPIB I protein levels (Chapter 6 ), indicating a 
possibility of cross-talk between the AhR- and ARE-regulated pathways. The up-
regulation of the CYPl family by erucin and sulforaphane was an unexpected and
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surprising observation, as these are small molecular weight aliphatic compounds. 
Extensive studies have shown that the inducers of the CYPl family are essentially 
aromatic planar compounds with a large area/depth^ ratio (Lewis et al., 1986; Lewis et 
al., 1987). Amongst the most avid ligands to the AhR receptor are the toxin TCDD 
(2,3,7,8-tetrachlorodibenzo-p-dioxin) and large hydrophobic planar aromatic compounds 
such as the polycyclic aromatic hydrocarbons (Denison et al., 2002; Denison and Nagy, 
2003 and Pushparajah et al., 2008), although compounds comprising a single 
substituted aromatic ring, such as diaminotoluenes, can also serve as agonists (Cheung 
et al., 1996). Erucin and sulforaphane, both small molecular weight aliphatic 
compounds, are clearly strong inducers of the CYPl family despite their structural 
unsuitability to function as Ah receptor agonists. However, up-regulation of the CYPl 
family, independent of binding to the Ah receptor, has been reported (Ayalogu et al, 
1995; Boyd et al, 1995; Lesca et al., 1995).
The inducing effect of erucin and sulforaphane on CYPl protein expression was clearly 
much less pronounced in human liver slices compared with the observations made in rat 
slices, incubated with these compounds under identical conditions. Neither ITC  
influenced CYPIA and C Y P IB I apoprotein levels in the liver from Donor 1, whereas both 
compounds modestly elevated expression of these enzymes the liver of Donor 2, but 
much less effectively compared with rat. These observations point to a possible species 
difference in the up-regulation of CYPl by these isothiocyanates. Alternatively, 
polymorphism in CYPl enzymes (Nagata, K. and Yamazoe, Y., 2002 ), AhR (Denison and 
Nagy, 2003) or co-activator and related regulating proteins may influence AhR affinity to 
agonists and, consequently, the CYPl inducibility in humans, although the impact of 
these polymorphic variations on the induction of CYPl proteins is not entirely clear 
(Harper et al., 2002). I t  is imperative that additional human samples are investigated for 
an unequivocal conclusion to be drawn.
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8.2 .1  E ffect o f  erucin a n d  SFN on B (a )P -m e d ia ted  induction o f  C YPIA
Both ITCs, erucin and SFN, attenuated B(a)P-mediated induction of CYPIA. The 
antagonistic effect of erucin and SFN on B(a)P-mediated up-regulation of C YP lA l is 
unlikely to be explained entirely by mechanism-based inactivation of this enzyme by ITC  
because, firstly, physiological GSH concentrations are sufficiently high to prevent the 
inhibiting activity of ITCs (Chapter 5) and, secondly, both compounds antagonised the 
effect of B(a)P not only at the activity, but also at the apoprotein level (Chapter 7). 
However, mechanism-based inhibitors, also known as suicidal substrates, can destroy 
cytochromes (Murray, 2007). In order to confirm that the observed decrease in CYPIA 
protein level is due to ITC-induced down-regulation of its expression and not the 
consequence of protein degradation, expression of this enzyme needs to be evaluated at 
the mRNA level.
ITCs may antagonise the inducing effect of B(a)P on AhR-controlled CYPl expression by 
virtue of direct binding to the receptor and disruption of co-activator recruitment and 
preventing the formation of the complexes necessary for the initiation of gene 
transcription. Direct interaction of SFN with the steroid and xenobiotic receptors (SXR) 
has been reported in primary human hepatocytes (Zhou et al., 2006). In view of the 
major involvement of AhR receptor in carcinogenesis, the potential of ITCs to modulate 
its function deserves further investigation. Furthemore, the biological function of the AhR 
is not Imited to the regulation of XME expression. The AhR is implicated in cellular 
processes such as endocrine homeostasis, cell proliferation, apoptosis and terminal 
differentiation (Puga et al., 2002, Pocar et al, 2005 and Barouki et al., 2007). Further 
studies into the effect of ITCs on the AhR receptor binding are required for better 
understanding of this aspect of their biological activity. However, clear antagonism of 
B(a)P-mediated C Y P lA l up-regulation was achieved at relatively high ITC concentrations 
of > 10 pM, but such effects, once again, are unlikely to persist in vivo following
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exposure to the dietary relevant doses of erucin and SFN, because of the low plasma 
levels.
8 .3  Effect o f erucin and SFN on m utagenicity  o f IQ
Both ITCs suppressed the excretion of indirect-acting mutagens in rats exposed to a
single dose of IQ , when mutagenicity was assessed in the presence of an activation
system, indicating the potential to influence the metabolic fate of this heterocyclic
amine, but only after repeated administration of ITC at approximate daily dose levels of
93.2 pmol/kg for erucin, and 84.7  pmol/kg for SFN. Erucin antagonised direct-acting
mutagenicity of IQ even at lower, dietary achievable (Howard et al., 1997) dose level of
18.6 pmol/kg (Chapter 7). The indirect-acting mutagenicity in the urine of rats exposed
to IQ mainly reflects levels of unchanged IQ (Barnes and Weisburger, 1985), since the
ring-hydroxylated metabolites (Tong et al., 1986 and loannides et al., 1989) and the N-
conjugates of IQ  such as the sulphamate (Turesky et al., 1986) lack mutagenic activity
and, furthermore, can not be metabolically converted to mutagens. Heterocyclic amines,
such as IQ , are bioactivated through A/-oxidation, catalysed by the CYPl family and, in
particular CYP1A2 and, to a lesser extent, C YP lA l and C Y P IB I (Kim and Guengerich,
2005 and Tu resky, 2005). Therefore, a decrease in the urinary indirect-acting
mutagenicity indicates enhanced metabolism of IQ. However, neither erucin nor SFN
elevated the hepatic CYP1A2 and C YPlA l activities, indicating that the enhanced
metabolism of IQ can not be attributed to up-regulation of these enzymes. Furthermore,
the observed favourable change in IQ metabolism can not be explained by augmented
reduction of the electrophilic hydroxylamine metabolite to the parent compound
(Turesky, 2005), because neither ITCs induced activity of GST when a broad-spectrum
substrate CDNB was used. The lack of modulating effect of low doses of ITCs on
activities of CYPIA and GST is consistent with observations made in the in vivo study
(Chapter 5). A feasible mechanism of the decreased mutagenic activity is enhancement
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by ITCs of other important detoxication pathways of IQ , including N-glucuronidation and 
sulphation (Turesky, 2005 and Armbrecht et al., 2007). PEITC enhanced UGP glucuronyl 
transferase (UGT) activity but decreased sulphotransferase in rats (Dingley et al., 2003). 
At the mRNA and protein levels, SFN up-regulated U G T lA l in HepG2 cells but not in 
human hepatocytes (Basten et al., 2002 and Bacon et al., 2003 ). The effect of erucin on 
these enzyme systems in the liver has not been investigated. Since activities of 
sulfotransferases and UGTs were not determined, it remains to be established whether 
direct conjugation with sulphate and/or glucuronide of the exocyclic amino group 
pathways can be modulated by ITCs. In contrast, the decrease in urinary excretion of 
the heterocyclic amines PhIP and 2-am ino-3,8-dim ethylim idazo(4,5-f)quinoxaline  
(MelQx) in humans after ingestion of Brussels sprouts and broccoli (Murray et al 2001) 
appears to be due to enhanced CYP1A2 activity and increased metabolism of the amines 
(Walters et al 2004). Whether this effect can be attributed to the ITC content of the 
vegetables or other constituents also significantly contribute to and/or synergistically 
enhance the anticarcinogenic effects of ITCs remains to be elucidated.
8 .4  Relative potencies o f SFN and erucin to  m odulate xenobiotic  m etabolising  
enzym es expression and m utagenicity  o f IQ
Overall, both compounds were equipotent modulators of xenobiotic metabolising 
enzymes expression in rat lung and rat and human liver. However, erucin was 
marginally more potent as mechanism-based inhibitor of hepatic EROD activity (Chapter 
5). Erucin also more effectively suppressed urinary mutagenicity of IQ  when 
administered to rats at low doses (Chapter 7). In the in vivo study, unlike erucin, SFN 
significantly induced hepatic GST when analysed using NBD-CI as a marker substrate 
(Chapter 5). Interestingly, human GSTs significantly vary in their catalytic efficiency 
towards different ITCs, with erucin being one of the best substrates for GSTs, in contrast 
to SFN, the poorest aliphatic substrate for all four human GSTs, despite their structural
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similarity. Due its sulphur oxidation state, SFN is relatively polar and, in contrast to 
erucin, does not bind readily to the hydrophobic substrate-binding site of GSTs (Zhang 
et al., 1994 and Kolm et al., 1995), suggesting that SFN is likely to have the lowest 
clearance rate and, therefore, the highest GST inducing potency. However, in the in vivo 
studies in rat (Chapter 5 ), and in incubated rat and human tissue slices (Chapter 6), 
both compounds were essentially equipotent inducers of GSTs, possibly as a result of in 
vivo metabolic reduction of SFN to erucin, one of its m ajor metabolites in rats (Kassahun 
et al., 1997; Bheemreddy and Jeffery, 2007).
8 .5  Liver and lung as ta rg e t tissues fo r ITCs
The overall pattern of ITC-induced modulation of phase I and phase I I  modulation was 
very similar in both tissues. However, the effect of both compounds on the xenobiotic 
metabolising enzymes expression in vivo was more pronounced in liver compared with 
lung, possibly reflecting differences in the anatomical location and metabolic capacity of 
these organs. Up-regulation of the rat pulmonary QR by the aliphatic ITC SFN was also 
reported previously in mice (Zhang at al., 1992). In contrast, aromatic PEITC failed to 
enhance QR activity in the lung (Guo et al., 1992 and Konsue and loannides, 2008), 
suggesting that effect of ITCs on this enzyme could be compound-specific a nd be 
influenced by the structure of the side-chain. Up-regulation of QR and GST enzyme 
systems by ITCs appears to be of greater importance in the lung. Lung is a m ajor target 
tissue for many tobacco carcinogens such as PAH and heterocyclic amines, which can 
damage this tissue following their in situ cytochromes P450-mediated metabolic 
bioactivation to genotoxic metabolites (loannides and Lewis 2004). Moreover, 
experimental evidence supports the view that reactive intermediates generated in the 
liver, the principal site of bioactivation, may be transported to extrahepatic tissues, 
although the underlying mechanism(s) has not been elucidated (Wall et al 1991; 
Kaderlik et al 1994). Since the extent of DNA-binding intermediates would dependent on
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both rate of their P450-catalysed formation and phase Il-m ediated  detoxification, up- 
regulation of enzyme systems such as QR and GSTs by both ITCs may be responsible, at 
least partially, for the observed chemopreventive activity of ITCs in this tissue following 
exposure of animals to polycyclic aromatic hydrocarbons (Conaway et al., 2002 and 
Conaway et al., 2005). More importantly, both compounds enhanced pulmonary QR 
expression and activity in vivo, following repeated administration to rats at dietary 
relevant doses (Chapter 5).
8 .6  Rat as surrogate  fo r hum an in studies re lating  to  ITCs
Rat may not be a good surrogate for human when studying potential of ITCs to modulate
expression of xenobiotic metabolising enzymes. Expression of QR was very modestly
elevated in only one of the two human livers studied, in marked contrast to the
observations made in rat (Chapter 6). This could reflect a compound-specific failure of
these aliphatic ITCs to induce human QR. However, the aromatic PEITC also failed to up-
regulate activity and protein levels of this enzyme in three human livers, whereas
increases were observed in rat slices incubated under identical conditions (N. Konsue,
personal communication). These data could also indicate a possible species differences
between rat and human with implications for the chemopreventive activity of these ITCs,
as it would imply that chemopreventive potential might be less pronounced in human
compared with rat. The failure of ITCs to induce human QR (Chapter 6) is surprising
given that erucin up-regulated QR mRNA in human colonic adenocarcinoma cells
(Jacubikova et al., 2005 ), whereas SFN potently augmented expression of QR in the skin
of human volunteers following topical application of broccoli preparations (Dinkova-
Kostova et al., 2007), in human retinal pigment epithelial cells (Gao and Talalay, 2004)
and various human cell lines (Brooks et ai., 2001 and Misiewicz et al., 2004). The
observed difference could be attributed to human polymorphism. A non-functioning QR
gene has been found in 20%  of Caucasians and almost 50%  of other ethnic proup
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(Gaedigk et al., 1998 and Begleiter et al., 2006). Furthermore, genetic polymorphism in 
human Nrf2, the transcriptional factor involved in activation of ARE-controlled genes 
encoding phase I I  enzymes, could influence its expression and function (Marzec et al., 
2007) and may lead to inter-individual differences in QR inducibility. A more definitive 
conclusion would require the analysis of additional human liver samples. Nevertheless, 
these studies highlight the need for caution when extrapolating from animals to humans.
In contrast, rat appeared to be an acceptable surrogate for human when studying the 
pharmacokinetic (PK) fate of SFN (Chapters 3 and 4). Although the calculated PK 
parameters in rat and human were broadly similar, several important points need to be 
considered when comparing the results of these two studies. The eating behaviour and 
diet composition of the two species are very different. Rats are nocturnal animals and 
eat mostly during the night time. They were dosed with SFN (Chapter 3) early in the 
morning, when their stomachs were likely to be full. In contrast, humans ingested 
broccoli (Chapter 4 ) after overnight fasting and had their breakfast and subsequent 
meals during the day time. I t  is pertinent to note that reactive ITCs can form covalent 
bonds with thiol, hydroxyl and amino groups of macromolecules (Keck et al., 2003). It  
remains to be established whether such spontaneous and non-specific binding to food 
constituents could limit bioavailability of orally ingested ITCs, especially when consumed 
concurrently with protein-rich food (m eat, fish, milk etc.). Reversible binding of ITCs to 
food thiols is likely to delay absorption. Moreover, the propensity of ITC to bind to 
plasma proteins is likely to limit their cellular uptake. Thus, following administration at 
dietary relevant dose levels, concentrations of SFN in tissues could be lower than in 
plasma and below the levels compatible with its biological activity (i.e. about 2 .5  pM).
Finally, maximum PEITC plasma concentrations in rats were higher after repeated oral
administration (N. Konsue, personal communications). In contrast, repeated
consumption of broccoli by humans was not associated with a rise in SFN Cmax.
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However, the dose of SFN ingested by humans was extrem ely low (Chapter 4 ), making 
direct comparison difficult. A definite conclusion as to whether rat is a good surrogate for 
human as far as ITCs are concerned would require additional studies using similar dose 
levels and allometric scaling.
8 .7  C hem opreventive effectiveness of erucin and SFN
The most marked effect manifested at low dose levels by both compounds in vivo was 
up-regulation of QR. This mechanism could be partially responsible for the documented 
chemopreventive effect of ITCs following exposure of animals to chemical carcinogens 
that are metabolised to quinones (reviewed by Hecht, 2000; Conaway et al., 2002 and 
Conaway et al., 2005). However, additional mechanisms, including induction of 
apoptosis, suppression of cell proliferation and inflammation are likely to contribute to 
the observed chemopreventive activity of these phytochemicals. These mechanisms 
appear to function at the in vivo ITC concentrations similar to those required for up- 
regulation of Phase I I  enzymes. SFN-induced cell cycle arrest was observed in vitro at 
concentrations as low as 2.5pM (Miziewizc et al., 2004) in lymphoblastoid cells, 3pM in 
human T-cell leukaemia cells (Fimognari et al., 2002) and 4.3pM  in human leukaemia 60 
cells (Zhang et al., 2003). SFN induced apoptosis at 2.5|nM in human lymphoblastoid 
cells (Miziewizc et al., 2004) and at > 5pM in medulloblastoma cells (Gingras et al.,
2004), but in most studies higher concentrations (1 0 -40  pM) were required (Cho et al., 
2005; Choi et al., 2007 and Karmakar, 2006). Erucin also inhibited cell proliferation in 
breast cancer MCF7 and Norman human mammary epithelial cells at 28 and 46pM  
respectively (Azarenko et al., 2006). At 5pM, SFN suppressed inflammatory response in 
airway epithelial cells stimulated with diesel extract (R itl^ W  ar.T"2006)7 Cbllectivelyr
these data demonstrate that minimal ITC concentrations necessary for their biological
activity could be achieved in vivo. Moreover, at these concentrations, ITCs could activate
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multiple chemopreventive mechanisms simultaneously. However, such concentrations 
can only be achieved in humans following ingestion of broccoli with high glucosinolate 
content, i.e broccoli sprouts, as discussed in section 8 .1 .1 . Alternatively, ITCs may be 
ingested as dietary supplements.
To achieve ITC plasma concentrations (around 2 .5 -5  pM) sufficient for their 
chemopreventive activity in vivo, a 70 kg person would have to ingest at least 560 mg of 
SFN (8 m g/kg) of ITCs, assuming that 100%  of the ingested dose is absorbed. This is 
equivalent to 43 kg of common broccoli per day. Therefore for chemopreventive 
purpose, ITCs would have to be used as dietary supplements rather than to be obtained 
from broccoli. However, repeated intake of excessively high doses (> 2 5  m g/kg) of ITCs 
was associated with mutagenicity in laboratory animals (Dannick et al., 1982; Rao et al., 
1995 and Kassie et al., 2003b). Therefore, if ITCs are to be taken repeatedly for long 
periods of time in the form of dietary supplements, it is essential that their daily dose be 
optimised to avoid overdose-induced toxicity.
8 .8  Fu tu re  w o rk
Of more than 100 naturally occurring glucosinolates, only very few (Hecht, 2000 and 
Conaway et al., 2002) have attracted attention. The chemopreventive potential of the 
remaining ITCs deserves evaluation.
Another point that should be considered is that Brassica vegetables contain a mixture of 
glucosinolates, and it is conceivable that the combined biological effect of their 
respective ITCs could result in either synergy or antagonism. Clinically important 
synergism among chemoprotective agents has already been reported (Brenner, 2000  
and Torrance et al., 2000). On the other hand, both P450 inhibition and induction were 
reported in rats fed different varieties of broccoli (Vang et al., 2001b ), presumably as a
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consequence of change in the glucosinolate ratio (Fahey et al., 1997 and Howard et al., 
1997).
The current studies demonstrated that long-term pre-treatm ent with dietary relevant 
doses of ITCs was effective at suppressing mutagenicity of IQ , presumably as a result of 
altered metabolism. I t  would be informative to establish whether the enhanced 
conjugation of IQ  with sulphate and glucuronide could be the underlying mechanism.
The important role of antiproliferative, anti-inflammatory and pro-apoptotic activity of 
ITCs in inhibition of the post-initiation stages of carcinogenesis has been increasingly 
recognised (Conaway et al., 2002; Myzak and Dashwood, 2006c and Juge et al., 2007). 
However, additional studies are needed to establish whether such mechanisms take 
place in vivo following administration of low doses of ITCs.
Finally, additional human livers are required to establish whether the observed 
differences in modulation of the QR and CYPl expression by ITCs are due to inter­
species differences or human polymorphism. Moreover, it is important to evaluate the 
ability of both compounds to antagonise B(a)P-mediated up-regulation of CYPIA in 
human liver, elucidate the mechanistic basis for this interaction and evaluate whether it 
can be achieved in vivo following oral administration of dietary relevant doses of both 
ITC and carcinogen.
8 .9  Conclusion
To summarise, the maximal plasma concentrations of SFN in humans, following
ingestion of Broccoli, or in rats, after oral administration of low doses approximating
human intake, were well below those required to achieve XEM modulation, antagonise
B(a)P-mediated induction of CYPIA or suppress mutagenic activity of IQ . Moreover, the
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observed peak in plasma SFN concentration was transient. However, up-regulated  
expression of QR and GSTs in humans can be achieved following ingestion of Broccoli 
with high glucosinolate content, i.e. Broccoli sprouts. Moreover, other Brassica 
constituents may contribute to and/or synergistically enhance the anticarcinogenic 
effects attributed to these phytochemicals.
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